

CURRICULUM VITAE
RANDALL C. STARLING, M.D., M.P.H., F.A.C.C., F.A.H.A., F.E.S.C., F.H.F.S.A.

FEBRUARY 2019

PERSONAL INFORMATION

Name: Starling, Randall Carson
Place of Birth: Pittsburgh, Pennsylvania, USA
Citizenship: United States of America

Education

University of Pittsburgh
Pittsburgh, Pennsylvania
B.S. Biology, Cum Laude
1969 – 1973

University of Pittsburgh, School of Public Health
Pittsburgh, Pennsylvania
M.P.H., Summa Cum Laude
1974 – 1975

Temple University School of Medicine
Philadelphia, Pennsylvania
M.D., Honor Graduate
1977 – 1981

Post-Graduate Training

The Ohio State University
Division of Cardiology
Columbus, Ohio
Director: Carl V. Leier, M.D.
Cardiology Fellowship
1985 – 1987

University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Director: Gerald S. Levey, M.D.
Chief Medical Resident
Instructor in Medicine
1984 – 1985

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Director: Gerald S. Levey, M.D.
Internal Medicine Residency
1982 - 1984

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Director: Gerald S. Levey, M.D.

Internal Medicine Internship
1981 - 1982

Contact Information

Office Address:

Cleveland Clinic
Department of Cardiovascular Medicine
Section of Heart Failure and Transplant Medicine
9500 Euclid Avenue / J3-4
Cleveland, Ohio 44195
Office Phone: (216) 444-2268
Facsimile: (216) 636-6974
E-mail: starlir@ccf.org

Home Address:

513 Fawn Court
Chagrin Falls, Ohio 44022
Home Phone: (440) 338-4301

PROFESSIONAL APPOINTMENTS

Member, Board of Trustees
Cleveland Clinic
Cleveland, OH
2013-2014

Interim Chairman, Department of Cardiovascular Medicine
Cleveland Clinic Florida
Weston, Florida
February 2011 – November 2012

Member, Board of Governors
5 Year Term
Cleveland Clinic
Cleveland, Ohio
2010 – 2015

Vice Chairman, Department of Cardiovascular Medicine
Cleveland Clinic
Cleveland, OH
2006 – 2016

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio
2006 – Present

Head, Section of Heart Failure and Cardiac Transplant Medicine
Cleveland Clinic
Department of Cardiovascular Medicine
Cleveland, Ohio
November 2003 – January 2016

Medical Director, Heart Transplant Program
UNOS Lead Physician
Cleveland Clinic Heart Transplant Program
January 2004 – March 2019

Medical Director, Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio
2003 – January 2016

Joint Appointment
Staff Physician
Cleveland Clinic
Multi-Organ Transplant Center
Cleveland, Ohio
1998 – Present

Program Director
Advanced Fellowship in Heart Failure and Cardiac
Transplant Medicine Fellowship
Cleveland Clinic
1995 – 2003

Staff Physician
Director, Heart Transplant Medical Services
Cleveland Clinic
Department of Cardiovascular Medicine
Cleveland, Ohio
1995 – 2003

Associate Professor of Medicine, ***with Tenure***
Medical Director, Cardiac Transplant Program
Director, Endomyocardial Biopsy Lab
The Ohio State University
Division of Cardiology
Columbus, Ohio
1994 – 1995

Assistant Professor of Medicine
Medical Director, Cardiac Transplant Program
Director, Endomyocardial Biopsy Lab
The Ohio State University
Division of Cardiology
Columbus, Ohio
1992 – 1994

Assistant Professor of Medicine
Medical Director, Cardiac Transplant Program
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
1991 – 1992

Adjunct Assistant Professor of Medicine
The Ohio State University
Division of Cardiology
Columbus, Ohio
1991 – 1992

Assistant Professor of Medicine
The Ohio State University
Division of Cardiology
Columbus, Ohio
1988 – 1991

Clinical Assistant
Professor of Medicine
The Ohio State University
Division of Cardiology
Columbus, Ohio
1987 – 1988

CERTIFICATION AND LICENSURE

2010 Florida (ME 107791)
2003 Massachusetts (218951)
2003 Michigan (4301082516)
2003 New York (230137)
1986 Ohio (35-053357)
1982 Pennsylvania (MD027607E)

2010 American Board of Internal Medicine
Advanced Heart Failure/Transplant Cardiology
Certified 11/08/2010 - 12/31/2020
2010 Re certified, Diplomat in Internal Medicine (97797)
American Board of Internal Medicine (97797)
1989 Diplomat in the Subspecialty of Cardiovascular Disease,
American Board of Internal Medicine (97797)
1984 Diplomat in Internal Medicine,
American Board of Internal Medicine (97797)
1982 National Board of Medical Examiners (254215)

HONORS AND AWARDS

Fellowship of the Heart Failure Society of America (Inaugural Group) - 2016
Temple University, Medical Alumni Achievement Award – 2016
Best Doctors in America, 2002, 2004-2015
Best Doctors in America, Midwest Region, 1996
National Institutes of Health Research Apprenticeship Program,
The Ohio State University College of Medicine, 1993
Mosby Book Scholarship Award, 1981
Alpha Omega Alpha, Temple University School of Medicine, 1980

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American College of Cardiology, Fellow
American Heart Association Council on Clinical Cardiology, Member, Fellow
American Society of Transplantation, Member inactive
Heart Failure Society of America, Member and Fellow
Heart Failure Association of the European Society of Cardiology, Member, Fellow
The European Society of Cardiology, Fellow
The International Society for Heart and Lung Transplantation, Member

PROFESSIONAL SERVICES

Editorial Boards:

Journal of the American College of Cardiology:
Past member editorial board, current ad hoc reviewer
JACC Heart Failure: Editorial Consultant 2011 – present
Heart Failure Reviews: Editorial Board. 2016—2018
Associate Editor 2018- present
Circulation, 2016 – present
Journal of Heart and Lung Transplantation:
Past member editorial board, current ad hoc reviewer
Greek Journal of Heart Failure: International Editor in Chief
New England Journal of Medicine, Lancet, JAMA: Ad hoc reviewer

COMMITTEE SERVICE

National:

American Board of Internal Medicine, Heart Failure and Transplant Committee, ad hoc member. November 2016.

Heart Failure Society of America, President, 2018 – 2019.

Heart Failure Society of America, Treasurer and member Strategic Planning Committee, 2016 – 2017.

2016 ACC/AHA/HFSA Focused Update on New Pharmacologic Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guidelines for the Management of Heart Failure – Peer Reviewer, April 2016

ACC Appropriateness Use Committee, Cardiovascular Imaging Committee Member, Denver, CO. September 2016.

ACC/AATS/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Non-Emergent, Non-Cardiac Surgery 2018-ongoing

American College of Cardiology Program Committee, Member, 2016 – 2019

American College of Cardiology, Committee Member Heart Failure and Transplant 2016-2019

American Medical Group Association, Member Heart Failure Collaborative. 2015 – 2017. Arlington, VA.

Heart Failure Society of American, Member, Finance Committee, Chevy Chase, MD, 2015 - 2018

Heart Transplant Representative to United Network for Organ Sharing (UNOS) Board of Directors, OPTN Board of Directors, June 2010 – June 2012

Heart Failure Society of America, Member, Program Committee, Minneapolis, Minnesota, 2010 – 2011

International Society for Heart and Lung Transplantation, 30th Annual Meeting and Scientific Sessions, Program Committee, Chicago, Illinois, April 21 -24, 2010

Heart Mate II Clinical Trial, Member, Publication Committee, February 2010

Heart Failure Society of America, Abstract Reviewer, 2010

Thoratec Corporation, Member, Publication Committee, HeartMate II Clinical Trial, Pleasanton, California, 2010

Member, American Board of Internal Medicine, ABIM Test Committee on Advanced Heart Failure and Transplant Cardiology, July 1, 2009 – June 30, 2015

Cleveland Clinic Heart and Vascular Institute Comprehensive International Symposium, The Treatment of Cardiovascular Disease: Legacy and Innovation, Program Committee, Cleveland, Ohio, June 3-5, 2009

International Society for Heart and Lung Transplantation, 29th Annual Meeting and Scientific Sessions, Program Chairman, Paris, France, April 22-25, 2009

Heart Failure Society of America, Member, Executive Council, Minneapolis, Minnesota, 2008 – 2014

Abstract Reviewer, International Society for Heart and Lung Transplantation, 2007, 2010, 2011

International Society of Heart and Lung Transplantation, Member, Board of Directors, Dallas, Texas 2006-2009

Annual Scientific Sessions, American College of Cardiology, Co-Chair, Program Committee, 2006 – 2008

Organ Procurement and Transplantation Network/ United Network for Organ Sharing, Membership and Professional Standards Committee AND Policy Compliance Subcommittee, 2006 – 2008

Medtronic, Incorporated, Cardiac Rhythm Disease Management Division, Advisor, Co-Management Council of Advisors, Minneapolis, Minnesota, March 2006 – present.

AHA/ACC/ESC Scientific Statement Writing Group, *The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease*, Member, 2006

World Heart Incorporated, Executive Committee, RELIANT Trial, 2006

Arrow International, Member, Clinical Events Review Committee for European Cor Aide Trial, Wyomissing, Pennsylvania, 2005 – Present

WellPoint, Incorporated, Member, National Transplant Quality Review Committee, Denver, Colorado, 2005-Present

American College of Cardiology, Abstract Reviewer, 2005-2008, 2012-2016.

Annual Scientific Sessions, American College of Cardiology, Program Committee, 2005 – 2008

Heart Failure Society of America, Member of the Guidelines Committee, Minneapolis, Minnesota, 2005-2008. Committee Chair 2009-2012.

AnGes MG, Incorporated, Consultant, HGF Global Steering Committee, Tokyo, Japan, 2005-2007

American Heart Association Scientific Sessions, Abstract Reviewer, 2005-2016.

American Transplant Congress, Abstract Reviewer, 2005-2007

Myocor, Incorporated, St. Paul, Minnesota, Member, Scientific Advisory Board, July 2005 – Present

NIH/UNOS/UAB, Member, Interagency Registry for Mechanical Assisted Circulatory Support (INTERMACS), Richmond, Virginia, 2004 – Present

Medtronic, Incorporated, Advisor, CRM-C Medical Advisory Team for Cardiac Rhythm Management, Minneapolis, Minnesota, November 2004 – 2005

Roche Laboratories, Incorporated, Member, National Cardiac Advisory Board, Nutley, New Jersey, 2004, 2005

American Society of Transplantation, Member, Training and Work Force Committee, 2002-2005

American Society of Transplantation, Member, Education Committee, 2001-2004

Data Safety Monitoring Board, Edwards Life Science Chronic Left Ventricular Assist Device Trial, INTREPID Study, Member, 2000-2003

American Society of Transplantation, Member, Practice Guidelines Committee, 1999-2002

American College of Cardiology, Member, Transplant and End-Stage Heart Failure Committee, 1996-1999

Cleveland Clinic

Member, Pharmacy and Therapeutics Committee, Transplant Subspecialty Section, 2005-Present

Member, Cardiovascular Medicine Strategic Planning Committee, 2005-2006

Member, Cleveland Clinic Center for Electrical Therapies of Heart Failure Committee, 2003-2010

Member, Regional Medical Practice Referring Physician Task Force, 2003-2005

Member, Search Committee, Chairman Medicine Institute, 2010

Member, Infectious Disease Department Chairman Search Committee, Cleveland Clinic, 2002-2004

Member, Internal Medicine Residency Interview Program, Cleveland Clinic

Member, Medical Division Committee, Cleveland Clinic, 1998-2005

Member, Medical Legal Risk Management Committee, Cleveland Clinic, 1999-2002

Member, Medical Student Education Council, Cleveland Clinic, 1996-Present

Member, Cardiac Transplant Selection Committee, Cleveland Clinic, 1995 - Present

Member, Executive Committee, Transplant Center

Member, Board of Governors, 2010 – 2015

Member, Board of Trustees, 2013-2015

Member, Board of Directors, 2014 – 2015

Member, Cleveland Clinic Heart and Vascular Institute Affiliates Review Committee.
Numerous heart failure program reviews, active participant.

Cleveland Clinic Lerner College of Medicine

Member, Admissions Committee, Cleveland Clinic Lerner School of Medicine,
2003- 2008

Faculty Research Mentor, Thomas E Hurst, July 2014 – July 2015

TEACHING ACTIVITIES

Presentations

1. A Computerized Literature Retrieval System for House Staff, Annual Meeting of the Association of Program Directors in Internal Medicine, Washington, DC. March 26, 1985.
2. Pneumococcal Pericarditis, Annual Meeting of Clinical Vignettes Associates Day at American College of Physicians, Washington, DC. March 30, 1985.
3. Digoxin Compromises the Effectiveness of Calcium Channel Blockers as Vasodilators in Isolated Human Coronary Arteries, American Federation for Clinical Research, San Diego, California. May 2, 1987.
4. Digoxin Compromises the Effectiveness of Calcium Channel Blockers as Vasodilators in Isolated Human Coronary Arteries, American Heart Association Research Day, Central Ohio Heart Chapter. June 4, 1987.
5. Preoperative Medical Evaluation of the Heart Transplant Candidate, Seventh Annual Cardiovascular Symposium of North Central Ohio, Mansfield General Hospital, Mansfield, Ohio. November 12, 1987.
6. Magnesium Relaxes Isolated Porcine Coronary Arteries by Calcium Blockade, American Heart Association Annual Meeting, Anaheim, California. November 17, 1987.
7. Hemodynamics at Rest and during Supine Bicycle Exercise in Cyclosporine Treated Orthotopic Heart Transplant Recipients, Annual Meeting of the American Federation for Clinical Research, Washington, DC. April 19, 1988.
8. Atrial Natriuretic Peptide Pre and Post Supine Bicycle Exercise in Orthotopic Heart Transplant Recipients, Annual Meeting of the American Federation for Clinical Research, Washington, DC. May 2, 1988.
9. Hemodynamics at Rest and during Supine Bicycle Exercise in Cyclosporine Treated Orthotopic Heart Transplant Recipients, The Ninth Annual Research Day Poster Presentations, American Heart Association Central Ohio Chapter. May 13, 1988.
10. Exercise Hemodynamics in Cardiac Transplant Recipients, Cardiology Research Conference, The Ohio State University Hospitals, Columbus, Ohio. September 1, 1988.
11. Disparity between Improvement in Left Ventricular Function and Changes in Clinical Status and Exercise Capacity during Chronic Inotropic Therapy, Annual Meeting of the Association of University Cardiologists, Carmel, California. January 19-20, 1989.
12. Preserved Atrial Natriuretic Peptide Secretory Function in Denervated Cardiac Transplant Recipients, American College of Cardiology Annual Meeting, Anaheim, California. March 23, 1989.

13. Endomyocardial Biopsy and the Assessment of Global Histologic Changes in Dilated Cardiomyopathy, Annual Landacre Day Scientific Session, Columbus, Ohio. April 13, 1989.
14. Results of Cardiac Transplantation in Active Myocarditis, International Society of Heart Transplantation, Munich, Germany. April 25, 1989.
15. ATP and Total Adenine Nucleotide Depletion in Failing Human Myocardium, International Society for Heart Research Annual Meeting, Ann Arbor, Michigan. May 1989.
16. Cardiac Transplant Program Research at The Ohio State University Hospitals, American Heart Association Affiliate Office, Columbus, Ohio. April 1989.
17. Cold Preservation, Adenine Nucleotide Content and Cardiac Performance after Heart Transplantation, American Heart Association Conference on Myocardial Cell Viability, New Mexico. July 1989.
18. Selection of Patients for Cardiac Transplantation, Medical Grand Rounds, The Ohio State University, Columbus, Ohio. July 27, 1989.
19. Preoperative Assessment of Candidates for Cardiac Transplantation, Medical Grand Rounds, Marshall University School of Medicine, Huntington, West Virginia. October 31, 1989.
20. Progressive Left Ventricular Hypertrophy in Cardiac Transplant Recipients, American Heart Association 62nd Scientific Sessions, New Orleans, Louisiana. November 15, 1989.
21. Medical Complications Following Cardiac Transplantation, Medical Grand Rounds, West Virginia University School of Medicine, Charleston, West Virginia. March 6, 1990.
22. Endomyocardial Biopsy Derived High Energy Phosphates: Pre-operative Studies in Heart Failure and Cardiac Transplantation, Division of Cardiology Research Conference, University of Utah, Salt Lake City, Utah. March 15, 1990.
23. Decreased Myocardial Utilization of Radio Labeled Fatty Acid in Cardiac Allograft Rejection, Annual Meeting of the American College of Cardiology. March 19, 1990.
24. Cold Preservation, Adenine Nucleotide Content and Cardiac Performance after Heart Transplantation, International Society for Heart Transplantation, Fort Lauderdale, Florida. April 5-7, 1990.
25. Pre-operative Assessment and Post-operative Care of the Cardiac Transplant Recipient, Medical Grand Rounds, Riverside Methodist Hospital, Columbus, Ohio. April 24, 1990.
26. Progress Report: Coronary Phenotypic Modulation after Cardiac Transplant, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. April 30, 1990.
27. Exercise Performance and Pressure Volume Relationships after Cardiac Transplantation, Annual Meeting of the American Federation for Clinical Research, Washington, DC. May 6, 1990.
28. Effect of Recipient Atrial Contraction Timing on Left Ventricular Filling in Transplanted Hearts, Annual Meeting for the American Federation for Clinical Research, Washington, DC. May 6, 1990.
29. Cardiac Transplantation 1990, Medical Grand Rounds, Veterans Administration Medical Center, Chillicothe, Ohio. May 16, 1990.
30. Progressive Myocardial Interstitial Fibrosis: The Consequence of Long-standing Dilated Cardiomyopathy, Midwest Section Meeting of American Federation for Clinical Research, Chicago, Illinois. November 2, 1990.
31. Application of Endomyocardial Biopsy in the Evaluation of Heart Disease, Good Samaritan Hospital, Wright State

University Medical School, Dayton, Ohio. November 20, 1990.

32. Empiric Antibiotic Selection by Physicians: Selection of Reasoning Strategies in a Prospective Study, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy 1990, No. 638, Atlanta, Georgia.
33. Cardiomyopathy, Logan County Cardiac Symposium, American Heart Association, Ohio Affiliate, Bellefontaine, Ohio. February 21, 1991.
34. Cardiac Transplantation, Logan County Cardiac Symposium, American Heart Association, Ohio Affiliate, Bellefontaine, Ohio. February 21, 1991.
35. OKT3 for Heart Transplants, Sixth Annual Professional Meeting, Ohio Solid Organ Consortium, Columbus, Ohio. February 23, 1991.
36. Selection of Candidates for Heart Transplantation, Scioto County Medical Society, Portsmouth, Ohio. March 12, 1991.
37. Heart Transplantation: Protocols and Accomplishments, Medical Grand Rounds, Grant Medical Center, Columbus, Ohio. March 19, 1991.
38. Exercise Performance and Pressure Volume Relationships after Cardiac Transplantation, Annual Scientific Meeting of the International Society of Heart Transplantation, Paris, France. April 9, 1991.
39. Role of Cardiac Transplantation for Intractable Congestive Heart Failure, Congestive Heart Failure Symposium, University of Pittsburgh Medical Center Continuing Medical Education, Pittsburgh, Pennsylvania. October 5, 1991.
40. Progress Report: Coronary Phenotypic Modulation after Cardiac Transplant, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. October 24, 1991.
41. Myocarditis Treatment Trial Investigators, Incidence and Clinical Characteristics of Myocarditis, American Heart Association Annual Meeting, Anaheim, California. November 12, 1991.
42. Reversible Functional and Biochemical Changes in the Human Donor Heart, American Heart Association Annual Meeting, Anaheim, California. November 17, 1991.
43. Acute Rejection after Cardiac Transplantation: A Multi-institutional Analysis, Twelfth Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, San Diego, California. April 2-4, 1992.
44. Infection Following Cardiac Transplantation: A Multi-institutional Analysis, Twelfth Annual Meeting and Scientific Sessions International of the Society for Heart and Lung Transplantation, San Diego, California. April 2-4, 1992.
45. Risk Factors for Death after Cardiac Transplantation: A Multi-institutional Study, Twelfth Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, San Diego, California. April 2-4, 1992.
46. Current Status of Cardiac Transplantation, 41st Annual American Heart Association G. Howard Wood Cardiac Symposium, Chillicothe, Ohio. April 9, 1992.
47. Hemodynamics, Renal Function and Allograft Coronary Disease in Cardiac Transplant Patient's Immunosuppressed with FK-506, American College of Cardiology 41st Annual Scientific Session, Dallas, Texas. April 12-16, 1992.
48. Histologic Assessment of Dilated Cardiomyopathy: Limitations of Right Ventricular Endomyocardial Biopsy, American College of Cardiology 41st Annual Scientific Session, Dallas, Texas. April 12-16, 1992.

49. Lack of Correlation between Ejection Fraction and Myocardial ATP in Cardiomyopathy, American College of Cardiology 41st Annual Scientific Session, Dallas, Texas. April 12-16, 1992.
50. Multicenter Randomized Trial of Epoprostenol in Patients with Severe Heart Failure, American College of Cardiology 41st Annual Scientific Session, Dallas, Texas. April 12-16, 1992.
51. Cardiac Transplantation: Update for 1992, Internal Medicine Grand Rounds, Mount Carmel Medical Center, Columbus, Ohio. April 23, 1992.
52. Selection of Cardiac Transplant Recipients and Post-op Care, Riverside Methodist Hospital Department of Medicine Conference, Columbus, Ohio. May 4, 1992.
53. Update of Cardiovascular Pharmacology: Panel Discussant, The Ohio State University College of Medicine, Columbus, Ohio. June 12, 1992.
54. Cardiac Transplantation: Review and Ohio State Update, Medical Grand Rounds, The Ohio State University Department of Internal Medicine, Columbus, Ohio. June 18, 1992.
55. Hypertensive Left Ventricular Dysfunction, Mansfield General Hospital, Mansfield, Ohio. September 1, 1992.
56. Cardiac Manifestations of Systemic Hypertension: Pathology and Treatment Implications, Ohio Valley Medical Center Cardiology Conference, Wheeling, West Virginia. September 28, 1992.
57. Cardiomyopathy: Prognosis and Therapeutic Advances, The Ohio State University College of Medicine Cardiology Update 1992, Columbus, Ohio. October 9, 1992.
58. Left Atrial Volume and Function in Orthotopic Heart Transplantation, American Heart Association Annual Meeting, New Orleans, Louisiana. November 12, 1992.
59. Heart Failure and Contractility: Measurement and Management of Myocardial Contractility, Department of Anesthesiology, The Ohio State University College of Medicine Continuing Medical Education, Columbus, Ohio. December 7, 1992.
60. Cardiac Transplantation, Mount Carmel East Medical Center, Columbus, Ohio. January 20, 1993.
61. Selection of Candidates for Heart Transplantation, Department of Medicine Grand Rounds, Chillicothe Veterans Administration Medical Center, Chillicothe, Ohio. February 23, 1993.
62. Meet the Experts Session, Myocarditis, Diagnostic and Therapeutic Advances, American College of Cardiology 42nd Annual Scientific Session, Anaheim, California. March 17, 1993.
63. Congestive Heart Failure: Therapeutic Options in 1993, Medical Grand Rounds, Shadyside Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. March 19, 1993.
64. Persistence of Abnormal Regulation of Blood Pressure Early after Cardiac Transplantation: Examination of Short and Long term Control Mechanisms, 36th Annual Landacre Day Scientific Session and Lecture, Columbus, Ohio. April 8, 1993.
65. Indications and Results for Cardiac Transplantation, Timken-Mercy Medical Center Grand Rounds, Canton, Ohio. April 18, 1993.
66. Update on Myocarditis, Department of Medicine Conference, Chillicothe Veterans Administration Medical Center, Chillicothe, Ohio. May 19, 1993.
67. Recent Advances in the Management of Heart Transplant Recipients, Ohio Valley Medical Center; Wheeling, West Virginia. May 26, 1993.

68. Treatment of the Complex Medical Patient with Hypertension, Cardiology Fellows Conference, University of Pittsburgh and Medical College of Pennsylvania, Pittsburgh, Pennsylvania. July 10, 1993.
69. Update on Myocarditis, Wright State University School of Medicine, Good Samaritan Hospital Cardiology Grand Rounds, Dayton, Ohio. September 29, 1993.
70. Management of Congestive Heart Failure, Dover General Hospital Grand Rounds, Dover, Ohio. October 20, 1993.
71. Cardiac Transplantation 1994, Toledo Hospital Cardiology Grand Rounds, Toledo, Ohio. March 2, 1994.
72. Selection and Management of Cardiac Transplant Recipients, Miami Valley Hospital Medical Grand Rounds, Dayton, Ohio. June 1, 1994.
73. A Prospective Study of Coronary Arterioles in Human Transplanted Hearts Examined with Quantitative Morphometric Analysis and Immunocytochemical Labeling, American Federation for Clinical Research Midwest Meeting, Chicago, Illinois. September 16, 1994.
74. Quantitative Morphometric Analysis of Coronary Arterioles in Human Transplanted Hearts, American Federation for Clinical Research Midwest Meeting, Chicago, Illinois. September 16, 1994.
75. Contrasting Patterns of Heart Rate and Blood Pressure Variability in Congestive Heart Failure: Evidence for Abnormal Oscillatory Blood Pressure Control in the Setting of Ventricular Dysfunction, American Heart Association Annual Meeting, Dallas, Texas. November 16, 1994.
76. Restoration of Diurnal Blood Pressure Variability after Cardiac Transplantation, American Heart Association Annual Meeting, Dallas, Texas. November 16, 1994.
77. Morphometric and Immunocytochemical Analysis of Coronary Arterioles in Human Transplanted Hearts, First International Symposium on Transplant Vascular Sclerosis, Bermuda, Bahamas. March 1, 1995.
78. Morphometric and Immunocytochemical Analysis of Coronary Arterioles in Human Transplanted Hearts, American Society of Transplant Physicians Annual Meeting, Chicago, Illinois. May 16, 1995.
79. The Epidemic and Economics of Heart Failure: How Can We Handle the Challenge? Heart Failure Summit, Anaheim, California. November 12, 1995.
80. Congestive Heart Failure, Cleveland Clinic Westlake Public Seminar Program, Westlake, Ohio. March 6, 1996.
81. Simplified Assessment of Pulmonary Hypertension in Heart Transplant Candidates, American College of Cardiology 45th Annual Scientific Session, Anaheim, California. March 25, 1996.
82. Update on Cardiac Transplantation, Cleveland Clinic Foundation Cardiology Grand Rounds, Cleveland, Ohio. April 12, 1996.
83. Treatment Options for End Stage Heart Failure: Transplantation and Permanent Left Ventricular Assist Devices, Riverside Methodist Hospital Grand Rounds, Columbus, Ohio. May 21, 1996.
84. Maturation of Heart Transplantation in Ohio: Evolving Outcomes and Changing Economics, American Society of Transplant Physicians, Dallas, Texas. May 27-30, 1996.
85. Advances in the Management of Congestive Heart Failure, Sixth Annual Cardiovascular Conference, Deaconess Hospital, Cleveland, Ohio. September 11, 1996.
86. Ventricular Remodeling Surgery: The U.S. Experience, Cleveland Clinic Foundation Heart Failure Summit II, Cleveland, Ohio. October 11-2, 1996.

87. Initial Experience and Short Term Results with Partial Left Ventricular Resection, UNOS Regional Meeting, Tampa, Florida. November 8, 1996.
88. The Batista Procedure: Indications and Current Results, The Working Group of Transplant Cardiologists and the Cardiac Transplant Research Database, Ochsner Medical Center, New Orleans, Louisiana. November 9, 1996.
89. A Novel Medical and Surgical Approach for Refractory Heart Failure: The Batista Procedure, NHLBI Research Conference, Department of Health and Human Services, Bethesda, Maryland. January 8, 1997.
90. The Cleveland Clinic Experience with Partial Left Ventricular Resection, University of Cincinnati Cardiology Grand Rounds, Cincinnati, Ohio. January 21, 1997.
91. Partial Left Ventriculotomy with Mitral Valve Repair, Society of Thoracic Surgeons 33rd Annual Meeting, San Diego, California. February 3, 1997 (video).
92. Partial Left Ventriculotomy for Dilated Cardiomyopathy, University of California, San Diego Annual Internal Medicine Review Course, San Diego, California. February 17, 1997.
93. Surgical Alternatives for End Stage Heart Failure, ASTP Consensus Conference on Listing Criteria for Heart Transplantation, NHLBI, Bethesda, Maryland. February 20, 1997.
94. Outpatient Strategies for the Treatment of Congestive Heart Failure, University of Southern California Heart Failure Symposium, Pasadena, California. March 1, 1997.
95. Partial Left Ventriculectomy: The Cleveland Clinic Experience, University of Southern California Congestive Heart Failure Symposium, Pasadena, California. March 1, 1997.
96. Preliminary Results with Partial Left Ventriculectomy, American College of Cardiology 46th Annual Scientific Session Press Conference, Anaheim, California. March 17, 1997.
97. Patient Selection for Ventricular Remodeling Surgery: Evolving Criteria and Outcomes, American College of Cardiology 46th Annual Scientific Session, Anaheim, California, March 18, 1997.
98. Patient Selection for Mechanical Support: Case Presentation, Novacor Investigators U.S. Meeting, San Francisco, California. April 25, 1997.
99. Left Ventricular Remodeling (Batista) Procedure, Surgical Approaches to Chronic Heart Failure Symposium, National Institutes of Health Continuing Medical Education, Tucson, Arizona. May 1, 1997.
100. Cardiac Transplantation and Alternative Strategies, Good Samaritan Hospital, Dayton, Ohio. June 11, 1997.
101. The Batista Procedure: The CCF Experience, University of Oregon Division of Cardiology, Portland, Oregon. June 24, 1997.
102. Grand Rounds Presentation, Rush Presbyterian / St. Luke's Medical Center Department of Cardiology, Chicago, Illinois. July 14, 1997.
103. An Integrated Service Approach to Heart Failure Management: Partial Left Ventriculectomy: Background and Patient Selection, Cleveland Clinic Heart Center Heart Failure Summit III, Cleveland, Ohio. September 4-5, 1997.
104. Partial Left Ventriculectomy: Background and Patient Selection, Advances in Cardiac Surgery, Tampa General Hospital, Tampa, Florida. February 7, 1998.
105. The Batista Procedure, Heart Failure: Success I, The Outpatient Experience, Botsford General Hospital, Farmington Hills, Michigan. February 25, 1998.

106. Surgical Options in Heart Failure, Eighteenth Annual Dimensions in Cardiac Care, Cleveland Clinic Foundation, Cleveland, Ohio. March 1, 1998.
107. Partial Left Ventriculectomy: A Viable Alternative to Cardiac Transplant, 34th Annual Robert M. Jeresaty, M.D. Cardiovascular Symposium, Hartford, Connecticut. May 6, 1998.
108. Approaches to the High Risk Renal Patient Undergoing Heart Transplantation, Evening Symposia, Intensive Care Issues in Post-Transplant Care for Heart and Lung Recipients, 17th Annual Scientific Meeting American Society of Transplant Physicians. May 12, 1998.
109. The Role of Cardiac Remodeling Surgery in Heart Failure, Workshop: Managing the End-Stage Patients, including Surgical Options, American College of Cardiology Annual Heart Failure Summit Symposium, Toronto, Ontario, Canada. June 12-13, 1998.
110. The Role of Coronary Revascularization in Heart Failure Management, Workshop: Managing the End-Stage Patients, including Surgical Options, American College of Cardiology Annual Heart Failure Summit Symposium, Toronto, Ontario, Canada. June 12-13, 1998.
111. Late Results of the Left Ventricular Volume Reduction. Left Ventricle Volume Reduction: The Batista Operation, Montesilvano, Pescara, Italy. June 25-26, 1998.
112. Update on Heart Transplantation, Cleveland Clinic Foundation Medical Grand Rounds, Cleveland, Ohio. July 9, 1998.
113. Best Heart Failure Treatment Strategies: An Analysis of Current Practice Guidelines. Attacking Heart Failure: Strategies to Improve Patient Care and Reduce Morbidity, Cleveland Clinic Health System Quality Institute, Cleveland, Ohio. September 9, 1998.
114. Current Status of the Batista Procedure, Heart Failure Society of America Second Annual Meeting, Boca Raton, Florida. September 14, 1998.
115. Latest Insight into the Pathophysiology of Heart Failure, Cleveland Clinic Foundation Heart Center Heart Failure Summit III, Cleveland, Ohio. October 9, 1998.
116. Left Ventricular Reduction, Plenary Session X at American Heart Association 71st Annual Scientific Session, Dallas, Texas. November 11, 1998.
117. Contemporary Management of Congestive Heart Failure, Maximizing Cardiovascular Risk Factor Reduction, The Cleveland Clinic Foundation, Cleveland, Ohio. December 5, 1998.
118. Management of the Sensitized Cardiac Transplant Patient, Ohio State University Transplant Program Research Conference, Columbus, Ohio. January 20, 1999.
119. Volume Reduction Surgery, Symposium: Progress in Non pharmacologic Approaches to the Management of Heart Failure, American College of Cardiology 48th Annual Scientific Session, New Orleans, Louisiana. March 7, 1999.
120. Immunosuppressive Agents in the Management of Heart Transplant Patients: Beyond Cyclosporine, Azathioprine and Steroids, Nineteenth Annual Dimensions of Cardiac Care, Cleveland Clinic Foundation, Cleveland, Ohio. March 14, 1999.
121. Surgical Therapy for Heart Failure: What are the Options? Cardiology Grand Rounds, Vanderbilt University, Nashville, Tennessee. March 24, 1999.
122. Diagnostic Evaluation of Heart Failure, Abiomed Chief Resident Symposium: New Treatment Modalities in Heart Failure, New Orleans, Louisiana. April 16, 1999.

123. Surgical Alternatives for Advanced Heart Failure, Managing Outcomes in Heart Failure, Inova Fairfax Hospital Department of Medicine, Section of Cardiology, Fairfax, Virginia. May 12, 1999.
124. Partial Left Ventriculectomy: The Facts and the Future, American College of Cardiology Second Toronto International Heart Failure Summit, Toronto, Ontario, Canada. June 12, 1999.
125. Ventricular Restoration for Ischemic Heart Disease, American College of Cardiology Second Toronto International Heart Failure Summit, Toronto, Ontario, Canada. June 12, 1999.
126. Session Moderator: Heart Failure in Perspective - Epidemiology, Economics, Physiology and Treatment Overview, Cleveland Clinic Foundation Heart Failure Summit V, Cleveland, Ohio. October 1, 1999.
127. Chronic Heart Failure Management, New Approaches to Heart Failure: Medical and Surgical Left Ventricular Remodeling, Scientific Council of the Center for Cardiothoracic Surgery of Monaco, Monte Carlo, Monaco. November 5, 1999.
128. Left Ventricular Volume Reduction: The Cleveland Clinic Experience, New Approaches to Heart Failure: Medical and Surgical Left Ventricular Remodeling, Scientific Council of the Center for Cardiothoracic Surgery of Monaco, Monte Carlo, Monaco. November 5, 1999.
129. Surgical Therapy for Advanced Heart Failure, Second Cardiology Congress of Central Greece, Larissa, Greece. December 5, 1999.
130. Diagnostic Evaluation of Heart Failure, Abiomed Chief Residents Symposium: New Treatment Modalities in Heart Failure II, Fort Lauderdale, Florida. January 29, 2000.
131. Does End-Stage Heart Failure Really Exist? Perspectives on Reverse Remodeling, Heart Failure 2000: Tackling Heart Failure in the New Millennium, New Orleans, Louisiana. February 12, 2000.
132. Luncheon Panel: End-Stage Congestive Heart Failure: Newer Options, American College of Cardiology 49th Annual Scientific Session, Anaheim, California. March 13, 2000.
133. How to Minimize the Risk of Heart Failure Following Myocardial Infarction, Turkish Society of Cardiology, Gaziantep, Turkey. April 2000.
134. New Approaches in the Treatment of Heart Failure, Turkish Society of Cardiology, Kayseri, Turkey. April 2000.
135. Diastolic Heart Failure, Turkish Society of Cardiology, Adana, Turkey. April 2000.
136. Indications for Heart Transplantation and the Management of Patients Awaiting Transplantation Practice of Evidence-Based Cardiology for the Clinician, McMaster University, Hamilton, Ontario, Canada. April 29, 2000.
137. Medical Therapy of Acute Severe Heart Failure, Practice of Evidence-Based Cardiology for the Clinician, McMaster University, Hamilton, Ontario, Canada. April 29, 2000.
138. Course Moderator, Mechanical Circulatory Support: A Viable Heart Failure Therapy American College of Cardiology International Heart Failure Summit Satellite Symposium, Toronto, Ontario, Canada. June 8, 2000.
139. Role of LVADs: A Cardiologist's Perspective. Mechanical Circulatory Support: A Viable Heart Failure Therapy, American College of Cardiology International Heart Failure Summit Satellite Symposium, Toronto, Ontario, Canada. June 8, 2000.
140. Managing the End-Stage Patient, Including Surgical Options, American College of Cardiology Heart Failure Summit Millennium Symposium: From Pathophysiology to Clinical Practice, Toronto, Ontario, Canada. June 9, 2000.
141. Partial Left Ventriculectomy and Mitral Valve Surgery for Heart Failure: The Facts and Future, American College

- of Cardiology Heart Failure Summit Millennium Symposium: From Pathophysiology to Clinical Practice, Toronto, Ontario, Canada. June 10, 2000.
142. Ventricular Restoration for Ischemic Heart Disease, American College of Cardiology Heart Failure Summit Millennium Symposium: From Pathophysiology to Clinical Practice, Toronto, Ontario, Canada. June 10, 2000.
 143. Device Based Left Ventricular Shape Change Immediately Improves Ventricular Function in a Canine Heart Failure Model, Poster Presentation, Heart Failure 2000 Meeting, Venice, Italy. July 1, 2000.
 144. Surgical Left Ventricular Reconstruction and Medical Therapy Optimizes Clinical Outcomes after Anterior Myocardial Infarction, Abstract Presentation, Fourth Annual Scientific Meeting, Heart Failure Society of America, Boca Raton, Florida. September 11, 2000.
 145. Assessing Left Ventricular Reduction Surgery: From Batista to Dor, 12th Annual Symposium, Transcatheter Cardiovascular Therapeutics, Washington, DC. October 20, 2000.
 146. Co-Chair of Symposia: New Therapies for Heart Failure: Non pharmacological Approaches, 50th Annual Scientific Session, American College of Cardiology, Orlando, Florida. March 19, 2001.
 147. Immunosuppressive Protocols and Drug Monitoring: Defend or Deny? 21st Annual Meeting and Scientific Session, International Society for Heart and Lung Transplantation, Vancouver, Canada. April 26, 2001.
 148. Systolic Heart Failure: Medical Management, Abiomed 2001 Chief Residents' Symposium, San Diego, California. May 5, 2001.
 149. New Options for the Treatment of Heart Failure, Cardiology Grand Rounds, Temple University School of Medicine, Philadelphia, Pennsylvania. May 18, 2001.
 150. Medical and Surgical Remodeling Therapies for the Heart Failure Patient, Cardiology Grand Rounds, University of Michigan Health System, Ann Arbor, Michigan. May 22, 2001.
 151. Acute Cardiomyopathy: Diagnosis and Treatment, New Trends in Cardiology, Thessaloniki, Greece. June 16, 2001.
 152. Cardiac Transplantation, New Trends in Cardiology, Thessaloniki, Greece. June 17, 2001.
 153. Ventricular Restoration for Ischemic Heart Disease, Fourth Toronto International Heart Failure Summit: From Pathophysiology to Clinical Practice at the Turn of the Millennium. July 6, 2001.
 154. The "Bad Pump": Medical Treatment, An Intensive Review of Cardiology, Cleveland Clinic Foundation Department of Cardiology, Cleveland, Ohio. October 9, 2001.
 155. Heart Failure Therapies in Special Populations, American Heart Association Scientific Sessions 2001, Anaheim, California. November 12, 2001.
 156. Sudden Cardiac Death, Heart Failure Death: Prognostic Factors, Guidant Intensive Heart Failure Program, Cleveland Clinic Foundation, Cleveland, Ohio. November 27, 2001.
 157. Management of Chronic Heart Failure, Internal Medicine Grand Rounds, Cleveland Clinic Foundation, Cleveland, Ohio. January 17, 2002.
 158. Sudden Cardiac Death, Heart Failure Death: Prognostic Factors, Guidant Intensive Heart Failure Program, Cleveland Clinic Foundation, Cleveland, Ohio. January 24, 2002.
 159. Heart Failure Trials: Perspective, Turkish Preceptorship Program, Cleveland Clinic Foundation, Cleveland, Ohio. February 6, 2002.

160. Batista Procedure: Lessons Learned and Future Implications, International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Session, Washington, DC. April 12, 2002.
161. Heart Failure: New Devices and Medicines, Advanced Preceptorship in Cardiovascular Medicine: Exploring Cardiology in the Heart of Cleveland, Cleveland Clinic Foundation, Cleveland, Ohio. May 31, 2002.
162. Modern Concepts in Heart Failure: Etiology, Pathophysiology and Recent Guidelines for Diagnosis and Treatment of Heart Failure Patients, Grand Rounds, Meridia South Pointe Hospital, Warrensville Heights, Ohio. September 10, 2002.
163. Modern Concepts in Heart Failure: Etiology, Pathophysiology and Recent Guidelines for Diagnosis and Treatment of Heart Failure Patients, Grand Rounds, Marymount Hospital, Garfield Heights, Ohio. September 18, 2002.
164. Presentation and Outcomes of Acute Heart Failure, Sixth Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, Florida. September 24, 2002.
165. Medical Treatment of Heart Failure, An Intensive Review of Cardiology, Cleveland Clinic Foundation Department of Cardiovascular Medicine, Cleveland, Ohio. September 26, 2002.
166. Surgical Alternatives for End Stage Heart Disease, University of Pittsburgh Medical Center Grand Rounds, Pittsburgh, Pennsylvania. October 1, 2002.
167. Modern Concepts in Heart Failure: Etiology, Pathophysiology and Recent Guidelines for Diagnosis and Treatment of Heart Failure Patients, Grand Rounds, Meridia Hillcrest Hospital, Mayfield Heights, Ohio. October 23, 2002.
168. Baseline Data and Patient Characteristics of Acorn Clinical Trial, Acorn Cardiovascular Fall Investigators Meeting, New York, New York. October 24, 2002.
169. Current Status of Outcomes for Heart Transplantation, Allianz LifeTrac Medical Management Conference, Minneapolis, Minnesota. November 11, 2002.
170. Beta Blocker Therapy for Heart Failure: Current Practice Guidelines, GlaxoSmithKline Visiting Faculty Talk, South Bend, Indiana. February 11, 2003.
171. Beta Blocker Therapy for Heart Failure: Current Practice Guidelines, Grand Rounds, Memorial Hospital of South Bend, South Bend, Indiana. February 12, 2003.
172. Hemodynamics of Acute Decompensated Heart Failure APE, Cleveland Clinic / Unitech Roundtable Meeting, Paradise Island, Bahamas. February 23, 2003.
173. Donor Intracranial Bleeding is Associated with Advanced Transplant Coronary Vasculopathy: Evidence From Intracranial Ultrasound, Presentation at International Society for Heart and Lung Transplantation, Vienna, Austria. April 10, 2003.
174. Transplant Coronary Artery Disease: Intravascular Ultrasound, Surrogate Markers and Treatment, Lunch Symposium Presentation at International Society for Heart and Lung Transplantation, Vienna, Austria. April 10, 2003.
175. Everolimus Dose Recommendation in De Novo Heart Transplantation – (RAD253) TDM Simulations, Presentation at International Society of Heart and Lung Transplantation, Vienna, Austria. April 11, 2003.
176. Donor Intracranial Bleeding is Associated with Upregulation of the Angiotensin Receptor, Presentation at International Society of Heart and Lung Transplantation, Vienna, Austria. April 12, 2003.
177. Efficacy and Safety of Daclizumab with Background Immunosuppressive Regimen in Primary Cardiac Recipients: 12 Month Analysis, Late Breaking Clinical Trial Presentation at International Society of Heart and Lung

- Transplantation, Vienna, Austria. April 12, 2003.
178. Natrecor: A Cardiologist's Perspective, Presentation at 2003 Scios National Sales Meeting, Palm Springs, California. April 28, 2003.
 179. Ventricular Restoration for Ischemic Heart Disease, Sixth Toronto International Heart Failure Summit / American College of Cardiology Extramural Program, Toronto, Ontario. June 12, 2003.
 180. The Use of Rapamycin in Cardiac Transplantation, Presentation for Novartis Pharmaceuticals Corporation, Cleveland, Ohio. September 18, 2003.
 181. Advances and Current Expectations for Medical Treatment, Heart Failure Society of America Satellite Symposium, Las Vegas, Nevada. September 21, 2003.
 182. Clinical Experience with Cardiac Support Devices, Heart Failure Society of America Satellite Symposium, Las Vegas, Nevada. September 23, 2003.
 183. Surgical Approaches to Achieve Reverse Remodeling, Heart Failure Society of America Symposium, Las Vegas, Nevada. September 23, 2003.
 184. Medical Treatment of Heart Failure, Cleveland Clinic Foundation Department of Cardiovascular Medicine Intensive Review of Cardiology, Cleveland, Ohio. September 25, 2003.
 185. Everolimus for Cardiac Transplantation, The Cleveland Clinic Foundation, Department of Cardiovascular Medicine Noon Conference, Cleveland, Ohio. September 29, 2003.
 186. Handling of Acute Insufficiency Cardiac, Presentation at XL Congreso Chileno de Cardiología y Cirugía Cardiovascular, Vina del Mar, Chile. December 9, 2003.
 187. Co-Chair: Scientific Symposium, Integrated Approach to Device Therapy for Congestive Heart Failure, 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana. March 7-10, 2004.
 188. Co-Chair: Scientific Sessions, Immunosuppression in Cardiac Transplantation, The Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Boston, Massachusetts. May 16, 2004.
 189. Lecture: "Surgical Therapies for Heart Failure," Division Grand Rounds, Henry Ford Hospital, Detroit, Michigan. July 26-27, 2004.
 190. Lecture: New Strategies for Cardiac Allograft Vasculopathy, Henry Ford Hospital, Detroit, Michigan. July 26-27, 2004.
 191. Cardiac Allograft Vasculopathy, Intravascular Ultrasound and mTOR Inhibitors in Heart Transplantation, University of Alabama Hospital, Cardiology Grand Rounds/LHRB 302, Reeves Conference Room, Birmingham, Alabama. September 21-22, 2004.
 192. Growing Interaction between Heart Failure and EP, Colorado EP Society, Saint Regis Hotel, Aspen, Colorado. October 1-3, 2004.
 193. Meet the Experts' Panel Discussion: A Patient with Refractory Heart Failure with CAD, LV Dysfunction and $\frac{3}{4}$ MR, Raffles City Convention Centre, Singapore. January 7-13, 2005.
 194. Meet the Experts' Panel Discussion: A Patient with Refractory Heart Failure with Significant Mitral and Aortic Valve Disease, Raffles City Convention Centre, Singapore. January 7-13, 2005.
 195. The Heart Failure Spectrum – Current Concepts and Therapeutic Implications, Raffles City Convention Centre, Singapore. January 7-13, 2005.

196. Focus Session, One of the Panel Experts: How to use Beta-Blockers in Heart Failure, Raffles City Convention Centre, Singapore. January 7-13, 2005.
197. Natrecor Asia Pacific Expert Forum, Raffles City Convention Centre, Singapore. January 7-13, 2005.
198. Natriuretic Peptides for Heart Failure, Raffles City Convention Centre, Singapore. January 7-13, 2005.
199. Restraining Devices and Surgical Alternatives, Raffles City Convention Centre, Singapore. January 7-13, 2005.
200. Who is an Appropriate Candidate for Destination Left Ventricular Assist Device Therapy? American College of Cardiology Annual Scientific Session 2005, Orlando, Florida. March 6-9, 2005.
201. Lecture: The Rationale and Results for Cardiac Support Devices for Heart Failure Therapy, Cleveland Clinic Weston, Cardiac Care for the New Millennium, Weston, Florida. April 3-4, 2005.
202. Lecture: Update on Medical Therapies for Heart Failure, Cleveland Clinic Weston, Cardiac Care for the New Millennium, Weston, Florida. April 3-4, 2005.
203. Co-Chair: Satellite Symposium, Cutting Edge Concepts in Heart Transplantation, 25th Anniversary Meeting of the International Society for Heart and Lung Transplantation (ISHLT), Philadelphia, Pennsylvania. April 6, 2005.
204. The Future Role of Pathologists in Cardiac Transplantation: Can We Meet the Clinician's Needs? The Eighth Banff Conference on Allograft Pathology, Westin Hotel. Edmonton, Albert Canada. July 19, 2005.
205. Welcome and Introduction, 9th Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, Florida. September 18, 2005.
206. Advanced Heart Failure: Is there a Need for Mechanical Circulatory Support Devices? Satellite Symposium: The Role of Mechanical Circulatory Support Devices (MCSA) in Advanced Heart Failure, 9th Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, Florida. September 18, 2005.
207. Diastolic Heart Failure, Heart Failure Update: Advances in Medical, Surgical and Device Therapies, Loyola University Chicago. October 15, 2005.
208. Emerging Therapies for Advanced Heart Failure, International Preceptorship Program, Department of Cardiovascular Medicine, Cleveland Clinic Foundation. October 17, 2005.
209. Surgical Therapy for Ischemic Cardiomyopathy, 8th Conference of Cardiology, Central Greece. October 22, 2005.
210. Advanced Heart Failure: Treatment Options for Stage D Heart Failure, 8th Conference of Cardiology, Central Greece. October 22, 2005.
211. Prevalence and Medical Treatment of Ischemic CHF, Cardio-Thoracic Centre De Monaco. November 11, 2005.
212. Session Chair, Cleveland Clinic Heart Failure Summit 2005, Dallas, Texas. November 13, 2005.
213. An Integrated Medical/Surgical Approach to Heart Failure, Cleveland Clinic Heart Failure Summit 2005, Dallas, Texas. November 13, 2005.
214. Destination VAD: A Cardiologist's Perspective, First Annual Heart Failure Holiday Symposium, Northwestern Memorial Hospital, Chicago, Illinois. December 3, 2005.
215. Human Cardiac Restraining Devices for Heart Failure, First Annual Heart Failure Holiday Symposium, Northwestern Memorial Hospital, Chicago, Illinois. December 3, 2005.
216. Cardiac Resynchronization Therapy: Utility of Non-invasive Studies, XX Inter American Congress of Cardiology

XXIV National Congress of Cardiology, Cancun, Mexico. January 30, 2006.

217. When to Refer a Patient for Tertiary Care, Breakout Session Workshop, 5th Annual ABC's of Heart Failure: From Diagnosis to Prognosis, Cleveland Marriott East, Cleveland, Ohio. February 25, 2006.
218. Options for Stage D Heart Failure: Mechanical Circulatory Support Devices Present & Future, Dinner Lecture, Hyde Park Prime Steakhouse, Beachwood, Ohio. March 8, 2006.
219. Session Co-Chair, "Invasive Therapies for Chronic Heart Failure," American College of Cardiology 2006 Annual Scientific Sessions, Georgia World Congress Center, Atlanta, Georgia. March 12, 2006.
220. Ventricular Remodeling Treatments, American College of Cardiology 2006 Annual Scientific Sessions, Georgia World Congress Center, Atlanta, Georgia. March 13, 2006.
221. Evidence Based Management of Advanced Heart Failure Guidelines for 2006, Internal Medicine Grand Rounds, Visiting Professor, Gill Heart Institute, University of Kentucky. March 24, 2006.
222. Update of Cardiac Transplantation: Results and Innovations, Cardiovascular Seminar Series, Visiting Professor, Gill Heart Institute, University of Kentucky. March 24, 2006.
223. LVADs and RVADs – Bridges to Transplant and Recovery, and Destination Therapies for Stage D Heart Failure, Grand Rounds, Metrohealth Medical Center, Cleveland, Ohio. May 9, 2006.
224. Session Chair, "Devices XII: CRT: Outcomes for Heart Failure Therapy," Heart Rhythm Society's 27th Annual Scientific Sessions, Boston, Massachusetts. May 19, 2006.
225. Cardiac Transplantation, Cleveland Clinic Heart-Brain Summit, Cleveland, Ohio. June 17, 2006.
226. Devices for CHF, PDL BioPharma Cardiovascular Preceptorship, Cleveland Clinic, Intercontinental Hotel and Conference Center, Cleveland, Ohio. May 25, 2006.
227. How Do We Choose Patients For Device Therapy (CRT, LVAD and Cardiac Support Devices)? Heart Failure Society of America 10th Annual Meeting Satellite Symposium, Washington State Convention & Trade Center, Seattle, Washington. September 11, 2006.
228. Passive Cardiac Support, Heart Failure Society of America 10th Annual Meeting, Seattle, Washington. September 12, 2006.
229. Heart Failure Therapy, 7th Annual Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio. September 21, 2006.
230. Meet the Expert Session, 7th Annual Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio. September 21, 2006.
231. Transplantation and Mechanical Circulatory Support Devices for Cardiac Failure: Options and Outcomes for 2006, 9th Cardiology Congress of Central Greece, Larissa, Greece. October 7, 2006.
232. Cardiac Transplantation: Current Status and Future Directions," Grand Rounds, Temple University School of Medicine, Philadelphia, Pennsylvania. October 13, 2006.
233. Lecture: Implantable Hemodynamic Monitoring: Will It Play a Role? 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes, Cleveland, Ohio. October 20, 2006.
234. Session Moderator, "From Bench to Bedside: Innovations in Heart Failure Medicine," 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes, Cleveland, Ohio. October 20, 2006.
235. Welcome and Announcements, 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical

Therapies for Better Outcomes, Cleveland, Ohio. October 20, 2006.

236. Lecture: HELP! When to Call the Surgeon to the Coronary Care Unit, 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes, Cleveland, Ohio. October 21, 2006.
237. Lecture: “ACE-I Plus ARB vs. ACE-I Plus Aldosterone Antagonist?” American Heart Association Scientific Sessions, Chicago, Illinois. November 14, 2006.
238. Session Moderator, “Featured Research: Surgical Treatment of Heart Failure Transplantation,” American Heart Association Scientific Sessions, Chicago, Illinois. November 15, 2006.
239. Update on Outcomes and Clinical Research in Cardiac Transplantation, Heart Center Grand Rounds, Case Western Reserve University, Cleveland, Ohio. January 11, 2007.
240. Device Therapy in Heart Failure, ABCs of Heart Failure: From Diagnosis to Prognosis Conference, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. February 24, 2007.
241. Cardiac Transplantation: Invasive and Non-Invasive Surveillance Strategies, Transplant Grand Rounds, Johns Hopkins Comprehensive Transplant Center, Baltimore, Maryland. March 2, 2007.
242. Treatment Options for Advanced Heart Failure: Why Specialized Heart Failure Centers are Necessary, Cardiology Grand Rounds, Allegheny General Hospital, Pittsburgh, Pennsylvania. March 14, 2007.
243. I.) Co-Chair: Late Breaking Clinical Trials I; II) Moderator: Special Session: Lessons Learned from Katrina; III) Lecture: Dilated Cardiomyopathy and Mitral Regurgitation: When to Operate?; IV) Lecture: Guideline-Based Management from Stage A to Stage D; V) Co-Chair: ACC Special Sessions: Meeting Highlights, American College of Cardiology 56th Annual Scientific Session, New Orleans, Louisiana. March 25-27, 2007.
244. I) Chairman: Find and Fight Rejection; II) Lecture: Clinical Application of Peripheral Blood Gene Profiling in the Management of Heart Transplant Recipients, ISHLT 27th Annual Meeting and Scientific Sessions, San Francisco, California. April 24-29, 2007.
245. Advanced Heart Failure: When Standard Therapy Fails, 3rd Annual Dartmouth Conference on Advances in Heart Failure, Lebanon, New Hampshire. May 21, 2007.
246. Panel Discussion for “Ventricular Assist Devices,” 2007 HFSA Workshop: Regulatory Issues Surrounding Heart Failure Devices, Heart Failure Society of America, Bethesda, Maryland. May 31-June 1, 2007.
247. Moderator: Mechanical Circulatory Support in Heart Failure. Heart Failure Society of America 11th Annual Scientific Meeting, Washington, DC. September 16-19, 2007.
248. Co-Director, Moderator: Round Table, Year in Review 2007; Lecture: The Year in Heart Failure, 10th Cardiology Congress of Central Greece, Larissa, Greece. October 11-14, 2007.
249. Co-Director, Chairman: Contemporary Controversies in Heart Failure Management; Chairman: Innovative Medical and Device Therapies for Acute and Chronic HF MA, Cleveland Clinic Heart Failure Summit, Cleveland, Ohio. October 18-20, 2007.
250. Oral Presentation of Abstract 3002, Left Ventricular Diameter Predicts Recovery in Acute Cardiomyopathy: Results of the IMAC 2 Trial, Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida. November 3-7, 2007.
251. “Ask the Experts: Advanced Heart Failure,” American Heart Association Scientific Sessions, Orlando, Florida. November 7, 2007.
252. Chairman, Update in Heart Failure Electrical Treatment, Session VI: Alternative Treatments of Heart Failure – Leads and Devices, XIII World Congress on Cardiac Pacing and Electrophysiology, Rome, Italy. December 2-7,

2007.

253. "Update on Outcomes and Clinical Research in Cardiac Transplantation," Grand Rounds, Mayo Clinic Arizona, Phoenix, Arizona. December 21, 2007.
254. "Heart Failure," Palm Beach Heart Ball, American Heart Association, Palm Beach, Florida. February 12-14, 2008.
255. Program Co-Director, "Chronic/Acute Heart Failure Guidelines and Role of the Heart Failure Specialist in 2008," Heart Failure Fellows Summit, Miami Beach, Florida. February 16-17, 2008.
256. Lectures: I) "Stage "D" Refractory Heart Failure: Therapeutic Options"; II) "Acute HF: What's New?" III) "HF is a Reversible Disease: Therapies to Reverse and Remodel," Egyptian Cardiology Society Annual Meeting, Cairo, Egypt. February 26-29, 2008.
257. "Diastolic Heart Failure," Cardiac Symposium 2008, Cleveland Clinic Foundation, Cleveland, Ohio. March 9-11, 2008.
258. Co-Chairman, Difficult Decisions of End-Stage Heart Failure, American College of Cardiology 57th Annual Scientific Session, Chicago, Illinois. March 29-April 1, 2008.
259. Chairman, Closing Plenary Session; Chairman, Concurrent Session 41: Revelations about Rotary Pumps; Lecture: "Diagnostic and Prognostic Approaches to Cardiac Allograft Vasculopathy," International Society Heart and Lung Transplant. Boston, Massachusetts. April 7-13, 2008.
260. Lecture: "What are the Important Questions for a Heart Failure ICD/CRT Database to Address?" Lecture: "Disease Management for HF – Does It Work or Do We Need More Data?" Heart Rhythm Society, 29th Annual Scientific Sessions, San Francisco, California. May 15-17, 2008.
261. Randomized Clinical Trials (RCT's) in Heart Transplantation, Lecture: "What are the Most Important Trials for the Future?" American Transplant Congress, Sunrise Symposium, Toronto, Canada. May 31-June 4, 2008.
262. "Acute Heart Failure: State of the Art," Cardiology Grand Rounds, Cardiovascular Research Institute Washington Hospital Center, Washington, DC. September 16, 2008.
263. Lecture: "Clinical Decision Trees in Advanced Heart Failure: Should we Implant VADs "Earlier?" Moderator: Heart Failure Guidelines: Updates and Applications, Heart Failure Society of America, 12th Annual Scientific Meeting, Toronto, Ontario, Canada. September 21-24, 2008.
264. Lecture: "Acute Decompensated Heart Failure and the Cardiorenal Syndrome," Lecture: "Diastolic Heart Failure, Heart Failure with Preserved Ejection Fraction or Simply Heart Failure?" 1th Cardiology Congress of Central Greece, Athens, Greece. October 9-12, 2008.
265. 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes, Moderator: 21st Century Treatment of Heart Failure: Insights into Critical Medical and Surgical Issues; Moderator: Cardiac Remodeling: Does it Happen and is it Important? Lecture: Do Evidence Based Medications do anything?" Cleveland Clinic Foundation, Cleveland, Ohio. October 16-18, 2008.
266. Lecture: "How to Improve 30-Day Mortality After Heart Failure Hospitalization," American Heart Association, Scientific Sessions 2008, New Orleans, Louisiana. November 10, 2008.
267. Lecture: "Acute Decompensated Heart Failure: Epidemiology, Economics and Treatment," Huron Road Hospital, Primary Care Dinner, Beachwood, Ohio. December 4, 2008.
268. Lecture: "The Future of Clinical Trials in ADHF: Hopes, Challenges and Expectations;" Lecture: "End Stage Heart Failure: Mechanical Circulatory Support and Cardiac Transplant," American College of Cardiology 2009, Orlando, Florida. March 30, 2009.
269. Co-Chair Opening Plenary Session. Lecture: Hospice Indicated for Inotrope-Dependent Heart Failure Patients

- Unable to Receive Transplantation or Ventricular Assist Device”; Lecture: “Mitral Valve Repair (MVR) in Heart Failure: 5 Year Follow-up from the MVR Stratum of the Acorn Trial,” International Society for Heart and Lung Transplantation, 29th Annual Meeting and Scientific Session. Palais des Congress, Paris, France. April 22-25, 2009.
270. The Treatment of Cardiovascular Disease: Legacy and Innovation. Lecture: “Current Outcomes,” Co-Moderator, Heart Failure Plenary Session, “Therapy for Heart Failure: Today and Tomorrow,” Cleveland Clinic Heart and Vascular Institute, A Comprehensive International Symposium, InterContinental Hotel & Bank of America Conference Center, Cleveland, Ohio. June 3-5, 2009.
 271. Lecture: “Systolic Heart Failure Management – Digitalis to Stem Cells,” Case Based Panel Discussion – “Systolic and Diastolic Heart Failure,” Cleveland Clinic Intensive Review of Cardiology, InterContinental Hotel & Bank of America Conference Center, Cleveland, Ohio. August 23, 2009.
 272. Destination, Life, Advanced Heart Failure Therapy in The New Era, Lecture: “Evolution of Patient Management,” Sheraton Wild Horse Pass, Chandler, Arizona. February 20, 2010.
 273. Lecture: “End Stage Heart Failure: Mechanical Circulatory Support and Cardiac Transplantation,” 59th Annual Scientific Session of the American College of Cardiology, Georgia World Congress Center, Atlanta, Georgia. March 15, 2010.
 274. Minimal Invasive Cardiac Surgery in 2010, Lecture: “Modern View of the Cardiologist Towards Heart Failure Treatment,” Verona, Italy. March 28, 2010.
 275. Lecture: “Left Ventricular Assist Devices for Heart Failure and Heart Transplantation,” Grand Rounds, Albert Einstein Medical Center, Philadelphia, Pennsylvania. April 7, 2010.
 276. Lecture: “End Stage Heart Failure: Mechanical Circulatory Support and Cardiac Transplantation,” Grand Rounds, Temple University, School of Medicine, Philadelphia, Pennsylvania. April 7, 2010.
 277. An Update on Acute Coronary Syndromes and Advanced Heart Failure, Lecture: “Management of Advanced Heart Failure: State of the Art 2010,” Mater Cardiac Symposium, Mater Misericordiae University Hospital, Dublin, Ireland. April 17, 2010.
 278. Lecture: “Atrial Fibrillation in Heart Failure – The Chicken or the Egg: A Heart Failure Perspective,” Heart Rhythm 2010, Denver, Colorado. May 15, 2010.
 279. Lecture: “The Cardio-Renal Syndrome. Do We Need a Change of Tactics?” Update in Heart Failure, A New Approach in 2 Days, Barcelona, Spain, June 18, 2010.
 280. Lecture: “Cardiac Allograft Vasculopathy,” 14th Annual Scientific Meeting, Heart Failure Society of America, San Diego, California. September 15, 2010.
 281. Lecture: “A Multidisciplinary Approach to the Management of Heart Failure,” Spotlight on Cleveland Clinic, OPTUM Health Conference, Cleveland, Ohio. October 4, 2010.
 282. Lecture: “Current Issues in Heart Failure,” 7th Annual BREATHE Symposium, Covington, Kentucky. October 8, 2010.
 283. Round Table: “Cardiovascular Pharmacogenetics for the Clinician,” Cardiology Congress of Central Greece, Larissa, Greece. October 15, 2010.
 284. Keynote Lecture: “Human Coronary Allograft Vasculopathy: A Twenty Year Journey,” The Ohio State University Medical Center Comprehensive Transplant Center Conference, Columbus, Ohio. October 27, 2010.
 285. Lecture: “Management of Decompensated Heart Failure,” Australian Preceptorship Program, Cleveland Clinic, Cleveland, Ohio. November 10, 2010.

286. Lecture: "Perioperative Management," Scientific Session 2010, American Heart Association, Chicago, Illinois. November 16, 2010.
287. Lecture: "Current Trends in Heart Failure Management," Bakken Symposium 2010: Heart Failure, University of Minnesota, Minneapolis, Minnesota. December 6 & 7, 2010.
288. Lecture: "Heart Transplant Update," 11th Annual New Frontiers in Heart Failure Therapy, New York, New York. January 22, 2011.
289. Workshop: "Prognostic Indicators for HF," 8th Annual ABC's of Heart Failure: Diagnosis, Prognosis, and Treatment – The Patient's Journey, Beachwood, Ohio. February 12, 2011.
290. Lecture: "Advances in Heart Mate II Outcomes," Destination. Life. Advanced Heart Failure Therapy in The New Era, Orlando, Florida. March 5, 2011.
291. Lecture: "The Role of Cardiac Transplantation and Ventricular Assist Devices for Heart Failure Management: Evolving Strategies," Massachusetts General Hospital, Cardiology Grand Rounds, Boston, Massachusetts. March 9, 2011.
292. Co-Chair ACC Spotlight Session #0151, "Integrated Imaging Spotlight: Imaging Challenges in CHF Answered by A Multi-Modality Approach," Panelist at ACC Meet the Experts, Session #0227, "Quality Indicators in Heart Failure," American College of Cardiology – ACC11, New Orleans, Louisiana. April 2-5, 2011.
293. Lecture: "How Many Walking Wounded Are There?" Poster: "Incidence of Coronary Artery Vasculopathy has Decreased with Modern Immunosuppression: Insights from Clinical Trials in Organ Transplantation," Co-chair Mini Oral Session 08, International Society for Heart and Lung Transplantation, 31st Annual Meeting and Scientific Sessions, San Diego, California. April 13-16, 2011.
294. Lecture: "The Role of Cardiac Transplantation and Ventricular Assist Devices for Heart Failure Management: Evolving Strategies." Drexel University College of Medicine, Department of Medicine Grand Rounds, Philadelphia, Pennsylvania. June 1, 2011.
295. Lecture: "Managing Right Heart Failure with LVAD's in Place: What Do We Do Next?" 2011 Gordon Research Conference on Assisted Circulation, Waterville Valley Resort, New Hampshire. June 14, 2011.
296. Debate Session: "LVAD Should be Standard of Care for Patients with Refractory Heart Failure Who Are Not Transplant Candidates," ESC 2011, Paris, France. August 31, 2011.
297. "Who Do You Send Home on Intravenous Inotropic Therapy?" Heart Failure Society of America, Annual Meeting & Scientific Sessions, Boston, Massachusetts. September 21, 2011.
298. "Heart Failure: Updated Protocols for the Treatment of Patients," Grand Rounds Presentation, The MedCentral Health System, Mansfield, Ohio. September 27, 2011.
299. Panel Discussion: "Treating the Heart Failure Patient: New Technology, New Promise," 2011 Medical Innovations Summit, State of the Heart, Cleveland, Ohio. October 4, 2011.
300. Moderator, "Innovations in Heart Failure and MCS," 2011 Medical Innovations Summit, State of the Heart, Shaping the Future of Cardiovascular Care: Progress and Controversies, Cleveland, Ohio. October 6, 2011.
301. "CRT Therapy for Severe Heart Failure Patients: Is this Reality Preferable to Destination LVAD Therapy," Venice Arrhythmias, Venice, Italy. October 10, 2011.
302. "Severe Heart Failure: Transplant or LVAD? What is the Future?" Larissa Congress 2011, Larissa, Greece. October 14, 2011.
303. "Treatment Options for Advanced Heart Failure: Past, Present & Future," Medicine Grand Rounds, Cleveland

Clinic, Cleveland, Ohio. November 3, 2011.

304. "Cardiac Transplant Update," Transplant Center Grand Rounds, Cleveland Clinic, Cleveland, Ohio. January 9, 2012.
305. Lecture (Key Note Address): "Highlighted Heart Failure Articles: Device Therapy in 2012," Lecture: "How to Overcome Diuretic Resistance in Heart Failure," Lecture: "VAD in Heart Failure: Who & When," Co-chair Session: Highlighted Oral Abstracts, 6th Asian Pacific Congress of Heart Failure, Chiang Mai, Thailand. February 4 & 5, 2012.
306. Lecture: "VAD Therapy for Advanced Heart Failure," Advances in Heart Failure: Mechanical Heart Devices, Singapore Cardiac Society, Republic of Singapore. February 6, 2012.
307. Co-Chair ACC Symposium, Session #669, "Joint Symposium of the Heart Failure Society of America and the American College of Cardiology: Management of Advanced Heart Failure and Transplantation," American College of Cardiology Annual Meeting, Chicago, Illinois. March 25, 2012.
308. Co-Chair ACC Symposium, Session # 694, "LVAD as Destination Therapy for Advanced Heart Failure," American College of Cardiology Annual Meeting, Chicago, Illinois. March 26, 20, 2012.
309. "The Genomics of Rejection," International Society for Heart and Lung Transplantation 32nd Annual Meeting and Scientific Sessions, Prague, Czech Republic. April 18, 2012.
310. Chair: Mini Oral Session 02: "Heart & Pediatric," International Society for Heart and Lung Transplantation 32nd Annual Meeting and Scientific Sessions, Prague, Czech Republic. April 19, 2012.
311. "Patient Selection and Outcomes (BTT & DT)," Thoratec Europe, LTD Outreach Meeting, Nancy, France. April 24, 2012.
312. "Patient Selection and Outcomes (BTT & DT)," Thoratec Europe, LTD Outreach Meeting, Lyon, France. April 25, 2012.
313. "Evaluation and Management of the RV Prior to Implant," Thoratec Europe, LTD Inreach Meeting, Lyon, France. April 26, 2012.
314. Workshop "Mechanical Circulatory Support Devices in Heart Failure," "Interventional and Surgical Treatment in Advanced Heart Failure: How to Use Risk Scoring and Stratification Strategies?" Heart Failure Association of the European Society of Cardiology, Wroclaw, Poland. April 27, 2012.
315. "Lessons Learned from Major Heart Failure Trials," National Kidney Foundation Spring Clinical Meeting. Cleveland Clinic Cardiorenal Update, Washington, DC. May 9, 2012.
316. "Older DT Patient Selection" Moderator Cardiologist, Destination. Life. Advanced Heart Failure Therapy, Las Vegas, Nevada. May 18, 2012.
317. Patient Experience Summit, Innovation Update Lightning Round, ROADMAP Update, Cleveland Clinic, Cleveland, Ohio. May 20, 2012.
318. "What They Do; Why They Do it and How They Do it," Cleveland Clinic, Cleveland Ohio. May 25, 2012.
319. Co-Chair: The Satellite on MCS," Heart Failure Society of America, Annual Meeting & Scientific Sessions, Seattle, Washington. September 9, 2012.
320. Moderator & Panelist, "Mineralocorticoid Receptor Antagonists (MRAs)," Heart Failure Society of America, Annual Meeting & Scientific Sessions, Seattle, Washington. September 10, 2012.
321. "LVAD Therapies for Heart Failure: In Evolution," Journal Club, Mayo Clinic, Rochester, Minnesota. October 2, 2012.

322. Round Table “Myocardial-Pericardial Disorders,” Cardiac Involvement with Amyloidosis, 15th Cardiology Congress of Central Greece, Larissa, Greece. October 12, 2012.
323. Round Table “Heart Failure: Pathophysiology, Diagnosis, Management,” “Drugs and Medical Treatment Algorithms in the Management of Acute Decompensated Heart Failure,” Scientific Debate: “Cardiac Resynchronization should be Tried before LVAD in Patients with NYHA IV Heart Failure,” 15th Cardiology Congress of Central Greece, Larissa, Greece. October 12, 2012.
324. “The Heart and the Kidney,” Director of Round Table “The Kidney in Hypertension and Heart Failure,” 15th Cardiology Congress of Central Greece, Cardiovascular Seminar, Larissa, Greece. October 14, 2012.
325. Heart Failure 2012 Critical Updates and State of the Science Moderator, 21st Century Treatment of Heart Failure, Cleveland Clinic, Cleveland Ohio. October 18, 2012.
326. Management of the Patient on Long Term MCS, Moderator, 21st Century Treatment of Heart Failure, Cleveland Clinic, Cleveland Ohio. October 19, 2012.
327. Session Moderator: In a Cardiovascular Seminar entitled “Management of Myocardial Ischemia in Heart Failure,” American Heart Association, Scientific Sessions 2012, Los Angeles, California. November 7, 2012.
328. “Strategies of Desensitization of Candidates to HTx,” Pan American Workshop: Mechanical Circulatory Support, Tampa, Florida. November 30, 2012.
329. Building a VAD Program for: Insights and Infrastructure: LVAD Patient, Panel Moderator, Pan American Workshop: Mechanical Circulatory Support, Tampa, Florida. December 1, 2012.
330. Research Priorities and Publications, MedaMACS, Arlington, Virginia. January 18, 2013.
331. “Mechanical Circulatory Support,” International Society for Heart and Lung Transplantation, Miami, Florida. February 1, 2013.
332. “LVAD Update,” Grand Rounds Presentation, Riverside Methodist Hospital, Columbus, Ohio. February 27, 2013.
333. “Preserve,” Heart Failure Network Steering Committee Meeting, San Francisco, California. March 8, 2013.
334. HFSA/ACC Joint Session I: Cardiac Transplantation versus Destination Therapy, Long Term Expectations for the DT LVAD Patient,” American College of Cardiology Annual Meeting, San Francisco, California. March 10, 2013.
335. Destination Life, Panel Discussion, INTERMACS 4 and 5 Patients, Moderator, Orlando, Florida. March 16, 2013.
336. Debate 2: An Annual Coronary Angiogram is Necessary for Improving Late Outcomes (PRO) during the CHT Symposium Session entitled Common Debates after Cardiac Transplantation, International Society for Heart and Lung Transplantation, Montreal, Canada. April 24, 2013.
337. Co-Chair the PATH Sunrise Session entitled, “Are the Pathology Working Formulations the Gold Standard for Diagnosing AMR in Heart and Lung in 2013,” International Society for Heart and Lung Transplantation, Montreal, Canada. April 25, 2013.
338. Treatment of Advanced Heart Failure, Cadence Health, Chicago, Illinois. May 4, 2013.
339. Anticoagulation Management: Trends, Treatment, and Outcomes, North American Cardiology Scientific Advisory Meeting, Boston, Massachusetts. May 10, 2013.
340. Chair Session: Ventricular Assist Devices/Artificial Heart, Cardiovascular Biotechnology from Cell to Man, Athens, Greece. May 31, 2013.

341. Speaker, Acute Heart Failure: Epidemiology and the First 60 Days after Hospitalization, China Heart Congress, Beijing, China. August 09, 2013.
342. Speaker, LVAD Therapy: What are the Results and the Limitations? China Heart Congress, Beijing, China. August 10, 2013.
343. The Challenging Heart Failure Patient: Management Option in 2013, American College of Cardiology Foundation, Orlando, Florida. August 17, 2013.
344. Treating Acute and Advanced Heart Failure, European Society of Cardiology, Amsterdam, Netherlands. September 3, 2013.
345. Case Studies, The Toughest Patients You May Ever See, Heart Failure Society of America, Orlando, Florida. September 22, 2013.
346. Heart Failure Readmissions: Appropriate or Misguided Efforts, Challenging the Metric: Is it in the Patient's Interest, Heart Failure Society of America, Orlando, Florida. September 23, 2013.
347. Advanced Heart Failure: Are We Making Advances, Grand Rounds, Beth Israel Deaconess Medical Center, Boston, Massachusetts. September 27, 2013.
348. Summit Panel Discussion, 11th Medical Innovations Summit, Cleveland, Ohio. October 16, 2013.
349. Round Table, Hot Cardiology Topics: Diagnosis and Management of LVAD Complications, 16th Cardiology Congress of Central Greece, Larissa, Greece. November 2, 2013.
350. Clinical Seminar: The Right Heart and the Pulmonary Circulation, Course Director, 16th Cardiology Congress of Central Greece, Larissa, Greece. November 3, 2013.
351. Ask the Experts: To Induce or not to Induce, American Heart Association, Dallas, Texas. November 17, 2013.
352. Keynote Address: Advanced Heart Failure: Are We Making Advances? Heart Failure Symposium. December 6, 2013.
353. Clinical Debate, "Transplant the Patient: Learn More before Establishing Recovery in Everyday Clinical Practice," Utah Cardiac Recovery Symposium. January 18, 2014.
354. Session 1: Step by Step "Systematic Approach to Risk Stratification in Heart Failure," Cleveland Clinic ACCC, India. February 15, 2014.
355. Session 2: What is New? "Management of Acute CHF Post AMI," Cleveland Clinic ACCC, India. February 15, 2014.
356. Session 3: When and How, "Beta Blockers in Management of Heart Failure," Cleveland Clinic ACCC, India. February 15, 2014.
357. "What is New With Oral Treatment Strategies after Ace-Inhibitors and Beta Blockers in Systolic HF?" Co-Chair, ACC, Joint Symposium of the Heart Failure Society of America and the American College of Cardiology I. March 30, 2014.
358. "Update and Harmonization in HF Practice Guidelines: Drug Therapy Across Different Guidelines HFSA, ACC?" AHA, ESC, Joint Symposium of the HFSA and ACC III. March 30, 2014.
359. Co-Chair the Sunrise Symposium 6: "The Aortic Valve – An Open and Shut Case?" International Society for Heart and Lung Transplantation 34th Annual Meeting and Scientific Sessions, San Diego, California. April 12, 2014.

360. Co-Chair the Concurrent Session 28: “Diagnosis and Monitoring of Pulmonary Hypertension,” International Society for Heart and Lung Transplantation 34th Annual Meeting and Scientific Sessions, San Diego, California. April 12, 2014.
361. Destination, Life, Presenter: State of the State and Moving Forward: Pump Thrombosis “Multicenter Experiences and Perspectives,” Salt Lake City, Utah. May 3, 2014.
362. Lecture: “Recent Advances in the Management of Heart Failure,” 50th Annual Robert M. Jeresaty, M.D. Cardiovascular Symposium, Hartford, Connecticut. May 8, 2014.
363. Lecture: “Heart Transplantation: An Update - Pre and Post-Operative Care,” European Society of Cardiology, Heart Failure 2014 Scientific Programme, Athens, Greece. May 17, 2014.
364. Chairperson: Advanced Heart Failure: Cutting Edge Information for the Clinician, Europe an Society of Cardiology, Heart Failure 2014 Scientific Programme, Athens, Greece. May 18, 2014.
365. Lecture: “How to Manage Congestion in Acute Heart Failure Patients with: Resistance to Diuretics,” European Society of Cardiology, Heart Failure 2014 Scientific Programme, Athens, Greece. May 19, 2014.
366. NHLBI/ACHA Working Group on Adult Congenital Heart Disease (ACHD), “Emerging Research Questions,” Heart Failure Group Presentations/Discussions Member, Bethesda, Maryland. June 23, 2014.
367. Pre-Meeting Session, Clinical Transplant Update: “Approach to Coronary Allograft Vasculopathy in 2014,” World Transplant Congress 2014, San Francisco, California. July 26, 2014.
368. Sunrise Symposia Session, Clinical Update: Cardiac Allograft Vasculopathy in Heart Transplantation: “CAV and IVUS: Are they Necessary?” World Transplant Congress 2014, San Francisco, California. July 29, 2014.
369. Lecture: “Trends and Treatment Options for LVAD Thrombosis Incidence and Prevalence of Thrombosis in Continuous Flow LVADs,” Heart Failure Society of America 18th Annual Scientific Meeting, Las Vegas, Nevada. September 15, 2014.
370. Lecture: “Combined Heart and Liver Transplantation,” 17th Cardiology Congress of Central Greece, Larissa, Greece. October 10, 2014.
371. Director – Cardiovascular Seminar: “Cardio-oncology,” 17th Cardiology Congress of Central Greece, organized by EMEKA, Larissa, Greece. October 12, 2014.
372. Moderator: “30 Years of Heart Failure Management: What Have We Learned from Our Failures?” Cleveland Clinic 21st Century Treatment of Heart Failure Summit, Cleveland, Ohio. October 16, 2014.
373. Lecture: MCS Beyond Survival: Pump Thrombosis, “Occurrence, Incidence and Outcomes of Pump Thrombosis,” Cleveland Clinic 21st Century Treatment of Heart Failure Summit, Cleveland, Ohio. October 17, 2014.
374. Keynote Address: “Ventricular Devices (VADs) and Heart Failure in 2014,” The Fourth Annual Hackensack UMC Heart & Vascular Symposium, Hackensack, New Jersey. October 29, 2014.
375. Lecture: “Destination LVAD Therapy: A Double-Edged Sword?” American Heart Association Scientific Sessions 2014, Chicago, Illinois. November 17, 2014.
376. Moderator – Abstract Oral Session: “Left Ventricular Assist Device Thrombosis,” American Heart Association Scientific Sessions 2014, Chicago, Illinois. November 18, 2014.
377. Co-Chairman, Joint Symposium of the Heart Failure Society of America and the American College of Cardiology: “What Important Changes Occur in the Patient With A Continuous Flow LVAD?” American College of

Cardiology Scientific Session 2015 (ACC.15), San Diego, California. March 14, 2015.

378. Presenter: "Left Ventricular Assist Device Therapy for Advanced Heart Failure." 17th South China International Congress of Cardiology, Guangzhou, China. April 10, 2015.
379. Debate and Rebuttal Con: INTERMACS Profile 4+: "The Timing is Right". ISHLT 35th Annual Meeting and Scientific Sessions, Nice, France. April 15, 2015.
380. Member - Advisory Committee Organization Efforts and Experiences – HF program descriptions: successes and challenges; future efforts planned. AMGF Heart Failure Collaborative Advisory Committee, Alexandria, VA. May 7, 2015.
381. Trial Data: "HM II: The Roadmap Trial". Joint NHLBI/FDA Workshop on The Current State of Thrombosis in Ventricular Assist Devices, Lincoln Heights, Maryland. May 14, 2015.
382. Presenter: "Renal Replacement Therapy". European Society of Cardiology, 2nd World Congress on Acute Heart Failure, Seville, Spain. May 23, 2015.
383. Presenter: "Novel Assist Devices". European Society of Cardiology, 2nd World Congress on Acute Heart Failure, Seville, Spain. May 23, 2015.
384. Presenter: "Management of Acute Heart Failure". 6th International Congress CCF & Fundacion CardioInfantil, Bogota, Columbia. September 24, 2015.
385. Presenter: "Risk Stratification in Patients with Heart Failure". 6th International Congress CCF & Fundacion CardioInfantil, Bogota, Columbia. September 24, 2015.
386. Presenter: "Advances in the Treatment of Chronic Heart Failure". 6th International Congress CCF & Fundacion CardioInfantil, Bogota, Columbia. September 24, 2015.
387. Presenter: "Heart Failure Quality Indicators". 6th International Congress CCF & Fundacion CardioInfantil, Bogota, Columbia. September 24, 2015.
388. Presenter: "Treatment Outcomes with Ventricular Assist Devices". 6th International Congress CCF & Fundacion CardioInfantil, Bogota, Columbia. September 25, 2015.
389. Presenter: How to Troubleshoot a VAD Session – "Anticoagulation and Anti-Platelets: Now what?" HFSA 19th Annual Scientific Assembly, National Harbor, Maryland. September 27, 2015.
390. Moderator: "Advances in the treatment of heart failure. Is it possible to improve survival further?" 18th Cardiology Congress of Central Greece, Larissa, Greece. October 9, 2015.
391. Presenter: "Current Practice in Long-Term Mechanical Circulatory Support." 18th Cardiology Congress of Central Greece, Larissa, Greece. October 10, 2015.
392. Director: Cardiovascular Seminar – "Exercise And The Heart" 18th Cardiology Congress of Central Greece, Larissa, Greece. October 11, 2015.
393. Lecture: "Vasodilators, Inotropes, and the Role of Medical Therapies" American Heart Association Scientific Sessions 2015, Orlando, Florida. November 9, 2015.
394. Lecture: "Innovations in Chronic LVAD Therapy: Trials and Tribulations" Cleveland Clinic, Sones/Favaloro Scientific Program and Lectures, Cleveland, Ohio. November 13, 2015.
395. Lecture: "Management of Highly Sensitized Transplant Candidate" Pan American Workshop, Tampa, Florida. December 11, 2015.

396. Lecture: “Destination LVAD Therapy: Is It Still a Work In Progress” Cardiology Grand Rounds, Columbia University, New York, New York. December 15, 2015.
397. Lecture: “Heart Failure Management: The Past, Present, and Future” Prince Mahidol Award Youth Program Conference 2016, Bangkok, Thailand. January 27, 2016.
398. Discussant: “Case-Based Learning in Heart Failure.” Prince Mahidol Award Youth Program Conference 2016, Bangkok, Thailand. January 27, 2016.
399. Lecture: “Challenges for the Treatment of Advanced Heart Failure 2016: What are the Options?” Cardiology Grand Rounds, University of Colorado, Denver, CO. February 12, 2016.
400. Moderator & Panelist: “Discussion on the New UNOS Heart Allocation Proposal” AST Cutting Edge of Transplantation Conference, CEOT Planning Committee, Phoenix, AZ. February 27, 2016.
401. Participant: Novartis-Sacubitril/Valsartan in Heart Failure Medical Advisory Board, Zurich, Switzerland. March 4, 2016.
402. Lecture: “Update on MVAD Trial: HeartWare” INTERMACS 10th Annual Meeting, Atlanta, GA. March 12, 2016.
403. Co-Chair, Heart Failure and Cardiomyopathies - Scientific Session, Session # 728: “Treatment of Patients With Stage D Heart Failure and Shock” ACC.16 - 65th Annual Scientific Session & Expo, Chicago, IL. April 4, 2016.
404. Discussant: How to Tackle Congestion in Heart Failure. ESC Heart Failure Association Congress, Florence, Italy. May 21, 2016.
405. Discussant: Global Campaign for Heart Failure. ESC Heart Failure Association Congress, Florence, Italy. May 22, 2016.
406. Discussant: Pump Thrombosis, ESC Heart Failure Association Congress, Florence, Italy. May 24, 2016.
407. Lecturer: LVAD Trials and Outcomes. University of Verona, Verona Italy. May 25, 2016.
408. Lecturer: Acute Heart Failure: Phenotype and Choice of Vasoactive Agents; Vasodilators or Inotropes. HFSA Annual Scientific Session. Orlando FL. September 17, 2016.
409. Lecturer and Discussant: Partnering with Industry to Design Large Registries. HFSA Annual Scientific Session. Orlando FL. September 19, 2016.
410. Lecture: Advances in Heart Failure Treatment, Keynote Lecture, 19th Annual Congress of Central Greece, Larissa, GR. October 7, 2016.
411. Lecture: Organization and Structure of a Heart Failure Program. University of Kentucky Cardiology Grand Rounds, Louisville, KY. October 12, 2016.
412. Lecture and Panelist: Heart Failure with Preserved Ejection Fraction. ACC Middle East Conference, Jeddah, SA. October 29, 2016.
413. Lecturer: Advanced Heart Failure, Options, Outcomes, and Challenges. Cardiology Grand Rounds University of Pittsburgh Medical Center, Pittsburgh PA. December 6, 2016.

LECTURES 2017 AND 2018 TO BE UPDATED

Trainees / Mentees

1. ClinShop Research Mentor, Dr. Farshad Raissi Shabari, 2005-2006
2. Mentor, Case Western Reserve University medical Student, Jamin Morrison, 2006-2007

3. Mentor, Case Western Reserve University Medical Student, Eric Chu, 2007-2010
4. M.D./M.S. Thesis Committee, Cleveland Clinic Lerner College of Medicine/Case Western Reserve University Student, Dustin Y. Yoon, MS, 2010-2011
5. Thomas E Hurst BS. Cleveland Clinic Lerner College of Medicine/Case Western Reserve University Student, Research Project Mentor, 2014 – 2015.
6. Andrew Xanthopoulos MD, PhD. Hellenic Society of Cardiology Scholar. Research Fellow Cardiovascular Medicine. 2017 April – 2018 September.

RESEARCH SUPPORT

Grants: Principal Investigator of Funded Research Projects:

- 1 Novartis, A 24 Month, Multi-Center, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration- Controlled Certican with Reduced Neoral Versus 3.0g MMF with Standard Dose Neoral in De Novo Heart Transplantation Recipients, Principle Investigator, IRB 8623, re-open May 2012.
- 2 NIAID, Clinical Trials in Organ Transplantation (CTOT-11), Study ID number U01-A1063589, U01-A163623, Principal Investigator & Protocol Chair, Started December 2010.
- 3 Novartis, LCZ696D2317 (PARADIGM-HF), Study ID number CLCZ696B2314, Principal Investigator, Started March 2010.
- 4 Biotronik, Clinical Protocol for the Echocardiography Guided Cardiac Resynchronization Therapy Clinical Investigation, (Echo CRT), Study ID number G080067, Principal Investigator, November 2008.
- 5 NIAID and NHLBI, Observational Study of Alloimmunity in Cardiac Transplant Recipients, Study ID number DAIT CTOT-05, Principal Investigator, Started June 2007.
- 6 Celladon Corporation, A Phase 1 Trial of Intracoronary Administration of MYDICAR™ (AAV1/SERCA2a) in Subjects with Heart Failure Divided Into Two Stages, CUPID TRIAL, Study ID number CELL-001, The CUPID Trial, Principal Investigator, May 2007.
- 7 Invasive Monitoring Attenuation Through Gene Expression (IMAGE) Trial, Principal Investigator, IMAGE TRIAL, Study ID number CA-0004, Started June 2006.
- 8 Cleveland Clinic, CRAD001A2310, A 24-Month, Multi-Center, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Certican with Reduced Neoral Versus 3.0 g MMF with Standard Dose Neoral in De Novo Heart Transplant Recipients, IRB# 8623, Principal Investigator, May 2006 – Ongoing.
- 9 The Cleveland Clinic Foundation, A Six-Month, Multicenter, Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral in Cardiac Transplant Recipients with Established Allograft Vasculopathy, Study CRAD001A2405, IRB#7346, Principal Investigator, January 2005 – May 2005.
- 10 The Cleveland Clinic Foundation, Fluid Accumulation Status Trial, a prospective, multi-center, non-randomized, IDE clinical trial designed to characterize the utility of the fluid status trend. No control will be required, neither the subject nor the physician will have access to the data, FAST, IRB#7771, Principal Investigator, April 2005 – Ongoing.
- 11 The Cleveland Clinic Foundation, A Facilitated Access Program to Provide Everolimus for Maintenance Patients Completing Therapy in RAD Trials in Solid Organ Transplantation, Study RAD 001-A2401, IRB#7275, Principal Investigator, January 2005- Ongoing.
- 12 The Cleveland Clinic Foundation, Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy, Protocol LVRecovery, IMAC II, IRB#7360, Principal Investigator, October 2004 – Ongoing.

- 13 The Cleveland Clinic Foundation, Cardiac Allograft Rejection Gene Expression Observational Study. This study will investigate the utility of using gene expression profiling to diagnose the presence and monitor the severity of cardiac transplant rejection, IRB#5687, Principal Investigator, April 2003 – Ongoing.
- 14 The Cleveland Clinic Foundation, A Retrospective Analysis of Cardiovascular and Immunologic Risk Factors Affecting Survival of De Novo Cardiac Transplant Recipients, IRB#5397, Principal Investigator, July 2002 – February 2003.
- 15 The Cleveland Clinic Foundation, Study Effects of Left Ventricular Reconstruction (DOR Procedure) on the Outcome of Heart Failure in Ischemic Cardiomyopathy, IRB#4642, Principal Investigator, November 2001 - Ongoing.
- 16 The Cleveland Clinic Foundation, APOMATE Imaging in Cardiac Transplant Patients, APOMATE, Principal Investigator, \$250,000 Total, October 2001 – May 2002.
- 17 The Cleveland Clinic Foundation, A Phase II Study of Serial APOMATE™ Imaging in Cardiac Transplant Patients: Comparison of Myocardial Apomate™ Uptake on Serial Imaging with Histopathologic Grading of the Corresponding Endomyocardial Biopsies, IRB#4201, Principal Investigator, August 2001 -May 2002.
- 18 The Cleveland Clinic Foundation, Natriuretic Gene Expression in Cardiac Allograft Rejection (ANF and BNP in Relation to Rejection in Transplant Patients), IRB#3270, Principal Investigator, January 2001 – October 2002.
- 19 The Cleveland Clinic Foundation, Clinical Evaluation of Acorn Cardiac Support Device Therapy in Patients with Dilated Cardiomyopathy (ACORN), IRB#3975, Co-Principal Investigator, \$283,750 Total. January 2001 - Ongoing.
- 20 The Cleveland Clinic Foundation, A Two-Year Extension to a Two-Year Prospective, Multicenter, Randomized, Double Blind, Double Dummy, Active Controlled, Safety and Efficacy Study of SDZ RAD (RAD001) versus Azathioprine as a Part of a Triple Immunosuppressive Therapy Regimen in De Novo Heart Transplant Recipients, IRB#4057, Principal Investigator, \$60,000 Total. December 2000 - ongoing.
- 21 The Cleveland Clinic Foundation, Impact of ATG on Clinical Outcome following Heart Transplantation: A Holiday from Steroids, IRB#4091, Principal Investigator, \$100,000 Total. November 2000 - November 2003.
- 22 The Cleveland Clinic Foundation, Multicenter Randomized Study and Registry to Evaluate the Efficacy of Monomurab-CD3, Cyclosporine and Prednisone in Subjects with Giant Cell Myocarditis, IRB#3810, Principal Investigator, May 2000 – January 2002.
- 23 The Cleveland Clinic Foundation, Comparison of Medical Therapy, pacing and defibrillation in Heart Failure (COMPANION), IRB#3541, Principal Investigator, \$100,000 Total. March 1, 2000 – March 1, 2004.
- 24 The Cleveland Clinic Foundation, A Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination with CellCept, Cyclosporine and Corticosteroids in Patients Undergoing Cardiac Transplantation, ZENAPAX, IRB#3214, Principal Investigator, \$450,000 Total, August 1, 1999 – March 1, 2002.
- 25 The Cleveland Clinic Foundation, A Two-Year Randomized, Multicenter, Double-Blind, Double Dummy Study of the Efficacy and Safety of SDZ RAD versus Azathioprine as part of an Immunosuppressive Therapy Regimen in De Novo Heart Transplant Recipients, SDZ RADB253, IRB#2590, Principal Investigator, \$450,000 Total, August 1998 – June 2003.
- 26 The Cleveland Clinic Foundation, Intervention in Myocarditis and Acute Cardiomyopathy with Intravenous Immunoglobulin (IMAC), RPC#1765, Principal Investigator, 1996 - 1999.
- 27 The Ohio State University College of Medicine Medical Center, Davis Research Grant, Serial Measurements of Myocardial Morphology and Histology in Myocarditis, Principal Investigator, \$18,000. July 1, 1993 - June 30, 1994.

- 28 Burroughs Wellcome Company, A Multi-Center Open Randomized Comparison of the Safety and Efficacy of Chronic Flolan Infusions to Conventional Therapy in Patients with Severe, Congestive Heart Failure: A Pilot Study, Principal Investigator, Contract: \$20,316 per randomized patient. February 12, 1991 – June 30, 1992.
- 29 National Heart, Lung and Blood Institute [R01 HL43370], Coronary Phenotypic Modulation after Cardiac Transplant, Co-Principal Investigator. Grant aid: \$608,900. Total Direct Costs. July 1989 – May 1995.
- 30 University of Utah, National Institutes of Health, Immunosuppressive Therapy for Biopsy-Proven Myocarditis, Multi-Center Study, Principal Investigator, Sub-contract: \$41,808. July 1, 1987 – May 1, 1989.
- 31 Central Ohio American Heart Association, Ohio Chapter, Atrial Natriuretic Peptide Pre and Post Cardiac Transplant, Principal Investigator, Grant in Aid: \$5000, July 1, 1987 – December 31, 1988.
- 32 Central Ohio American Heart Association, Ohio Chapter, Drug Responses in Isolated Coronary Arteries, Principal Investigator, Grant in Aid: \$10,400, January 1, 1986 – June 30, 1987.
- 33 Central Ohio American Heart Association, Ohio Chapter, Drug Responses in Isolated Coronary Arteries, Principal Investigator, Fellowship: \$18,000, July 1, 1986 – June 30, 1987.
- 34 Thoratec Corp, Risk Assessment and Comparative Effectiveness Of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP), IRB# 12-091, Principal Investigator, Contract: \$139,950, March 15, 2012 – March 14, 2019.
- 35 Novartis, Chart Review Long Term Outcome Follow-Up of the RAD001 B253 Study, Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipient, IRB# 12-871, Principal Investigator, Contract: \$17,901, October 22, 2012 – August 31, 2017.
- 36 NIH, Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RITUXAN®) Therapy in Cardiac Transplantation (CTOT-11), IRB# 10-968, Principal Investigator, Sub-Contract: \$1,088,566. September 1, 2009 – August 31, 2015.
- 37 NIH, Medical Records: CTOT-18 A Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study, IRB# 14-978, Principal Investigator, Sub Contract: \$7,500, September 1, 2014 – February 28, 2015.
- 38 CareDx, Inc., OAR/D-OAR Outcome Allomap, IRB# 15-436, Principal Investigator, \$172,050. April 17, 2015 – April 16, 2017.

COOPERATIVE RESEARCH PROJECTS:

- 1 Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF), Study ID numbers CR013954, A093, ASCEND-HF; NATRECORAHF3002, Co-Investigator, Started June 2007.
- 2 The Cleveland Clinic Foundation, A Prospective Evaluation of Closed Loop Stimulation in Heart Failure Patients, HF-CLS, IRB#7167, Co-Investigator, September 2004- February 2005.
- 3 The Cleveland Clinic Foundation, Centers for Heart Failure Arrhythmia Research and Therapy, CHART, IRB#5614, Co-Investigator, April 2003 -?
- 4 National Institutes of Health, Allograft Rejection, Tolerance and VCAM-1, Co-Investigator, \$996,860. Total Direct Costs, August 1993 – June 1997.
- 5 Otsuka America Pharmaceuticals, Incorporated, A Randomized Multiple Dose Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure, Co-Investigator, Fixed Contract: \$3780. per patient,

June 1, 1993 – May 31, 1995.

- 6 Smith Kline Beecham Pharmaceuticals, Carvedilol in Heart Failure Trial: A Six Month Double Blind Multi-Center Comparison of Oral Carvedilol bid with Placebo in patients with Mild Congestive Heart Failure, NYHA Class II. Co-Investigator. Fixed Contract: \$8686.00 per patient. April 1, 1993 – January 31, 1995.
- 7 Smith Kline Beecham Pharmaceuticals, Carvedilol in Heart Failure Trial: A Six Month Double Blind Multi-Center Comparison of Oral Carvedilol bid with Placebo in Patients with Severe Congestive Heart Failure, NYHA Class III-IV. Co-Investigator. Fixed Contract: \$8450.00 per patient. April 1, 1993 – January 31, 1995.
- 8 Smith Kline Beecham Pharmaceuticals, Carvedilol in Heart Failure Trial: A Six Month Double Blind Multi-Center Comparison of Oral Carvedilol b.i.d. with Placebo in Patients with Congestive Heart Failure, NYHA Class II-IV, Co-Investigator, Fixed Contract: \$8999 per patient, April 1, 1993 – January 31, 1995.
- 9 Otsuka America Pharmaceuticals, Incorporated, An Open Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure, Co-Investigator, Fixed Contract: \$2760 per patient, February 1, 1993 – January 31, 1995.
- 10 Sanofi Winthrop Pharmaceuticals, A Randomized Multi-Center Study Comparing the Efficacy and Safety of Intravenous Milrinone and Intravenous Nitroglycerin in Patients with Severe Congestive Heart Failure, Co-Investigator, Fixed Contract: \$6721.60 per patient, January 1, 1993 – June 30, 1994.
- 11 Searle Pharmaceuticals, Dose-Ranging Study of Spironolactone versus Placebo in Patients with Symptomatic Heart Failure, Co-Investigator, Fixed Contract: \$6193 per patient. January 1, 1993 – April 1, 1994.
- 12 Otsuka America Pharmaceuticals, Incorporated, A Stepwise Open Titration Study of Pharmacodynamics and Pharmacokinetics of OPC-18790 in Subjects with Heart Failure, Co-Investigator, Fixed contract: \$8236 per patient, April 1, 1992 – December 31, 1993.
- 13 Boots Pharmaceutical, A Double Blind Randomized Placebo Controlled Study of the Effects of Flosequinan on the Survival of Patients with Chronic Congestive Heart Failure, Co-Investigator, Fixed Contract: \$4452 per patient, April 15, 1992 – April 15, 1993.
- 14 The Cleveland Clinic Foundation, Transform System Randomized Clinical Trial for Dynamic Cardiomyopathy, RPC #3538, Co-Investigator.
- 15 The Cleveland Clinic Foundation, Multicenter, Randomized, Double-Blind Study of the Safety Tolerability and Vascular Effects of Neoral versus Sandimmune in the Heart Transplant Patient, RPC #5035, Co-Investigator.
- 16 The Cleveland Clinic Foundation, PRAISE-II Study: Prospective Randomized Amlodipine Survival Evaluation-2, a Randomized, Double-Blind, Dose Titration, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Amlodipine on Survival in Patients with Congestive Heart Failure, RPC #5480, Co-Investigator.
- 17 The Cleveland Clinic Foundation, The BEST Study: Beta-Blocker Evaluation of Survival Trial, RPC #5566, Co-Investigator.
- 18 The Cleveland Clinic Foundation, An Open, Multiple Dose Study of Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure, Protocol No. 22-95-209, RPC#5300, Co-Investigator.
- 19 The Cleveland Clinic Foundation, Study of Patients Intolerant of Converting Enzyme Inhibitors, SPICE (SH-HAS-0002), RPC#1762, Co-Investigator.
- 20 The Cleveland Clinic Foundation, A Phase III Open Label Titration Study of the Chronic Efficacy and Safety of OPC-18790 for the Treatment of Patients with Heart Failure Protocol 103-95-202, RPC#5960, IRB#1808, Co-Investigator.
- 21 The Cleveland Clinic Foundation, Oral Levosimendan as a Substitute for Intravenous Inotropic Support for

- Patients with End Stage Failure, RPC#2002, Co-Investigator.
- 22 The Cleveland Clinic Foundation, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study in Patients with Congestive Heart Failure to Evaluate the Effects of Various Doses of RS-25560 on Transmyocardial Catecholamines after Four Weeks and the Safety and Tolerability of RS-25560 over 12 Weeks, RPC#2003, Co-Investigator.
 - 23 The Cleveland Clinic Foundation, Long-term, Open-Label Safety Study of RS-25560 in Patients with Congestive Heart Failure, RPC#2350, Co-Investigator.
 - 24 The Cleveland Clinic Foundation, A Phase 3, Randomized, Double Blind, Dose Response, Positive Control Evaluation of the Efficacy and Safety of Toborinone (OPC-18790) in the Treatment of Patients with Heart Failure, OPC Protocol 103-97-201 REST, RPC#2314, Co-Investigator.
 - 25 The Cleveland Clinic Foundation, A Randomized, Double Blind, Placebo-Controlled, Sequential-Panel, Single Dose Study to Investigate the Acute Hemodynamic Effects of IV 1753037 (BQ4508-2) in Patients with Symptomatic Heart Failure, Protocol 005-01, RPC#2320, Co-Investigator.
 - 26 The Cleveland Clinic Foundation, Evaluation of the Safety / Tolerability of Long Term Treatment with DMP Inhibitor BMS-186716 or Lisinopril in Subjects with Heart Failure, CV 137-018, RPC# 2066, Co-Investigator.
 - 27 The Cleveland Clinic Foundation, A Parallel Dose-Response Study of Sustained-Release Moxonidine in Patients with Congestive Heart Failure, MOXSE protocol B3N-MC-EUBK, RPC#2269, Co-Investigator.
 - 28 The Cleveland Clinic Foundation, Multicenter, Randomized Study of the Long-Term Hemodynamic Effects and Safety of the Dual Metalloprotease Inhibitor BMS-18676 in Treatment of Heart Failure, CV 137-012, RPC#2067, Co-Investigator.
 - 29 The Cleveland Clinic Foundation, Comparison of the Acute Hemodynamic Effects and Safety of the Endothelin Receptor Antagonist BMS-193884 versus Placebo in Subjects with Heart Failure, CV144-013, RPC#1782, Co-Investigator.
 - 30 The Cleveland Clinic Foundation, A Study to Evaluate the Survival Time and Quality of Life of Patients with Chronic Heart Failure not Eligible for Cardiac Transplantation, CXEH001 C121, Co-Investigator.
 - 31 The Cleveland Clinic Foundation, Chemokine Gene Expression in Human Cardiac Allograft Rejection, Co-Investigator.
 - 32 The Cleveland Clinic Foundation, LaRoche Pharmaceutical, Incorporated and Pfizer, Incorporated, Cardiac Protein Expression in Human Cardiac Transplantation: Pathophysiological Mechanism of Graft Failure (Grant), #6297, Co-Investigator.
 - 33 The Cleveland Clinic Foundation, In Vitro Detection and Grading of Cardiac Allograft Rejection by Fluorescence Spectroscopy: Correlation with Histopathology (Grant), Co-Investigator.
 - 34 The Cleveland Clinic Foundation, A Randomized, Double-Blind, Positive and Placebo Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy, Tolerability and Safety of SB217242 in Patients with Stable NYHA Class II-III Congestive Heart Failure, Protocol 217242/073, IRB#2900, Co-Investigator.
 - 35 The Cleveland Clinic Foundation, VALIANT is an International, Multicenter, Phase III Clinical Trial Comparing Valsartan, Captopril and their Combination in High Risk Patients after Acute Myocardial Infarction, IRB#2935, Co-Investigator.
 - 36 The Cleveland Clinic Foundation, A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Effect of Carvedilol Mortality in Patients with Severe Chronic Heart Failure, COPERNICUS MF447/SB287, IRB#2745, Co-Investigator.
 - 37 The Cleveland Clinic Foundation, Candesartan Cilexetil (Candesartan) in Heart Failure Assessment of Reduction

- in Mortality and Morbidity, Candesartan in Patients with Heart Failure and Preserved Left Ventricular Function, CHARM, IRB#2952, Co-Investigator.
- 38 The Cleveland Clinic Foundation, Tumor Necrosis Factor Receptor in Patients with Congestive Heart Failure, RENAISSANCE, Tnfr:fc, IRB#2999, Co-Investigator.
 - 39 The Cleveland Clinic Foundation, Warfarin and Antiplatelet Therapy Study in Chronic Heart Failure, WATCH, IRB#2982, Co-Investigator.
 - 40 American Society of Echocardiography, Echocardiographic Predictors of Response to Beta-Blocker Therapy, Co-Investigator.
 - 41 The Cleveland Clinic Foundation, Multicenter InSync™ Randomized Clinical Evaluation MIRACLE, IRB#2872, Co-Investigator.
 - 42 The Cleveland Clinic Foundation, Clinical Investigation of the InSync™ System and the Models 2187, 10499, 11511 or 10512 Transvenous Left Ventricular Cardiac Vein Pacing Leads, MIRACLE ICD, IRB#3342, Co-Investigator.
 - 43 The Cleveland Clinic Foundation, Defibrillators in Non-Ischemic Cardiomyopathy; Primary Prevention Trial for Non-Ischemic Cardiomyopathy, DEFINITE, IRB#, Co-Investigator.
 - 44 The Cleveland Clinic Foundation, Sudden Cardiac Death in Heart Failure Trial, SCD HeFT, IRB#1436, Co-Investigator.
 - 45 The Cleveland Clinic Foundation; sponsored by Roche Pharmaceuticals, Chemokine Gene Expression in Human Cardiac Allograft Rejection, IRB#2944, Co-Investigator.
 - 46 The Cleveland Clinic Foundation, High Dose Corticosteroids vs. Conversion to Tacrolimus Therapy, IRB#3894, Co-Investigator.
 - 47 The Cleveland Clinic Foundation, US Feasibility Study for the Myocor Myosplint System, MYOCOR, IRB#4095, Co-Investigator.
 - 48 The Cleveland Clinic Foundation, Use of the VE HeartMate for those Patients who are at Risk of Soon Dying of their Heart Failure who are not Listed as Waiting for Heart Transplantation, PRIDE, Co-Investigator.
 - 49 The Cleveland Clinic Foundation, Implantation of Autologous Myoblasts Derived from Skeletal Muscle into the Wall of the Left Ventricle of Patients undergoing CABG Surgery Following Myocardial Infarction with Secondary Objective to Obtain Preliminary Information on Graft Survival and the Effect of the Transplant on Functional Characteristics of the Heart, DIACRIN. Co-Investigator.
 - 50 HeartWare Inc., A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure, IRB# 13-1211. Co-Investigator.
 - 51 NIH, MedaMACS Study (The Medical Arm of Mechanical Circulatory Support) IRB# 13-288, Co-Investigator.
 - 52 Thoratec / University of Louisville, Remission from Stage D. Heart Failure (RESTAGE-HF) IRB# 13-726, Co-Investigator.
 - 53 Heart Failure Network, IRONOUT-HF: Oral Iron Repletion Effects On Oxygen Uptake In Heart Failure- IRB# 14-806, Co-Investigator.
 - 54 NHLBI and Roche Diagnostics, GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) IRB# 12-975, Co-Investigator.
 - 55 Heart Failure Network, Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) IRB# 13-066, Co-

Investigator.

56 Heart Failure Network, Infrastructure, NHLBI, IRB # 12-224, Co-Investigator.

57 ATHENA-HF, Duke University, IRB # 14-1379.

58 NEAT-HFPEF: Nitrates Effect, Duke University, IRB # 14-211.

BIBLIOGRAPHY

Peer Reviewed Articles

- 1 Solano Jr FX, **Starling RC**, Levey GS. Myxedema megacolon. *Archives of Internal Medicine* 1985; 145:231.
- 2 **Starling RC**, Yu VL, Shillington D, Galgiani J. Pneumococcal pericarditis. Diagnostic usefulness of counterimmunoelectrophoresis and computed tomographic scanning. *Archives of Internal Medicine* 1986; 146:1174-1176.
- 3 Binkley P, Galbraith T, Shaffer P, **Starling RC**, Murray K, Howanitz P, Watson K, Myerowitz PD. Influence of an extracorporeal artificial ventricle on native ventricular performance. *American Heart Journal* 1988; 115:1119-1121.
- 4 **Starling RC**, Galbraith TA, Baker P, Howanitz EP, Murray KD, Binkley PF, Watson KM, Unverferth DV, Myerowitz PD. Successful management of acute myocarditis with biventricular assist devices and cardiac transplantation. *The American Journal of Cardiology* 1988; 62:341-344.
- 5 **Starling RC**, Baker PB, Hirsch SC, Myerowitz PD, Galbraith TA, Binkley PB. An echocardiographic and anatomic description of the donor-recipient anastomosis after orthotopic cardiac transplantation. *The American Journal of Cardiology* 1989; 64:109-111.
- 6 Leier CV, Binkley PF, **Starling RC**, Huss-Randolph P. Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy. *Archives of Internal Medicine* 1989; 117:1092-1098.
- 7 **Starling RC**, Cody RJ. Cardiac transplant hypertension. *The American Journal of Cardiology* 1990; 65:106-111.
- 8 Hohl CM, Hu B, Wimsatt DK, Fertel RH, **Starling RC**, Brierley GP, Altschuld RA. Isolated myocytes from a normal human heart. *Progress in Clinical and Biological Research* 1990; 327:735-742.
- 9 Li Q, Biagi B, Hohl C, **Starling RC**, Stokes B, Altschuld R. Effects of isoproterenol and caffeine on calcium transients and action potentials in human ventricular cardiomyocytes. *Progress in Clinical and Biological Research* 1990; 327:743-750.
- 10 O'Connell JB, Dec GW, Goldenberg IF, **Starling RC**, Mudge GH, Augustine SM, Costanzo-Nordin MR, Hess ML, Hosenpud JD, Icenogle TB, Menlove RL, Billingham ME. Results of cardiac transplantation for active lymphocytic myocarditis. *Journal of Heart Transplantation* 1990; 9:351-356.
- 11 **Starling RC**, Hammer DF, Unverferth DV. Cyclic adenosine monophosphate content of endomyocardial tissue obtained by biopsy in cyclosporine immunosuppressed human cardiac transplant recipients. *The American Journal of Cardiology* 1990; 66:887-888.
- 12 Gbur CJ, Hammer DF, Lucas JG, **Starling RC**. An unusual form of biliary obstruction in an orthotopic heart transplant recipient managed with cyclosporine. *The Journal of Heart and Lung Transplantation* 1991; 10:464-466.
- 13 Yu VL, Stoehr GP, **Starling RC**, Shogan JE. Empiric antibiotic selection by physicians: Evaluation of reasoning strategies. *American Journal of the Medical Sciences* 1991; 301:165-172.

- 14 **Starling RC**, Van Fossen DB, Hammer DF, Unverferth DV. Morbidity of endomyocardial biopsy in cardiomyopathy. *The American Journal of Cardiology* 1991; 68:133-136.
- 15 **Starling RC**, Binkley PF, Hammer DF, Galbraith TA, Howanitz EP, Murray KD, Lowe PA, Watson KM, Myerowitz PD. Adenine nucleotide content in cold preserved human donor hearts and subsequent cardiac performance after orthotopic heart transplantation. *The Journal of Heart and Lung Transplantation* 1991; 10:508-517.
- 16 Payne ME, Murray KD, Watson KM, Galbraith TA, Howanitz EP, **Starling RC**, Myerowitz PD. Permanent pacing in heart transplant recipients: Etiology and long-term results. *The Journal of Heart and Lung Transplantation* 1991; 10:738-742.
- 17 **Starling RC**, O'Dorisio TM, Cody RJ. Rapid reduction but lack of normalization in atrial natriuretic peptide levels in patients with congestive heart failure after cardiac transplantation. *Archives of Internal Medicine* 1991; 122:258-261.
- 18 **Starling RC**, O'Dorisio TM, Malarkey WB, Murray KB, Myerowitz PD, Cody RJ. Preserved atrial natriuretic peptide secretory function after cardiac transplantation. *The American Journal of Cardiology* 1991; 68:237-241.
- 19 Binkley PF, **Starling RC**, Hammer DF, Leier CV. Usefulness of hydralazine to withdrawal from dobutamine in severe heart failure. *The American Journal of Cardiology* 1991; 68:1103-1106.
- 20 Altschuld RA, Hohl CM, **Starling RC**, Castillo LC, Garleb AA, Brierley GP. Cyclosporine inhibits mitochondrial calcium reflux in isolated adult rat ventricular cardiomyocytes. *American Journal of Physiology* 1992; 262:H1699-H1704.
- 21 **Starling RC**, Binkley PF, Haas GJ, Hatton PS, Wooding-Scott M. Thermodilution measures of right ventricular ejection fraction and volumes in cardiac transplant recipients: A comparison with radio nuclide angiography. *The Journal of Heart and Lung Transplantation* 1992; 11:1140-1146.
- 22 Binkley PF, Haas GJ, **Starling RC**, Nunziata E, Hatton PA, Leier CV, Cody RJ. Sustained augmentation of parasympathetic tone with angiotensin converting enzyme inhibition in patients with congestive heart failure. *Journal of the American College of Cardiology* 1993; 21:655-661.
- 23 Pasiarski TJ, Pearson AC, **Starling RC**, Binkley PF. Echocardiographic evaluation of pulmonary artery distensibility. *Chest* 1993; 103:1080-1083.
- 24 Triposkiadis F, **Starling RC**, Haas GJ, Sparks E, Myerowitz PD, Boudoulas H. Timing of recipient atrial contraction: A major determinant of transmittal diastolic flow in orthotopic cardiac transplantation. *Archives of Internal Medicine* 1993; 126:1175-1181.
- 25 Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, Cintron GB, Bhat G, **Starling RC**. Pre transplantation risk factor for acute rejection after heart transplantation: A multi-institutional study. The Transplant Cardiologists Research Database Group. *Journal of Heart Transplantation* 1993; 12:355-366.
- 26 Bourge RC, Naftel DC, Costanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, Olivari MT, Kasper EK, **Starling RC**. Pre transplantation risk factors for death after heart transplantation: a multi-institutional study. The Transplant Cardiologists Research Database Group. *The Journal of Heart and Lung Transplantation* 1993; 12:549-562.
- 27 Triposkiadis F, Haas GJ, Sparks E, Myerowitz PD, Boudoulas H, **Starling RC**. Effects of recipient atrial contraction on mitral valve motion in orthotopic cardiac transplantation. *The American Journal of Cardiology* 1994; 73:1003-1006.
- 28 Young JB, Naftel DC, Bourge RC, Kirklin JK, Clemson BS, Porter CB, Rodeheffer RJ, Kenzora JL, **Starling RC**. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multi-institutional report. The Cardiac Transplant Research Database Group. *The Journal of Heart*

and *Lung Transplantation* 1994; 13:353-364

- 29 Jarcho J, Naftel DC, Shroyer TW, Kirklin JK, Bourge RC, Barr ML, Pitts DG, **Starling RC** and the Cardiac Transplant Research Database Group. Influence of HLA mismatch on rejection after cardiac transplantation: A multi-institutional study. *The Journal of Heart and Lung Transplantation* 1994; 13:583-596.
- 30 Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, Jarcho J, Hobbs RE, Mills RM, **Starling RC**. Infection after heart transplantation: a multi-institutional study. The Cardiac Transplant Research Database Group. *The Journal of Heart and Lung Transplantation* 1994; 13:381-392.
- 31 Khot UN, Binkley PF, Haas GJ, Myerowitz PD, **Starling RC**. Restoration of diurnal blood pressure variability after cardiac transplantation. *Transplantation Proceedings* 1994; 26:2736-2737.
- 32 Boudoulas H, **Starling RC**, Vavuranakis M, Haas GJ, Sparks E, Myerowitz PD, Wooley CF. Left atrial volumes and function in orthotopic cardiac transplantation. *American Heart Journal* 1995 Apr; 129(4):774-782.
- 33 Bornstein RA, **Starling RC**, Myerowitz PD, Haas GJ. Neuropsychological function in patients with end-stage heart failure before and after cardiac transplantation. *Acta Neurologica Scandinavica* 1995; 91:260-265.
- 34 Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, **Starling RC**, and the Myocarditis Treatment Trial Investigators. Efficacy of immunosuppressive therapy in patients with myocarditis. *The New England Journal of Medicine* 1995; 333:269-275.
- 35 Altschuld RA, **Starling RC**, Hamlin RL, Billman GE, Hensley J, Castillo L, Fertel RH, Hohl CM, Robitaille P-ML, Jones LR, Xiao R-P, Lakatta EG. Response of failing canine and human heart cells to β_2 -adrenergic stimulation. *Circulation* 1995; 92:1612-1618.
- 36 Khot UN, Binkley PF, Haas GJ, **Starling RC**. Prospective study of the circadian pattern of blood pressure after heart transplantation. *The Journal of Heart and Lung Transplantation* 1996 Apr; 15(4):350-359.
- 37 **Starling RC**, Boudoulas H. Left atrial dysfunction after orthotopic heart transplantation. *The Journal of Heart and Lung Transplantation* 1996 Apr; 15(4):431-432.
- 38 Armstrong AT, Strauch AR, Kardan A, **Starling RC**. Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. *The Journal of Heart and Lung Transplantation* 1996 Aug; 15(8):818-826.
- 39 James KB, Ratliff N, **Starling RC**, Young JB. Inflammatory cardiomyopathy. The controversy of diagnosis and management. *Rheumatic Diseases Clinics of North America* 1997; 23:333-343.
- 40 **Starling RC**. Radical alternatives to transplantation. *Current Opinion in Cardiology* 1997 Mar; 12(2):166-171.
- 41 Armstrong AT, Strauch AR, **Starling RC**, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts. *Transplantation* 1997 Apr; 63(7):941-947.
- 42 McCarthy PM, Young JB, Smedira NG, Hobbs RE, Vargo RL, **Starling RC**. Permanent mechanical circulatory support with an implantable left ventricular assist device. *The Annals of Thoracic Surgery* 1997 May; 63(5):1458-1461.
- 43 Armstrong AT, Strauch AR, **Starling RC**, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac allografts: II. Rate and location of lesion development. *Transplantation* 1997 Jul; 64(2):322-328.
- 44 Armstrong AT, Strauch AR, **Starling RC**, Sedmak DD, Orosz, CG. Morphometric analysis of neointimal formation in murine cardiac grafts: III. Dissociation of interstitial fibrosis from neointimal formation. *Transplantation* 1997 Oct; 64(8):1198-1202.
- 45 McCarthy PM, **Starling RC**, Wong J, Scalia GM, Buda T, Vargo RL, Goormastic M, Thomas JD, Smedira NG,

- Young JB. Early results with partial left ventriculectomy. *The Journal of Thoracic and Cardiovascular Surgery* 1997 Nov; 114(5):755-763; discussion 763-765.
- 46 **Starling RC.** Patient selection for ventricular remodeling surgery: evolving criteria and outcomes. *ACC Current Journal Review* 1998 Jan/Feb; 7(1):55.
- 47 **Starling RC.** Radical alternatives to transplantation. *Current Opinion in Organ Transplantation* 1998; 3:6-11.
- 48 **Starling RC,** Hammer DF, Altschuld RA. Human myocardial ATP content and *in vivo* contractile function. *Molecular and Cellular Biochemistry* 1998 Mar; 180(1-2):171-177.
- 49 McCarthy PM, Smedira NO, Vargo RL, Goormastic M, Hobbs RE, **Starling RC,** Young JB. One hundred patients with the HeartMate left ventricular assist device: Evolving concepts and technology. *The Journal of Thoracic and Cardiovascular Surgery* 1998 Apr; 115(4):904-912.
- 50 **Starling RC,** Liebes R, Medeiros D, Altschuld RA. ATP and cytochrome C oxidase in the failing human heart. *Advances in Organ Biology* 1998; 4A:143-158.
- 51 McCarthy JF, McCarthy PM, **Starling RC,** Smedira NG, Scalia GM, Wong J, Kasirajan V, Goormastic M, Young JB. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. *European Journal of Cardiothoracic Surgery* 1998 Apr; 13(4):337-343.
- 52 **Starling RC,** Smedira NG, McCarthy PM. Surgical interventions for patients with nonischemic dilated cardiomyopathy. *Cardiology in Review* 1998; 6:334-344.
- 53 Scalia GM, **Starling RC,** Wong J, Buda T, Thomas JD, Smedira NG, Young JB, McCarthy PM. Early results with the Batista procedure for end-stage heart failure. *The Asia Pacific Heart Journal* 1998 May; 7(1):10-15.
- 54 **Starling RC.** The heart failure pandemic: Changing patterns, costs, and treatment strategies. *Cleveland Clinic Journal of Medicine* 1998 Jul/Aug; 65(7):351-358.
- 55 McCarthy JF, Cook DJ, Massad MG, Sano Y, O'Malley KJ, Ratliff NR, Stewart RW, Smedira NG, **Starling RC,** Young JB, McCarthy PM. Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. *European Journal of Cardiothoracic Surgery* 1998 Aug; 14(2):197-200.
- 56 Fukamachi K, McCarthy PM, **Starling RC,** Young JB. Effects of partial left ventriculectomy on cardiac performance. *Circulation* 1998 Nov; 98(19):2101-2102.
- 57 Kapadia SR, Nissen SE, Ziada KM, Guetta V, Crowe TD, Hobbs RE, **Starling RC,** Young JB, Tuzcu EM. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: Comparison by serial intravascular ultrasound imaging. *Circulation* 1998 Dec; 98(24):2672-2678.
- 58 McCarthy JF, Cook DJ, Smedira NG, O'Malley KJ, Massad MG, Sano Y, Young JB, **Starling RC,** Ratliff NB, McCarthy PM. Vascular rejection in cardiac transplantation. *Transplantation Proceedings* 1999 Feb; 31(1-2):160.
- 59 Stull, DE, **Starling RC,** Haas GJ, Young JB. Becoming a patient with heart failure. *Heart and Lung* 1999 Jul/Aug; 28(4):284-292.
- 60 Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, Sheffield C, Hoercher K, **Starling RC,** Young JB, Smedira NJ, McCarthy PM. Outcome of de novo hepatitis C virus infection in heart transplant recipients. *Hepatology* 1999; 30:1293-1298.
- 61 Fukamachi K, McCarthy PM, Smedira NG, Vargo RL, **Starling RC,** Young JB. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. *The Annals of Thoracic Surgery* 1999 Dec; 68(6):2181-2184.
- 62 Park MH, **Starling RC,** Ratliff NB, McCarthy PM, Smedira NS, Pelegrin D, Young JB. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. *The Journal of Heart and Lung*

Transplantation 1999 Dec; 18(12):1224-1227.

- 63 **Starling RC**, McCarthy PM. Partial left ventriculectomy: Sunrise or sunset? *European Journal of Heart Failure* 1999 Dec; 1(4):313-317.
- 64 Yamani MH, **Starling RC**, Pelegrin D, Platt L, Majercik M, Hobbs RE, McCarthy P, Young JB. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. *The Journal of Heart and Lung Transplantation* 2000 Apr; 19(4):337-342.
- 65 Bishay ES, Cook DJ, **Starling RC**, Ratliff Jr NB, White J, Blackstone EH, Smedira NG, McCarthy PM. The clinical significance of flow cytometry crossmatching in heart transplantation. *European Journal of Cardiothoracic Surgery* 2000 Apr; 17(4):362-369.
- 66 Yamani MH, **Starling RC**, Goormastic M, Van Lente F, Smedira N, McCarthy P, Young JB. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. *Transplantation* 2000 Jun; 69(11):2326-2330.
- 67 Bishay ES, Cook DJ, El Fettouh H, **Starling RC**, Young JB, Smedira NG, McCarthy PM. The impact of HLA sensitization and donor cause of death in heart transplantation. *Transplantation* 2000 Jul; 70(1):220-222.
- 68 Binkley PF, Nunziata E, Haas GJ, **Starling RC**, Leier CV, Cody RJ. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure. *American Heart Journal* 2000 Jul; 140(1):34-42.
- 69 Kasirajan V, McCarthy PM, Hoercher KJ, **Starling RC**, Young JB, Banbury MK, Smedira NG. Clinical experience with long-term use of implantable left ventricular assist devices: Indications, implantation, and outcomes. *Seminars in Thoracic and Cardiovascular Surgery* 2000 Jul; 12(3):229-237.
- 70 McCarthy PM, **Starling RC**, Young JB, Smedira NG, Goormastic M, Buda T. Left ventricular reduction surgery with mitral valve repair. *The Journal of Heart and Lung Transplantation* 2000 Aug; 19(8 supplement):S64-S67.
- 71 Corales R, Chua J, Mawhorter S, Young JB, **Starling R**, Tomford JW, McCarthy P, Braun WE, Smedira N, Hobbs R, Haas G, Pelegrin D, Majercik M, Hoercher K, Cook D, Avery RK. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: An emerging clinical phenomenon? *Transplant Infectious Disease* 2000 Sep; 2(3):133-139.
- 72 Yamani MH, **Starling RC**. Long-term medical complications of heart transplantation: Information for the primary care physician. *Cleveland Clinic Journal of Medicine* 2000 Sep; 67(9):673-680.
- 73 Yamani MH, van de Poll SW, Ratliff NB, Kuban BE, **Starling RC**, McCarthy PM, Young JB. Fluorescence spectroscopy of endomyocardial tissue post-human heart transplantation: Does it correlate with histopathology? *The Journal of Heart and Lung Transplantation* 2000 Nov; 19(11):1077-1080.
- 74 Park MH, **Starling RC**. Does aspirin interact with ACE inhibitors in patients with heart failure? *The Ochsner Journal* 2000; 2(1).
- 75 **Starling RC**, McCarthy PM, Buda T, Wong J, Goormastic M, Smedira NG, Thomas JD, Blackstone EH, Young JB. Results of partial left ventriculectomy for dilated cardiomyopathy: Hemodynamic, clinical and echocardiographic observations. *Journal of the American College of Cardiology* 2000 Dec; 36(7):2098-2103.
- 76 Stevenson LW, Kormos RL, Bourge RC, Gelijns A, Griffith BP, Hershberger RE, Hunt S, Kirklin J, Miller LW, Pae Jr WE, Pantalos G, Pennington DG, Rose EA, Watson JT, Willerson JT, Young JB, Barr ML, Costanzo MR, Desvigne-Nickens P, Feldman AM, Frazier OH, Friedman L, Hill JD, Konstam MA, McCarthy PM, Michler RE, Oz MC, Rosengard BR, Sapirstein W, Shanker R, Smith CR, **Starling RC**, Taylor DO, Wichman A. Mechanical cardiac support 2000: Current applications and future trial design. Jun 15-16, 2000. Bethesda, Maryland. *Journal of the American College of Cardiology* 2001 Jan; 37(1):340-370.
- 77 Stevenson LW, Kormos RL, Barr ML, Costanzo MR, Desvigne-Nickens P, Feldman AM, Frazier OH, Friedman L,

- Hill JD, Konstam MA, McCarthy PM, Michler RE, Oz MC, Rosengard BR, Sapirstein W, Shanker R, Smith CR, **Starling RC**, Taylor DO, Wichman. Mechanical cardiac support 2000: Current applications and future trial design. Jun 15-16, 2000, Bethesda, Maryland. *The Journal of Heart and Lung Transplantation* 2001 Jan; 20(1):1-38.
- 78 Stevenson LW, Kormos RL, Barr ML, Costanzo MR., Desvigne-Nickens P, Feldman AM, Frazier OH, Friedman L, Hill JD, Konstam MA, McCarthy PM, Michler RE, Oz MC, Rosengard BR, Sapirstein W, Shanker R, Smith CR, **Starling RC**, Taylor DO, Wichman A. Mechanical cardiac support 2000: Current applications and future trial design: Jun 15-16, 2000. Bethesda, Maryland. *Circulation* 2001 Jan; 103(2):337-342.
- 79 Young AA, Dokos S, Powell KA, Sturm B, McCulloch AD, **Starling RC**, McCarthy PM, White RD. Regional heterogeneity of function in nonischemic dilated cardiomyopathy. *Cardiovascular Research* 2001 Feb; 49(2):308-318.
- 80 Scott RL, Ratliff NB, **Starling RC**, Young JB. Recurrence of giant cell myocarditis in cardiac allograft. *The Journal of Heart and Lung Transplantation* 2001 Mar; 20(3):375-380.
- 81 Yamani MH, Avery RK, Mawhorter SD, Young JB, Ratliff NB, Hobbs RE, McCarthy PM, Smedira NG, Goormastic M, Pelegrin D, **Starling RC**. Hypogammaglobulinemia following cardiac transplantation: A link between rejection and infection. *The Journal of Heart and Lung Transplantation* 2001 Apr; 20(4):425-430.
- 82 Jimenez J, Kapadia SR, Yamani MH, Platt L, Hobbs RE, Rincon G, Bott-Silverman C, **Starling RC**, Young JB, Nissen SE, Tuzcu M, Ratliff NB. Cellular rejection and rate of progression of transplant vasculopathy: A 3-year serial intravascular ultrasound study. *The Journal of Heart and Lung Transplantation* 2001 Apr; 20(4):393-398.
- 83 Franco-Cerceda A, McCarthy PM, Blackstone EH, Hoercher KJ, White JA, Young JB, **Starling RC**. Partial left ventriculectomy for dilated cardiomyopathy: Is this an alternative to transplantation? *The Journal of Thoracic and Cardiovascular Surgery* 2001 May; 121(5):879-893.
- 84 McNamara DM, Holubkov R, **Starling RC**, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM, for the Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) Investigators. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. *Circulation* 2001 May; 103(18):2254-2259.
- 85 Bybel B, **Starling RC**, Brunken RC. Clinical picture: Disseminated tuberculosis. *The Lancet* 2001 Jul; 358:187.
- 86 Yamani MH, Haji S, **Starling RC**, Kelly L, Albert N, Knack DL, Young JB. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. *American Heart Journal* 2001 Dec; 142(6):998-1002.
- 87 Yamani MH, Avery R, Mawhorter S, Young JB, McNeill A, Cook DJ, Ratliff NB, McCarthy P, **Starling RC**. Hypogammaglobulinemia after heart transplantation: Impact of pre-emptive use of immunoglobulin replacement (CytoGam®) on infection and rejection outcomes. *Transplant Infectious Disease* 2001 Dec; 3(SII):40-43.
- 88 Danovitch GM, Hariharan S, Pirsch JD, Rush D, Roth D, Ramos E, **Starling RC**, Cangro C, Weir MR. Management of the waiting list for cadaveric kidney transplants: Report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. *Journal of the American Society of Nephrology* 2002 Feb; 13(2):528-535.
- 89 Triantafyllidi H, **Starling RC**, Hobbs RE, Toutouzas P. Heart transplantation: A hope for the future. *Heart and Vessels (Greece)* 2002; 7:17-23.
- 90 Triantafyllidi H, Hobbs RE, **Starling RC**, Toutouzas P. Heart transplantation: The next day. *Heart and Vessels (Greece)* 2002; 7:127-134.
- 91 Yamani MH, Yang J, Masri CS, Ratliff NB, Bond M, **Starling RC**, McCarthy P, Plow E, Young JB. Acute cellular rejection following human heart transplantation is associated with increased expression of vitronectin receptor (integrin $\alpha\beta 3$). *American Journal of Transplantation* 2002 Feb; 2:129-133.

- 92 Yamani MH, Masri CS, Ratliff NB, Bond M, **Starling RC**, Tuzcu EM, McCarthy PM, Young JB. The role of vitronectin receptor ($\alpha v\beta 3$) and tissue factor in the pathogenesis of transplant coronary vasculopathy. *Journal of the American College of Cardiology* 2002 Mar; 39(5):804-810.
- 93 Yamani MH, Haji SA, **Starling RC**, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, Crowe T, Secic M, McCarthy P, Young JB. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. *Journal of the American College of Cardiology* 2002 Mar; 39(6):970-977.
- 94 Ferri C, Properzi G, Tomassoni G, Santucci A, Desideri G, Giuliani AE, **Starling RC**, Ratliff NB, Cook DJ, McCarthy P, Young JB, Yamani MH. Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. *Circulation* 2002 Apr; 105(15):1768-1771.
- 95 Yamani MH, Tuzcu EM, **Starling RC**, Ratliff NB, Yu Y, Vince DG, Powell K, Cook D, McCarthy P, Young JB. Myocardial ischemic injury after heart transplantation is associated with up regulation of vitronectin receptor ($\alpha v\beta 3$), activation of the matrix metalloproteinase induction system, and subsequent development of coronary vasculopathy. *Circulation* 2002 Apr; 105(16):1955-1961.
- 96 **Starling RC**. Introduction: Cardiac surgery for heart failure. *Seminars in Thoracic and Cardiovascular Surgery* 2002 Apr; 14(2):122-124.
- 97 McCarthy PM, Franco-Cerceda A, Blackstone EH, Hoercher K, White JA, Young JB, **Starling RC**. A question of terminology [comment]. *The Journal of Thoracic and Cardiovascular Surgery* 2002 Apr; 123(4):830.
- 98 Yamani MH, Kinter MT, **Starling RC**, Willard BB, Ratliff NB, Yu Y, Cook DJ, McCarthy PM, Young JB. Increased β -myosin heavy chain in acute cellular rejection following human heart transplantation. *American Journal of Transplantation* 2002 Apr; 2:386-388.
- 99 Yamani MH, Tuzcu EM, **Starling RC**, Young JB, Cook DJ, Haji SA, Abdo A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Ratliff NB. Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. *The Journal of Heart and Lung Transplantation* 2002 Aug; 21(8):850-859.
- 100 Faber C, McCarthy PM, Smedira NG, Young JB, **Starling RC**, Hoercher KJ. Implantable left ventricular assist device for patients with post infarction ventricular septal defect. *The Journal of Thoracic and Cardiovascular Surgery* 2002 Aug; 124(2):400-401.
- 101 Yamani MH, **Starling RC**, Young JB, Cook D, Yu Y, Vince DG, McCarthy P, Ratliff NB. Acute vascular rejection is associated with up-regulation of vitronectin receptor ($\alpha v\beta 3$), increased expression of tissue factor, and activation of the extracellular matrix metalloproteinase induction system. *The Journal of Heart and Lung Transplantation* 2002 Sep; 21:983-989.
- 102 Mahon NG, Blackstone EH, Francis GS, **Starling RC**, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. *Journal of the American College of Cardiology* 2002 Sep; 40(6):1106-1113.
- 103 Yen MH, Pilkington G, **Starling RC**, Ratliff NB, McCarthy PM, Young JB, Chisolm GM, Penn MS. Increased tissue factor expression predicts development of cardiac allograft vasculopathy. *Circulation* 2002 Sep; 106(11):1379-1383.
- 104 O'Neill JO, **Starling RC**. Surgical remodeling in ischemic cardiomyopathy. *Current Treatment Options in Cardiovascular Medicine* 2003; 5:311-319.
- 105 Fahmy NM, Yamani MH, **Starling RC**, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. *Transplantation* 2003 Jan; 75(1):72-78.

- 106 Khot UN, Mishra M, Yamani MH, Smedira NG, Paganini E, Yeager M, Buda T, McCarthy PM, Young JB, **Starling RC**. Severe renal dysfunction complicating cardiogenic shock is not a contraindication to mechanical support as a bridge to cardiac transplantation. *Journal of the American College of Cardiology* 2003 Feb; 41(3):381-385.
- 107 **Starling RC**. Improving care of chronic heart failure: Advances from drugs to devices. *Cleveland Clinic Journal of Medicine* 2003 Feb; 70(2):141-146.
- 108 Masri K, Mahon N, Rosario A, Mirza I, Keys TF, Ratliff NB, **Starling RC**. Reactive hemophagocytic syndrome associated with disseminated histoplasmosis in a heart transplant recipient. *The Journal of Heart and Lung Transplantation* 2003 Apr; 22(4):487-491.
- 109 Tsutsui H, Schoenhagen P, Ziada KM, Crowe TD, Klingensmith JD, Vince DG, Bott-Silverman C, **Starling R**, Hobbs RE, Young J, Nissen SE, Tuzcu EM. Early constriction or expansion of the external elastic membrane area determines the late remodeling response and cumulative lumen loss in transplant vasculopathy: An intravascular ultrasound study with 4-year follow-up. *The Journal of Heart and Lung Transplantation* 2003 May; 22(5):519-525.
- 110 Yamani MH, Ratliff NB, **Starling RC**, Tuzcu EM, Yu Y, Cook DJ, Crow T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Quilty lesions are associated with increased expression of vitronectin receptor ($\alpha v\beta 3$) and subsequent development of coronary vasculopathy. *The Journal of Heart and Lung Transplantation* 2003 Jun; 22(6):687-690.
- 111 Fahmy NM, Yamani MH, **Starling RC**, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. *Transplantation* 2003 Jun; 75(12):2044-2047.
- 112 Setser RM, Kasper JM, Lieber ML, **Starling RC**, McCarthy PM, White RD. Persistent abnormal left ventricular systolic torsion in dilated cardiomyopathy after partial left ventriculectomy. *The Journal of Thoracic and Cardiovascular Surgery* 2003 Jul; 126(1):48-55.
- 113 Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valentine-von Kaeppler HA, **Starling RC**, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. *The New England Journal of Medicine* 2003 Aug; 349(9):847-858.
- 114 Qin JX, Shiota T, McCarthy PM, Asher CR, Hail M, Agler DA, Popovic ZB, Greenberg NL, Smedira NG, **Starling RC**, Young JB, Thomas JD. Importance of mitral valve repair associated with left ventricular reconstruction for patients with ischemic cardiomyopathy: A real-time three-dimensional echocardiographic study. *Circulation* 2003 Sep; 108(SII):II241-II246.
- 115 Masri SC, Yamani MH, Russell MA, Ratliff NB, Yang J, Almasan A, Apperson-Hansen C, Li J, **Starling RC**, McCarthy P, Young JB, Bond M. Sustained apoptosis in human cardiac allografts despite histologic resolution of rejection. *Transplantation* 2003 Sep; 76(5):859-864.
- 116 Yamani MH, **Starling RC**, Cook DJ, Tuzcu EM, Abdo A, Paul P, Powell K, Ratliff NB, Yu Y, McCarthy PM, Young JB. Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. *Circulation* 2003 Oct; 108(14):1724-1728.
- 117 Setser RM, White RD, Sturm B, McCarthy PM, **Starling RC**, Young JB, Kasper J, Buda T, Obuchowski N, Lieber ML. Noninvasive assessment of cardiac mechanics and clinical outcome after partial left ventriculectomy. *The Annals of Thoracic Surgery* 2003 Nov; 76(5):1576-1585; discussion 1585-1586.
- 118 Tang WH, Girod JP, Lee MJ, **Starling RC**, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. *Circulation* 2003 Dec; 108(24):2964-2966.

- 119 Hoercher KJ, Gonzalez-Stawinski GV, Taylor DO, McCarthy PM, Young JB, **Starling RC**. Cardiac transplantation at the Cleveland Clinic. *Clinical Transplantation* 2003; 267-274.
- 120 Yamani MH, Lauer MS, **Starling RC**, Pothier CE, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, McNeil A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. *American Journal of Transplantation* 2004 Feb; 4(2):257-261.
- 121 Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, **Starling RC**, Young JB, Thomas JD, Klein AL. Plasma B-type natriuretic peptide levels in systolic heart failure: Importance of left ventricular diastolic function and right ventricular systolic function. *Journal of the American College of Cardiology* 2004 Feb; 43(3):416-422.
- 122 O'Neill JO, Taylor DO, **Starling RC**. Immunosuppression for cardiac transplantation - the past, present and future. *Transplantation Proceedings* 2004 Mar; 36(S2):309S-313S.
- 123 Yousufuddin M, Haji S, **Starling RC**, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, Saad Y, Karnik SS, Wang D, McCarthy PM, Young JB, Yamani MH. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. *European Heart Journal* 2004 Mar; 25(5):377-385.
- 124 Haji SA, **Starling RC**, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, Cook DJ, Ratliff NB, McCarthy PM, Young JB, Yamani MH. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. *The Journal of Heart and Lung Transplantation* 2004 Mar; 23(3):277-283.
- 125 Yamani MH, Yousufuddin M, **Starling RC**, Tuzcu M, Ratliff NB, Cook DJ, Abdo A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Does acute cellular rejection correlate with cardiac allograft vasculopathy? *The Journal of Heart and Lung Transplantation* 2004 Mar; 23(3):272-276.
- 126 Yousufuddin M, Cook DJ, **Starling RC**, Abdo A, Paul P, Tuzcu EM, Ratliff NB, McCarthy PM, Young JB, Yamani MH. Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. *Journal of the American College of Cardiology* 2004 May; 43(9):1565-1573.
- 127 O'Neill JO, McCarthy PM, Brunken RC, Buda T, Hoercher K, Young JB, **Starling RC**. PET abnormalities in patients with nonischemic cardiomyopathy. *Journal of Cardiac Failure* 2004 Jun; 10(3):244-249.
- 128 Kubo SH, Schulman S, **Starling RC**, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York heart association classification. *Journal of Cardiac Failure* 2004 Jun; 10:228-235.
- 129 Mann DL, Acker MA, Jessup M, Sabbah HN, **Starling RC**, Kubo SH, on behalf of Acorn Investigators and Study Coordinators. Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. *Journal of Cardiac Failure* 2004 Jun; 10(3):185-192.
- 130 Kumpati GS, Cook DJ, Blackstone EH, Rajeswaran J, Abdo AS, Young JB, **Starling RC**, Smedira NG, McCarthy PM. HLA sensitization in ventricular assist device recipients: Does type of device make a difference? *The Journal of Thoracic and Cardiovascular Surgery* 2004 Jun; 127:1800-1807.
- 131 Nash PJ, Avery RK, Tang WH, **Starling RC**, Taege AJ, Yamani MH. Encephalitis owing to human herpesvirus-6 after cardiac transplantation. *American Journal of Transplantation* 2004 Jul; 4(7):1200-1203.
- 132 Yamani MH, Cook DJ, Tuzcu EM, Abdo A, Paul P, Ratliff NB, Yu Y, Yousufuddin M, Feng J, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB, **Starling RC**. Systemic up-regulation of angiotensin II type 1 receptor in cardiac donors with spontaneous intracerebral hemorrhage. *American Journal of Transplantation* 2004 Jul; 4(7):1097-1102.
- 133 Schenk S, McCarthy PM, **Starling RC**, Hoercher KJ, Hail MD, Ootaki Y, Francis GS, Doi K, Young JB, Fukamachi K. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy.

The Journal of Thoracic and Cardiovascular Surgery 2004 Jul; 128(1):38-43.

- 134 Mahon NG, O'Neill JO, Young JB, Bennett R, Hoercher K, Banbury MK, Navia JL, Smedira NG, McCarthy PM, **Starling RC**. Contemporary outcomes of outpatients referred for cardiac transplantation evaluation to a tertiary heart failure center: Impact of surgical alternatives. *Journal of Cardiac Failure* 2004 Aug; 10(4):273-278.
- 135 Schenk S, Popovic ZB, Ochiai Y, Casas F, McCarthy PM, **Starling RC**, Kopcak Jr MW, Dessoffy R, Navia JL, Greenberg NL, Thomas JD, Fukamachi K. Preload-adjusted right ventricular maximal power: Concept and validation. *American Journal of Physiology – Heart and Circulatory Physiology* 2004 Oct; 287(4):H1632-H1640.
- 136 Yamani MH, Erinc K, **Starling RC**, Young JB, Ratliff NB, Cook DJ, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, Bennett R, Smedira N, Tuzcu EM. Donor intracranial bleeding is associated with advanced transplant coronary vasculopathy: Evidence from intravascular ultrasound. *Transplantation Proceedings* 2004 Nov; 36(9):2564-2566.
- 137 Erinc K, Yamani MH, **Starling RC**, Young JB, Crowe T, Ratliff NB, Cook DJ, Hobbs R, Bott-Silverman C, Rincon G, Smedira N, Tuzcu EM. The influence of donor gender on allograft vasculopathy: Evidence from intravascular ultrasound. *Transplantation Proceedings* 2004 Dec; 36(10):3129-3131.
- 138 **Starling RC**. Worldwide clinical experience with the CorCap Cardiac Support Device. *Journal of Cardiac Failure* 2004 Dec; 10(S6):S225-S233.
- 139 **Starling RC**, Hare JM, Hauptman P, McCurry KR, Mayer HW, Kovarik JM, Schmidli H. Therapeutic drug monitoring for Everolimus in heart transplant recipients based on exposure-effect modeling. *American Journal of Transplantation* 2004 Dec; 4:2126-2131.
- 140 Sun JP, Abdalla IA, Asher CR, Greenberg NL, Popovic ZB, Taylor DO, **Starling RC**, Thomas JD, Garcia MJ. Non-invasive evaluation of orthotopic heart transplant rejection by echocardiography. *The Journal of Heart and Lung Transplantation* 2005 Feb; 24(2):160-165.
- 141 O'Neill JO, Bott-Silverman CE, McRae III AT, Troughton RW, Ng K, **Starling RC**, Young JB. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. *American Heart Journal* 2005 Feb; 149(2):363-369.
- 142 Navia JL, Atik FA, Vega PR, Garcia M, **Starling RC**, Gonzalez-Stawinski GV, Smedira NG, Cosgrove DM. Tricuspid valve repair for biopsy-induced regurgitation in a heart transplant recipient. *Journal of Heart Valve Disease* 2005 Mar; 14(2):264-267.
- 143 Gonzalez-Stawinski GV, Atik FA, McCarthy PM, Roselli EE, Hoercher K, Navia JL, Smedira NG, **Starling RC**, Young JB, Cook DJ. Early and late rejection and HLA sensitization at the time of heart transplantation in patients bridged with left ventricular assist devices. *Transplantation Proceedings* 2005 Mar; 37(2):1349-1351.
- 144 O'Neill JO, McRae III AT, Troughton RW, Ng K, Taylor DO, Yamani MH, Young JB, **Starling RC**. Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients. *The Journal of Heart and Lung Transplantation* 2005 Apr; 24(4):416-420.
- 145 Navia JL, Atik FA, Grimm RA, Garcia M, Vega PR, Myhre U, **Starling RC**, Wilkoff BL, Martin D, Houghtaling PL, Blackstone EH, Cosgrove DM. Minimally invasive left ventricular epicardial lead placement: Surgical techniques for heart failure resynchronization therapy. *The Annals of Thoracic Surgery* 2005 May; 79(5):1536-1544 (Discussion).
- 146 Eisen H, Kobashigawa J, **Starling RC**, Valantine H, Mancini D. Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors. *Transplantation Proceedings* 2005 May; 37(S):4-17.
- 147 Tuzcu EM, Kapadia SR, Sachar R, Ziada KM, Crowe TD, Feng J, Magyar WA, Hobbs RE, **Starling RC**, Young JB, McCarthy P, Nissen SE. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. *Journal of the American College of Cardiology* 2005 May; 45(9):1538-1542.

- 148 Gonzalez-Stawinski GV, Cook DJ, Chang AS, Atik F, Navia JL, Banbury M, Roselli E, Young JB, **Starling RC**, Smedira NG. Early and midterm risk of coronary allograft vasculopathy in patients bridged to orthotopic heart transplantation with ventricular assist devices. *Transplantation* 2005 May 5; 79(9):1175-1179.
- 149 Kobashigawa JA, Tobis JM, **Starling RC**, Tuzcu EM, Smith AL, Valentine HA, Yeung AC, Mehra MR, Anzai H, Oeser BT, Abeywickrama KH, Murphy J, Cretin N. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. *Journal of the American College of Cardiology* 2005 May; 45(9):1532-1537.
- 150 **Starling RC**. Inducible nitric oxide synthase in severe human heart failure: Impact of mechanical unloading. *Journal of the American College of Cardiology* 2005 May; 45(9):1425-1427.
- 151 Murphy RT, **Starling RC**. Genetics and cardiomyopathy: Where are we now? *Cleveland Clinic Journal of Medicine* 2005 Jun; 72(6):465-466, 469-470, 472-473, 477-480 passim.
- 152 Hershberger RE, **Starling RC**, Eisen HJ, Bergh C-H, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD. Daclizumab to prevent rejection after cardiac transplantation. *The New England Journal of Medicine* 2005 Jun; 352(26):2705-2713.
- 153 Troughton RW, Prior DL, Frampton CM, Nash PJ, Pereira JJ, Martin M, Fogarty A, Morehead AJ, **Starling RC**, Young JB, Thomas JD, Lauer MS, Klein AL. Usefulness of tissue Doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). *The American Journal of Cardiology* 2005 Jul; 96(2):257-262.
- 154 Navia JL, Atik FA, Marullo A, **Starling RC**, Garcia M, Vega PR, Smedira NG, McCarthy PM. Bench repair of donor aortic valve with minimal access orthotopic heart transplantation. *The Annals of Thoracic Surgery* 2005 Jul; 80:313-315.
- 155 Brizzio ME, Navia JL, Atik FA, Martin D, Gillinov AM, Gonzalez-Stawinski GV, Wilkoff B, **Starling RC**. Combined minimally invasive pulmonary vein isolation, left atrial appendage excision and cardiac resynchronization therapy for heart failure: Case report. *The Heart Surgery Forum* 2005 Aug; 8(4):E249-E252.
- 156 Yamani MH, Cook DJ, Tuzcu EM, Paul P, Ratliff NB, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, Smedira N, Young JB, **Starling RC**. Systemic activation of integrin alphaVbeta3 in donors with spontaneous intracerebral hemorrhage is associated with subsequent development of vasculopathy in the heart transplant recipient. *The Journal of Heart and Lung Transplantation* 2005 Aug; 24(8):1014-1018.
- 157 Erinc K, Yamani MH, **Starling RC**, Crowe T, Hobbs R, Bott-Silverman C, Rincon G, Young JB, Feng J, Cook DJ, Smedira N, Tuzcu EM. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. *The Journal of Heart and Lung Transplantation* 2005 Aug; 24(8):1033-1038.
- 158 Ogawa T, Veinot JP, Davies RA, Haddad H, Smith SJ, Masters RG, Hendry PJ, **Starling RC**, de Bold MK, Ponce A, Ma KK, Williams K, de Bold AJ. Neuroendocrine profiling of humans receiving cardiac allografts. *The Journal of Heart and Lung Transplantation* 2005 Aug; 24(8):1046-1054.
- 159 Yamani MH, Ratliff NB, Cook DJ, Tuzcu EM, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Smedira N, **Starling RC**. Peritransplant ischemic injury is associated with up-regulation of stromal cell-derived factor-1. *Journal of the American College of Cardiology* 2005 Sep 20; 46(6):1029-1035.
- 160 **Starling RC**, Kovarik JM. Therapeutic drug monitoring for Everolimus in heart transplant recipients: Flawed model or a model for future use? *American Journal of Transplantation* 2005 Sep; 5(9):2330.
- 161 Poggio ED, Roddy M, Riley J, Clemente M, Hricik DE, **Starling RC**, Young JB, Gus B, Yamani MH, Heeger PS. Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. *The Journal of Heart and Lung Transplantation* 2005 Oct; 24(10):1606-1013.

- 162 O'Neill JO, **Starling RC**, Khaykin Y, McCarthy PM, Young JB, Hail M, Albert NM, Smedira N, Chung MK. Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery. *Journal of Thoracic and Cardiovascular Surgery* 2005 Nov; 130(5):1250-1256.
- 163 Yamani MH, Erinc SK, McNeill A, Ratliff NB, Sendrey D, Zhou L, Cook DJ, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Banbury M, Navia J, Smedira N, **Starling RC**. The impact of donor gender on cardiac peri-transplantation ischemia injury. *The Journal of Heart and Lung Transplantation* 2005 Nov; 24(11):1741-1744.
- 164 Yamani MH, Avery R, Mawhorter SD, McNeill A, Cook D, Ratliff NB, Pelegri D, Colosimo P, Kiefer K, Ludrosky K, Hobbs R, Taylor D, Buda T, Yeager M, Young JB, Smedira N, **Starling RC**. The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: A randomized single-center study. *The Journal of Heart and Lung Transplantation* 2005 Nov; 24(11):1766-1769.
- 165 Ozduran V, Yamani MH, Chuang HH, Sipahi I, Cook DJ, Sendrey D, Tong L, Hobbs R, Rincon G, Bott-Silverman C, James K, Taylor DO, Young JB, Navia J, Banbury M, Smedira N, **Starling RC**. Survival beyond 10 years following heart transplantation: The Cleveland Clinic Foundation experience. *Transplant Proceedings* 2005 Dec; 37(10):4509-4512.
- 166 Deng MC, Eisen HJ, Mehra, MR, Billingham M, Marboe, CC, Berry G, Kobashigawa J, Johnson FL, **Starling RC**, Murali S, Pauly DF, Baron H, Wohlgemuth JG, Woodward RN, Klingler TM, Walther D, Lal PG, Rosenberg S, Hunt S. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. *American Journal of Transplantation* 2006 Jan; 6(1):150-160.
- 167 Schenk S, McCarthy PM, Blackstone EH, Feng J, **Starling RC**, Navia JL, Zhou L, Hoercher KJ, Smedira NG, Fukamachi K. Duration of inotropic support after left ventricular assist device implantation: Risk factors and impact on outcome. *Journal of Thoracic and Cardiovascular Surgery* 2006 Feb; 131(2):447-454.
- 168 Verma A, Kilicaslan F, Martin DO, Minor S, **Starling RC**, Marrouche NF, Almahammed S, Wazni OM, Duggal S, Zuzek R, Yamaji H, Cummings J, Chung MK, Tchou PJ, Natale A. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. *Heart* 2006 Feb; 92(2):190-195, Epub 2005 May 27.
- 169 Haji SA, Avery RK, Yamani MH, Tuzcu EM, Crowe TD, Cook DJ, Mawhorter SD, Hobbs R, Young JB, Smedira N, **Starling RC**. Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy. *The Journal of Heart and Lung Transplantation* 2006 Mar; 25(3):294-297.
- 170 Tayara W, **Starling RC**, Yamani MH, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: Comparing aggressive intervention with conservative treatment. *The Journal of Heart and Lung Transplantation* 2006 May; 25(5):504-509, Epub 2006 Mar 30.
- 171 Gonzalez-Stawinski GV, Cook DJ, Chang AS, Banbury MK, Navia JL, Hoercher K, Lober C, Atik FA, Taylor DO, Yamani MH, Young JB, **Starling RC**, Smedira NG. Ventricular assist devices and aggressive immunosuppression: Looking beyond overall survival. *The Journal of Heart and Lung Transplantation* 2006 Jun; 25(6):613-618, Epub 2006 Mar 23.
- 172 Murphy RT, Sigurdsson G, Mulamalla S, Agler D, Popovic ZB, **Starling RC**, Wilkoff BL, Thomas JD, Grimm RA. Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy. *American Journal of Cardiology* 2006 Jun 1; 97(11):1615-1621, Epub 2006 Apr 7.
- 173 Wagoner LE, **Starling RC**, O'Connor CM. Cardiac function and heart failure. *Journal of the American College of Cardiology* 2006 Jun 6; 47(11 Suppl):D18-22.
- 174 Yamani MH, Chuang HH, Ozduran V, Avery RK, Mawhorter SD, Cook DJ, Zilka C, Zeroske K, Buda T, Hobbs RE, Taylor DO, Smedira NG, **Starling RC**. The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. *The Journal of Heart and Lung Transplantation* 2006 Jul; 25(7):820-824, Epub 2006 May 30.

- 175 Gonzalez-Stawinski GV, Chang AS, Navia JL, Banbury MK, Buda T, Hoercher K, **Starling RC**, Taylor DO, Smedira NG. Regional referral system for patients with acute mechanical support: Experience at The Cleveland Clinic Foundation. *ASAIO J* 2006 Jul/Aug; 52(4):445-449.
- 176 Acker MA, Bolling S, Shemin R, Kirklin J, Oh JK, Mann DL, Jessup M, Sabbah HN, **Starling RC**, Kubo SH; Acorn Trial Principal Investigators and Study Coordinators. Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial. *Journal of Thoracic and Cardiovascular Surgery* 2006 Sep; 132(3):568-577, 577.e1-4, Epub 2006 Jul 31.
- 177 Mehra MR, Kobashigawa J, **Starling RC**, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation Guidelines for the care of cardiac transplant candidates - 2006. *The Journal of Heart and Lung Transplantation* 2006 Sep; 25(9):1024-1042.
- 178 Kobashigawa JA, **Starling RC**, Mehra MR, Kormos RL, Bhat G, Barr ML, Sigouin CS, Kolesar J, Fitzsimmons W. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. *The Journal of Heart and Lung Transplantation* 2006 Sep; 25(9):1063-1069, Epub 2006 Jul 18.
- 179 O'Neill JO, **Starling RC**, McCarthy PM, Albert NM, Lytle BW, Navia J, Young JB, Smedira N. The impact of left ventricular reconstruction on survival in patients with ischemic cardiomyopathy. *European Journal of Cardio-Thoracic Surgery* 2006 Nov; 30(5):753-759, Epub 2006 Oct 4.
- 180 Boyle JM, Moualla S, Arrigain S, Worley S, Bakri MH, **Starling RC**, Heyka R, Thakar CV. Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. *American Journal of Kidney Diseases* 2006 Nov; 48(5):787-796.
- 181 Yamani MH, Cook DJ, Rodriguez ER, Thomas DM, Gupta S, Alster J, Taylor DO, Hobbs R, Young JB, Smedira N, **Starling RC**. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. *The Journal of Heart and Lung Transplantation* 2006 Nov; 25(11):1283-1289, Epub 2006 Oct 17.
- 182 Carmichael BB, Setser RM, Stillman AE, Lieber ML, Smedira NG, McCarthy PM, **Starling RC**, Young JB, Weaver JA, Lawrence AG, White RD. Effects of surgical ventricular restoration on left ventricular function: Dynamic MR imaging. *Radiology* 2006 Dec; 241(3):710-717.
- 183 Stehlik J, **Starling RC**, Movsesian MA, Fang JC, Brown RN, Hess ML, Lewis NP, Kirklin JK; Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: A multi-institutional analysis. *The Journal of Heart and Lung Transplantation* 2006 Dec; 25(12):1402-1409.
- 184 **Starling RC**, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH, Kobashigawa J, McCurry K, Marboe C, Mehra MR, Zuckerman A, Deng MC; Working Group on Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant recipients: Initial clinical experience. *The Journal of Heart and Lung Transplantation* 2006 Dec; 25(12):1389-1395.
- 185 Sipahi I, **Starling RC**. Cardiac allograft vasculopathy: An update. *Heart Failure Clinics* 2007 Jan; 3(1):87-95.
- 186 Griffin MT, Lee YH, Salman A, Seo Y, Marin PA, **Starling RC**, Fitzpatrick JJ. Spirituality and well-being among elders: Differences between elders with heart failure and those without heart failure. *Clinical Interventions in Aging* 2007; 2(4):669-675.
- 187 Neaton, JD, Normand SL, Gelijns A. **Starling RC**, Mann DL, Konstam MA. Designs for mechanical circulatory support device studies. *Journal of Cardiac Failure* 2007 Feb; 13(1):63-74.
- 188 Yamani MH, **Starling RC**. Heart transplantation: A magnified model of heart-brain interactions. *Cleveland Clinic Journal of Medicine* 2007 Feb; 74 Suppl 1:S110-3.
- 189 Ng K, Kedia N, Martin D, Tchou P, Natale A, Wilkoff B, **Starling R**, Grimm RA. The benefits of biventricular

pacing in heart failure patients with narrow QRS, NYHA class II and right ventricular pacing. *Pacing and Clinical Electrophysiology* 2007 Feb; 30(2):193-198.

- 190 O'Neill JO, **Starling RC**, Chung MK. Reply to Di Donato and colleagues [Incidence of ventricular arrhythmias after left ventricular reconstructive surgery]. *Journal of Thoracic and Cardiovascular Surgery* 2007; 133:292-293.
- 191 Shea KJ, Sopko NA, Ludrosky K, Hoercher K, Smedira NG, Taylor DO, **Starling RC**, Gonzalez-Stawinski GV. The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation. *European Journal of Cardiothoracic Surgery* 2007; 31:452-456.
- 192 Yamani MH, Taylor DO, Rodriguez ER, Cook DJ, Zhou L, Smedira N, **Starling RC**. Transplant vasculopathy is associated with increased allo map gene expression score. *The Journal of Heart and Lung Transplantation* 2007 Apr; 26(4):403-406.
- 193 Maybaum S, Mancini D, Xydas S, **Starling RC**, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G; LVAD Working Group. Cardiac improvement during mechanical circulatory support: A prospective multicenter study of the LVAD Working Group. *Circulation* 2007 May 15; 115(19):2497-2505.
- 194 Gonzalez-Stawinski GV, Cook DJ, Smedira NG, Navia JL, Taylor DO, Yamani MH, Hoercher K, **Starling RC**, Banbury MK. Attrition from heart transplant waiting list for patients on ventricular assist devices is not affected by desensitization strategies. *Transplantation Proceedings* 2007 Jun; 39(5):1571-1572.
- 195 Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpon LA, Renlund D, Abeywickrama K, Cretin N, **Starling RC**, Eisen HJ; RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by Everolimus in cardiac transplant recipients: A 24-month analysis. *The Journal of Heart and Lung Transplantation* 2007 Jun; 26(6):584-592.
- 196 Baris N, Sipahi I, Kapadia SR, Nicholls SJ, Erinc K, Gulel O, Crowe TD, Hobbs R, Yamani MH, Taylor DO, Smedira N, **Starling RC**, Nissen SE, Tuzcu EM. Coronary angiography for follow-up of heart transplant recipients: Insights from TIMI frame count and TIMI myocardial perfusion grade. *The Journal of Heart and Lung Transplantation* 2007 Jun; 26(6):593-597.
- 197 Hsich E, Chadalavada S, Krishnaswamy G, **Starling RC**, Pothier CE, Blackstone EH, Lauer MS. Long-term prognostic value of peak oxygen consumption in women versus men with heart failure and severely impaired left ventricular systolic function. *American Journal of Cardiology* 2007 Jul 15; 100(2):291-295, Epub 2007 Jun 4.
- 198 Yamani MH, Taylor DO, Haire C, Smedira N, **Starling RC**. Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression. *Clinical Transplantation* 2007 Jul-Aug; 21(4):523-525.
- 199 Tuzcu EM, **Starling RC**, Thomas JD; Highlights of the 56th Annual Scientific Session of the American College of Cardiology, Mar 24-27, 2007. ACC.07 and i2 Summit Highlights: A conversation with the experts. *Journal of the American College of Cardiology* 2007 Aug 21; 50(8 Suppl):C2-31.
- 200 Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, **Starling RC**, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: Design of the invasive monitoring attenuation through gene expression (IMAGE) trial. *The Journal of Heart and Lung Transplantation* 2007 Aug; 26(8):808-814.
- 201 Mann DL, Acker MA, Jessup M, Sabbah HN, **Starling RC**, Kubo SH; Acorn Trial Principal Investigators and Study Coordinators. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. *Annals of Thoracic Surgery* 2007 Oct; 84(4):1226-1235.
- 202 **Starling RC**, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, Kubo SH. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: Three year follow-up results from the Acorn clinical trial. *Annals of Thoracic Surgery* 2007 Oct; 84(4):1236-1242.
- 203 Gonzalez-Stawinski GV, Cook DJ, Chui J, Gupta S, Navia JL, Hoercher K, Taylor DO, Yamani MH, **Starling RC**, Smedira NG. A comparative analysis between survivors and nonsurvivors with antibody mediated cardiac allograft

rejection. *Journal of Surgical Research* 2007 Oct; 142(2):233-238, Epub 2007 Aug 29.

- 204 Sopko N, Shea KJ, Ludrosky K, Smedira N, Hoercher K, Taylor DO, **Starling RC**, Gonzalez-Stawinski GV. Survival is not compromised in donor hearts with echocardiographic abnormalities. *Journal of Surgical Research* 2007 Nov; 143(1):141-144.
- 205 Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, **Starling RC**, Towbin J, Virmani R; American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *Journal of the American College of Cardiology* 2007 Nov 6; 50(19):1914-1931.
- 206 Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, **Starling RC**, Towbin J, Virmani R; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *Circulation* 2007 Nov 6; 116(19):2216-2233, Epub 2007 Oct 24.
- 207 Hill JA, Hummel M, **Starling RC**, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to Everolimus. *Transplantation* 2007 Dec 15; 84(11):1436-1442.
- 208 Sun JP, Niu J, Banbury MK, Zhou L, Taylor DO, **Starling RC**, Garcia MJ, Stewart WJ, Thomas JD. Influence of different implantation techniques on long-term survival after orthotopic heart transplantation: An echocardiographic study. *The Journal of Heart and Lung Transplantation* 2007 Dec; 26(12):1243-1248, Epub 2007 Nov 19.
- 209 Mehra MR, Kobashigawa JA, Deng MC, Fang KC, Klingler TM, Lal PG, Rosenberg S, Uber PA, **Starling RC**, Murali S, Pauly DF, Dedrick R, Walker MG, Zeevi A, Eisen HJ; CARGO Investigators. Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. *The Journal of Heart and Lung Transplantation* 2007 Dec; 26(12):1255-1263, Epub 2007 Nov 26.
- 210 Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, **Starling RC**, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *European Heart Journal* Dec; 28(24):3076-3093, Epub 2007 Oct 24.
- 211 Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, Hobbs R, Smedira N, **Starling RC**. Thymoglobulin induction and steroid avoidance in cardiac transplantation: Results of a prospective, randomized, controlled study. *Clinical Transplantation* 2008 Jan-Feb; 22(1): 76-81.
- 212 Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, **Starling RC**, Paganini E, Tang WH. Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function? *Journal of the American College of Cardiology* 2008 Jan 22; 51(3):300-306.
- 213 Wong RC, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, **Starling R**, Taylor D. Tricuspid regurgitation after cardiac transplantation: An old problem revisited. *The Journal of Heart and Lung Transplantation* 2008 Mar; 27(3):247-252 (Review).
- 214 Mehra MR, Kobashigawa JA, Deng MC, Fang KC, Klingler TM, Lal PG, Rosenberg S, Uber PA, **Starling RC**, Murali S, Pauly DF, Dedrick R, Walker MG, Zeevi A, Eisen HJ, CARGO Investigators. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. *The Journal of Heart and Lung Transplantation* 2008 Mar; 27(3):297-301.
- 215 González-Stawinski GV, Tan CD, Smedira NG, **Starling RC**, Rodríguez ER. Decay-accelerating factor expression

may provide immunoprotection against antibody-mediated cardiac allograft rejection. *The Journal of Heart and Lung Transplantation* 2008 Apr; 27(4):357-361.

- 216 Hoercher KJ, Nowicki ER, Blackstone EH, Singh G, Alster JM, Gonzalez-Stawinski GV, **Starling RC**, Young JB, Smedira NG. Prognosis of patients removed from a transplant waiting list for medical improvement: Implications for organ allocation and transplantation for status 2 patients. *Journal of Thoracic and Cardiovascular Surgery* 2008 May; 135(5):1159-1166.
- 217 Mullens W, Abrahams Z, Skouri HN, Taylor DO, **Starling RC**, Francis GS, Young JB, Tang WH. Prognostic evaluation of ambulatory patients with advanced heart failure. *American Journal of Cardiology* 2008 May 1; 101(9):1297-1302.
- 218 Mullens W, Abrahams Z, Francis GS, Taylor DO, **Starling RC**, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. *Journal of Cardiac Failure* 2008; 14(6):508-514, Epub 2008 May 27.
- 219 Mullens W, Abrahams Z, Francis GS, Skouri HN, **Starling RC**, Young JB, Taylor DO, Tang WH. Sodium nitroprusside for advanced low-output heart failure. *Journal of the American College of Cardiology* 2008; 52(3):200-207.
- 220 Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, **Starling RC**, Klein AL. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. *Journal of Cardiac Failure* 2008; 14(5):394-399, Epub 2008 May 27.
- 221 Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, **Starling RC**, Mancini D, Jessup M. Design of a phase ½ trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. *Journal of Cardiac Failure* 2008 Jun; 14(5):355-367, Epub 2008 May 27.
- 222 Buller DB, Woodall WG, Zimmerman DE, Slater MD, Heimendinger J, Waters E, Hines JM, **Starling RC**, Hau B, Burris-Woodall P, Davis GS, Saba L, Cutter GR. Randomized trial on the 5 a day, the Rio Grande Way Website, a web-based program to improve fruit and vegetable consumption in rural communities. *Journal of Health Communication* 2008 Apr-May; 13(3):230-249.
- 223 Mullens W, Abrahams Z, Sokos G, Francis GS, **Starling RC**, Young JB, Taylor DO, Tang WH. Gender differences in patients admitted with advanced decompensated heart failure. *American Journal of Cardiology* 2008 Aug 15; 102(4):454-458, Epub 2008 May 22.
- 224 Angheloiu GO, Rahaby M, **Starling RC**, Angheloiu V, McNamara DM, Yamani MI, Young JB. Myocardial degradation and left bundle branch block predict conversion to low ejection fraction in heart failure with preserved systolic function. *Congestive Heart Failure* 2008 Jul-Aug; 14(4):192-196.
- 225 Marwick TH, **Starling RC**. The riddle of determining cardiac resynchronization therapy response a physiologic approach to dyssynchrony therapy. *Journal of the American College of Cardiology* 2008 Oct 21; 52(17):1410-1412.
- 226 Khan MN, Jais P, Cummings J, DiBiase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, **Starling RC**, Dello Russo A, Pelagronio G, Brachmann J, Schibgilla V, Bonso A, Cassella M, Raviele A, Haissaguerre M, Natale A; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *New England Journal of Medicine* 2008 Oct 23; 359(17):1778-1785.
- 227 Tang WH, Mullens W, Borowski AG, Tong W, Shrestha K, Troughton RW, Martni MG, Kassimatis K, Agler D, Jasper S, Grimm RA, **Starling RC**, Klein AL. Relation of mechanical dyssynchrony with underlying cardiac structure and performance in chronic systolic heart failure: Implications on clinical response to cardiac resynchronization. *Europace* 2008 Dec; 10(12):1370-1374, Epub 2008 Nov 6.
- 228 Keslar K, Rodriguez ER, Tan CD, **Starling RC**, Heeger PS. Complement gene expression in human cardiac

allograft biopsies as a correlate of histological grade of injury. *Transplantation* 2008 Nov 15; 86(9):1319-1321.

- 229 Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, **Starling RC**, Deng MC, Menon S, Mullen GM, Jaski B, Bailey KR, Cunningham MW, Dec GW; Giant Cell Myocarditis Treatment Trial Investigators. Usefulness of immunosuppression for giant cell myocarditis. *American Journal of Cardiology* 2008 Dec 1; 102(11):1535-1539, Epub 2008 Sep 18.
- 230 Zahr F, Ootaki Y, **Starling RC**, Smedira NG, Yamani M, Thuita L, Fukamachi K. Preoperative risk factors for morality after biventricular assist device implantation. *Journal of Cardiac Failure* 2008 Dec; 14(10):844-849, Epub 2008 Oct 14.
- 231 Ezekowitz JA, Hernandez AF, **Starling RC**, Yancy CW, Massie B, Hill JA, Krum H, Diaz R, Ponikowski P, Metra M, Howlett JG, Gennevois D, O'Connor CM, Califf RM, Fonarow GC. Standardizing care for acute decompensated heart failure in a large mega trial: The approach for the acute studies of clinical effectiveness of nesiritide in subjects with decompensated heart failure (ASCEND-HF). *American Heart Journal* 2009 Feb; 157(2):219-228, Epub 2008 Nov 28.
- 232 Hernandez AF, O'Connor CM, **Starling RC**, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM. Rationale and design of the acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). *American Heart Journal* 2009 Feb; 157(2):271-277, Epub 2008 Dec 19.
- 233 Styron JF, Jois-Bilowich P, **Starling RC**, Hobbs RE, Kontos MC, Pang PS, Peacock WF. Initial emergency department systolic blood pressure predicts left ventricular systolic function in acute decompensated heart failure. *Congestive Heart Failure* 2009 Jan- Feb; 15(1):9-13.
- 234 Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, **Starling RC**, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *Journal of the American College of Cardiology* 2009 Feb 17; 53(7):589-596.
- 235 Mullens W, Vergaq T, Grimm RA, **Starling RC**, Wilkoff BL, Tang WH. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. *Journal of the American College of Cardiology* 2009 Feb 17; 53(7):600-607.
- 236 Mullens W, Grimm RA, Verga T, Dresing T, **Starling RC**, Wilkoff BL, Tang WH. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. *Journal of the American College of Cardiology* 2009 Mar 3; 53(9):765-773.
- 237 Kobashigawa J, Mehra M, West L, Kerman R, George J, **Starling RC**, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed EF; Consensus conference participants. *The Journal of Heart and Lung Transplantation* 2009 Mar; 28(3):213-225.
- 238 Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, Schoenhagen P, **Starling RC**, Flamm SD, Desai MY. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: A delayed hyper enhancement cardiac magnetic resonance study. *JACC: Cardiovascular Imaging* 2009 Jan; 2(1):34-44.
- 239 Mullens W, Abrahams Z, Francis GS, Sokos G, **Starling RC**, Young JB, Taylor DO, Tang WH. Usefulness of isosorbide dinitrate in hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. *American Journal of Cardiology* 2009 Apr 15; 103(8):1113-1119, Epub 2009 Feb 21.
- 240 Mountis MM, **Starling RC**. Management of left ventricular assist devices after surgery: Bridge, destination and recovery. *Current Opinions in Cardiology* 2009 May; 24(3):252-256.
- 241 Triposkiadis F, Parissis JT, **Starling RC**, Skoularigis J, Louridas G. Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. *Expert Opinion on Investigational Drugs* 2009 Jun; 18(6): 695-707, DOI: 10.1517/13543780902922660.

- 242 Austin BA, Duffy B, Tan C, Rodriguez ER, **Starling RC**, Desai MY. Comparison of functional status, electrocardiographic and echocardiographic parameters to mortality in Endomyocardial – biopsy proven cardiac Amyloidosis. *American Journal of Cardiology* 2009 May 15; 103(10):1429-1433, Epub 2009 Apr 1.
- 243 Styron JF, Jois-Bilowich P, Tallman T, Emerman C, **Starling RC**, Frank Peacock W. Outcomes associated with Nesiritide administration for acute decompensated heart failure in the emergency department observation unit: A single center experience. *Congestive Heart Failure* 2009 May-Jun; 15(3):103-107.
- 244 Hsich E, Gorodeski EZ, **Starling RC**, Blackstone EH, Ishwaran H, Lauer MS. Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction. *Circulation* 2009 Jun 30; 119(25):3189-3197, Epub 2009 Jun 15.
- 245 Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volina S, Calin GA, Kotwal A, Moravec CS, **Starling RC**, Perez DM, Sen S, Wu Q, Plow EF, Croce CM, Karnik S. A unique micro RNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. *Journal of Biological Chemistry* 2009 Jul 29, Epub ahead of print.
- 246 Cantillon DJ, Gorodeski EZ, Caccamo M, Smedira NG, Wilkoff BL, **Starling RC**, Saliba W. Long term outcomes and clinical predictors for pacing after cardiac transplantation. *The Journal of Heart and Lung Transplantation* 2009 Aug; 28(8):791-798.
- 247 Kwon DH, Halley CM, Popovic ZB, Carrigan TP, Zysek V, Setser R, Schoenhagen P, Flamm SD, **Starling RC**, Desai, MY. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. *European Journal of Heart Failure* 2009 Oct; 11 (10):937-944.
- 248 Wong RC, Dumont CA, Austin BA, Kwon DH, Flamm SD, Thomas JD, **Starling RC**, Desai MY. Relation of ventricular-vascular coupling to exercise capacity in ischemic cardiomyopathy: A cardiac multi-modality imaging study. *International Journal of Cardiovascular Imaging* 2009 Oct; 26(2):151-159. DOI: 10.1007/s10554-009-9516-4.
- 249 Xu DS, Hartman D, Ludrosky K, Campbell J, **Starling RC**, Taylor DO, Smedira NG, Gonzalez-Stawinski GV. Impact of donor high-risk social behaviors on recipient survival in cardiac transplantation. *Transplantation* 2010 Apr 15; 89(7):873-878, DOI: 10.1097/TP.0b013e3181ca56e0.
- 250 Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, **Starling RC**, Wilkoff BL. Improved Survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. *Heart Rhythm* 2010 Apr; 7(4):466-471, Epub 2010 Jan 4.
- 251 Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, **Starling RC**, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ. Clinical management of continuous flow left ventricular assist devices in advanced heart failure. *The Journal of Heart and Lung Transplantation* 2010 Feb 23, (Epub ahead of print).
- 252 **Starling RC**. Improved quantity and quality of life: A winning combination to treat advanced heart failure. *Journal of the American College of Cardiology* 2010 Apr 27; 55(17):1835-1836 (no abstract available).
- 253 Verhaert D, Grimm RA, Puntawangkoon C, Wolski K, De S, Wilkoff BL, **Starling RC**, Tang WH, Thomas JD, Popovic ZB. Long term reverse remodeling with cardiac resynchronization therapy: Results of extended echocardiographic follow-up. *Journal of the American College of Cardiology* 2010 Apr 27; 55(17):1788-1795.
- 254 Smedira NG, Hoercher KJ, Yoon DY, Rajeswaran J, Klingman L, **Starling RC**, Blackstone EH. Bridge to transplant experience: Factors influencing survival to and after cardiac transplant. *Journal of Thoracic and Cardiovascular Surgery* 2010 May; 139(5):1295-1305, 1305.e1-4.
- 255 Eckman PM, Hanna M, Taylor DO, **Starling RC**, Gonzalez-Stawinski GV. Management of the sensitized adult heart transplant candidate. *Clinical Transplantation* 2010 May 10, (Epub ahead of print).

- 256 Pham MX, Teuteberg JJ, Kfoury AG, **Starling RC**, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valentine HA; IMAGE Study Group. Gene expression profiling for rejection surveillance after cardiac transplantation. *New England Journal of Medicine* 2010 May 20; 362(20):1890-1900, Epub 2010 Apr 22.
- 257 Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, **Starling RC**, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guidelines. *Journal of Cardiac Failure* 2010 Jun; 16(6):e1-194.
- 258 Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen J, Parameshwar J, **Starling RC**, Uber PA. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy – 2010. *The Journal of Heart and Lung Transplantation* 2010 Jul; 29(7):717-727.
- 259 Gorodeski EZ, **Starling RC**, Blackstone EH. Are all readmissions bad readmissions? *New England Journal of Medicine* 2010 Jul 15; 363(3):297-298.
- 260 West RL, Hernandez AF, O'Connor CM, **Starling RC**, Califf RM. A review of dyspnea in acute heart failure syndromes. *American Heart Journal* 2010 Aug; 160(2):209-214 (review).
- 261 Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsieh E, **Starling RC**. Application of the Seattle heart failure model in ambulatory patients presented to an advanced heart failure therapeutics committee. *Circulation: Heart Failure* 2010 Aug 26, (Epub ahead of print).
- 262 Srinivas TR, Stephany BR, Budev M, Mason DP, **Starling RC**, Miller C, Goldfarb DA, Flechner SM, Poggio ED, Schold JD. An emerging population: Kidney transplant candidates who are placed on the waiting list after liver, heart and lung transplantation. *Clinical Journal of the American Society of Nephrology* 2010 Oct; 5(10):1881-1886, Epub 2010 Sep 2.
- 263 Toma M, **Starling RC**. Inotropic therapy for end-stage heart failure patients. *Current Treatment Options in Cardiovascular Medicine* 2010 Oct; 12(5):409-419.
- 264 Cantillon DJ, Tarakji KG, Hu T, Hsu A, Smedira NG, **Starling RC**, Wilkoff BL, Saliba WI. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: Analysis of the UNOS/OPTN cardiac transplant database. *Heart Rhythm*, 2010 Nov; 7(11):1567, 1571, DOI:10.1016/j.hrthm.2010.06.026, Epub 2010 Jun 22.
- 265 Giamouzis G, Butler J, **Starling RC**, Karayannis G, Nastas J, Parisi C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, Skoularigis J, Westermann D, Tschope C, Triposkiadis F. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. *Journal of Cardiac Failure* 2010 Dec; 16(12):922-930.
- 266 Kobashigawa J, Crespo-Leiro M, Ensminger S, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Heimann N, Kfoury A, Mancini D, Mohacsi P, Patel J, Pereira N, Platt J, Reed E, Reinsmoen N, Rodriguez R, Rose M, Russell S, **Starling RC**, Suciuc-Focia N, Tallaj J, Taylor DO, VanBakel A, West L, Zeevi A, Zuckermann A. Report from a consensus conference on antibody-mediated rejection in heart transplantation. *The Journal of Heart and Lung Transplantation* 2011 Mar; 30(3):252-269.
- 267 **Starling RC**, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee EC, Cotts WG, Denofrio D, Pham DT, Farrar DJ, Pagani FD. Results of the post-U.S. Food and Drug Administration – approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation a prospective study using the INTERMACS (interagency registry for mechanically assisted circulatory support). *Journal of the American College of Cardiology* 2011 May 10; 57(19):1890-1898. DOI: 10.1016/j.jacc.2010.10.062.
- 268 Tanaka H, Tanabe M, Simon MA, **Starling RC**, Markham D, Thohan V, Mather P, McNamara DM, Gorcsan J III. Left ventricular mechanical dyssynchrony in acute onset cardiomyopathy: Association of its resolution with

improvements in ventricular function. *JACC: Cardiovascular Imaging* 2011 May; 4(5):445-456.

- 269 O'Connor CM, **Starling RC**, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajada M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dhalstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Fleker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesride in patients with acute decompensated heart failure. *New England Journal of Medicine* 2011, Jul 7; 365(1):32-43.
- 270 Mann DL, Kubo SH, Sabbah HN, **Starling RC**, Jessup M, Oh JK, Acker MA. Beneficial effects of the CorCap Cardiac Support Device: Five-year results from the Acorn Trial. *Journal of Thoracic and Cardiovascular Surgery* 2011 Jul 13 (Epub ahead of print).
- 271 Frank DL, Baumann M, Khorshid L, Grossman-McKee A, Kiffer J, Tang W, **Starling RC**, McKee MG, Moravec CS. Biofeedback in heart failure patients awaiting transplantation. *Cleveland Clinic Journal of Medicine* 2011 Aug; 78 Suppl. 1:S80a.
- 272 McNamara DM, **Starling RC**, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, Gorscan J III, Kip KE, Dec GW; IMAC Investigators. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy) 2 Study. *Journal of the American College of Cardiology* 2011 Sep 6; 58(11):1112-1118.
- 273 Acker MA, Jessup M, Bolling SF, Oh J, **Starling RC**, Mann DL, Sabbah HN, Shermin R, Kirklin J, Kubo SH. Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. *Journal of Thoracic and Cardiovascular Surgery* 2011 Sep; 142(3):569-574.e1, Epub 2011 Jan 26.
- 274 **Starling RC**, Farrar DJ. Correspondence Reply. *Journal of the American College of Cardiology* 2011 Sep 13; 58(12):1285-1286, DOI: 10.1016/j.jacc.2011.06.013
- 275 Rickard J, Brennan DM, Martin DO, Hsieh E, Tang WH, Lindsay BD, **Starling RC**, Wilkoff BL, Grimm RA. The impact of left ventricular size on response to cardiac resynchronization therapy. *American Heart Journal* 2011 Oct; 162(4):646-653, Epub 2011 Sep 14.
- 276 Verhaert D, Popovic ZB, De S, Puntawangkoon C, Wolski K, Wilkoff BL, **Starling RC**, Tang WH, Thomas JD, Griffin BP, Grimm RA. Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy. *Circulation: Cardiovascular Imaging* 2011 Nov (Epub ahead of print).
- 277 Triposkiadis F, **Starling RC**, Boudoulas H, Giamouzis G, Butler J. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? *Heart Failure Review* 2011 Nov 16, (Epub ahead of print).
- 278 Patarroyo M, Simbaqueba C, Shrestha K, **Starling RC**, Smedira N, Tang WH, Taylor DO. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. *The Journal of Heart and Lung Transplantation* 2011 Nov. 21, (Epub ahead of print).
- 279 Hanna MA, Tang WH, Teo BW, O'Neill JO, Weinstein DM, Lau SM, Van Lente F, **Starling RC**, Paganini EP, Taylor DO. Extracorporeal ultrafiltration vs conventional diuretic therapy in advanced decompensated heart failure. *Congestive Heart Failure* 2012 Jan; 18(1):54-63.
- 280 Cantillon DJ, Bianco C, Wazni OO, Kanj M, Smedira NG, Wilkoff BL, **Starling RC**, Saliba WI. Electrophysiologic characteristics and catheter ablation of ventricular tachyarrhythmias among patients with heart failure on ventricular assist device support. *Heart Rhythm*, 2012 Jan 28, (Epub ahead of print).
- 281 Greenberg BH, Anand IS, Burnett JC Jr, Chin J, Dracup KA, Feldman AM, Force T, Francis GS, Houser SR, Hunt SA, Konstam MA, Lindenfeld J, Mann DL, Mehra MR, Paul SC, Piano MR, Ross HJ, Sabbah HN, **Starling RC**, Udelson JE, Yancy CW, Zile MR, Massie BM. The Heart Failure Society of America in 2020: A vision for the

future. *Journal of Cardiac Failure* 2012 Feb; 18(2):90-93.

- 282 Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, **Starling RC**. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guidelines Committee. *Journal of Cardiac Failure* 2012 Feb; 18(2):94-106.
- 283 McNamara DM, **Starling RC**, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, Gorscan J III, Kip KE, Dec GW. Correspondence Reply. *Journal of the American College of Cardiology* 2012 Feb 21; 59(8):776-777.
- 284 Shah MR, **Starling RC**, Schwartz Longacre L, Mehra MR, Working Group Participants. Heart transplantation research in the next decade—a goal to achieving evidence-based outcomes: National Heart, Lung, and Blood Institute working group. *Journal of the American College of Cardiology* 2012 Apr 3; 59(14):1263-1269.
- 285 Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, **Starling RC**. Update on aldosterone antagonists used in heart failure with reduced left ventricular ejection fraction heart failure Society of America Guidelines Committee. *Journal of Cardiac Failure* 2012 Apr; 18(4):265-281.
- 286 Ezekowitz JA, Hernandez AF, O'Connor CM, **Starling RC**, Prouix G, Weiss MH, Bakal JA, Califf RM, McMurray JJ, Armstrong PW. Assessment of dyspnea in acute decompensated heart failure: Insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. *Journal of the American College of Cardiology* 2012 Apr 17; 59(16):1441-1448.
- 287 Fukamachi K, Shiose A, Massiello AL, Horvath DJ, Golding LAR, Lee S, **Starling RC**. Implantable continuous-flow right ventricular assist device: Lessons learned in development of a Cleveland Clinic device. *Annals of Thoracic Surgery* 2012 May; 93(5):1746-1752.
- 288 Krum H, Lemke B, Birnie D, Lee KL, Aonuma K, **Starling RC**, Gasparini M, Gorscan J, Rogers T, Sambelashvili A, Kalmes A, Martin D. A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial. *American Heart Journal* 2012 May; 163(5):747-752.e1.
- 289 Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, **Starling RC**, Mann DL. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. *American Heart Journal* 2012 Jun; 163(6):954-962.e1.
- 290 Chamogeorgakis T, Koval CE, Smedira NG, **Starling RC**, Gonzalez-Stawinski GV. Outcomes associated with surgical management of infections related to the HeartMate II left ventricular assist device: Implications for destination therapy patients. *The Journal of Heart and Lung Transplantation* 2012 Aug; 31(8):904-906.
- 291 Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, **Starling RC**, O'Connor CM. Troponin I in acute decompensated heart failure: Insights from the ASCEND-HF study. *European Journal of Heart Failure* 2012 Nov; 14(11):1257-1264, DOI: 10.1093/eurjhf/hfs110, Epub 2012 Jul 4.
- 292 Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, Gasparini M, **Starling RC**, Milasinovic G, Rogers T, Sambelashvili A, Houmsse M, Gorscan J III; Adaptive CRT Study Investigators. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the Adaptive CRT Trial. *Heart Rhythm* 2012 Nov; 9(11):1807-1814. DOI: 10.1016/j.hrthm.2012.07.009, Epub 2012 Jul 14.
- 293 Grant AD, Smedira NG, **Starling RC**, Marwick TH. Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation.

- 294 Kwon DH, Hachamovitch R, Popovic ZB, **Starling RC**, Desai MY, Flamm SD, Lytle BW, Marwick TH. Survival in patients with severe ischemic cardiomyopathy undergoing revascularization versus medical therapy: Association with end-systolic volume and viability. *Circulation* 2012 Sep 11; 126(11 Suppl 1):S3-8.
- 295 Patarroyo M, Wehbe, Hanna M, Taylor DO, **Starling RC**, Demirjian S, Tang WH. Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. *Journal of the American College of Cardiology* 2012 Nov 6; 60(19):1906-12, DOI: 10.1016/j.jacc.2012.08.957, Epub 2012 Oct 10.
- 296 Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, **Starling RC**, O'Connor CM, Ponikowski P. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: Findings from ASCEND-HF. *European Journal of Heart Failure* 2013 Apr; 15(4):456-64, DOI: 10.1093/eurjhf/hfs188, Epub 2012 Nov 15.
- 297 Lee Sangjin, Fukamachi Kiyotaka, Golding Leonard, Moazami Nader, **Starling, RC**. Left ventricular assist devices: From the bench to the clinic. *Cardiology* 2013; 125:1-12, DOI: 10.1159/00346865.
- 298 Mihaljevic T, Planinc M, Williams SJ, Gillinov AM, Sabik JF 3rd, Svensson LG, **Starling RC**, Smedira NG, Blackstone EH. Less invasive versus conventional heart valve surgery in patients with severe heart failure. *Journal of Thoracic and Cardiovascular Surgery* 2013 Oct 10, pii: S0022-5223(13)00949-5. DOI: 10.1016/j.jtcvs.2013.08.029.
- 299 Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin- Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, **Starling RC**. Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. *Journal of Cardiac Failure* 2013; 19(6):371-389, DOI: 10.1016/j.cardfail.2013.04.002.
- 300 Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, Lewinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, **Starling RC**, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. *JAMA* 2013 Nov 18; 310(23):2533-2543. DOI: 10.1001/jama.2013.282190.
- 301 Askar M, Hsich E, Reville P, Nowacki AS, Baldwin W, Bakdash S, Daghestani J, Zhang A, Klingman L, Smedira N, Moazami N, Taylor DO, **Starling RC**, Gonzalez-Stawinski G. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. *The Journal of Heart and Lung Transplantation* 2013 Dec; 32(12):1241-1248, DOI: 10.1016/j.healun.2013.08.014, Epub 2013 Sep 24.
- 302 Reed SD, Kaul P, Li Y, Eapen ZJ, Davidson-Ray L, Schulman KA, Massie BM, Armstrong PW, **Starling RC**, O'Connor CM, Hernandez AF, Califf RM. Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: Findings from ASCEND-HF. *Journal of Cardiac Failure* 2013 Sep; 19(9):611-620, DOI: 10.1016/j.cardfail.2013.07.003.
- 303 Bunte MC, Blackstone EH, Thuita L, Fowler J, Joseph L, Ozaki A, **Starling RC**, Smedira NG, Mountis MM. Major bleeding during HeartMate II support. *Journal of The American College of Cardiology* 2013 Dec 10; 62(23):2188-2196, DOI: 10.1016/j.jacc.2013.05.089, Epub 2013 Aug 28.
- 304 Howlett JG, Ezekowitz JA, Podder M, Hernandez AF, Diaz R, Dickstein K, Dunlap ME, Corbalán R, Armstrong PW, **Starling RC**, O'Connor CM, Califf RM, Fonarow GC; ASCEND-HF Investigators. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). *Circulation: Cardiovascular Quality and Outcomes* 2013 Sep 1; 6(5):534-542, DOI: 10.1161/CIRCOUTCOMES.113.000119, Epub 2013 Jul 30.

- 305 Park JH, Kwon DH, **Starling RC**, Marwick TH. Role of imaging in the detection of reversible cardiomyopathy. *Journal of Cardiovascular Ultrasound* 2013 Jun; 21(2):45-55.
- 306 Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, **Starling RC**, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, O'Connor CM, Califf RM, Hernandez AF. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates? Findings from ASCEND-HF. *Circulation: Heart Failure* 2013 Jul; 6(4):727-732. DOI: 10.1161/CIRCHEARTFAILURE.112.000265, Epub 2013 Jun 14.
- 307 Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, **Starling RC**, Hernandez AF. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: Results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). *Journal of the American College of Cardiology* 2013 Sep 24; 62(13):1177-1183. DOI: 10.1016/j.jacc.2013.04.073, Epub 2013 Jun 7.
- 308 Tang WH, Patarroyo M, Wehbe E, Hanna M, Taylor DO, Demirjian S, **Starling RC**. Ultrafiltration in refractory heart failure. Correspondence Reply. *Journal of the American College of Cardiology* 2013; 61(15):1659, DOI:10.1016/j.jacc.2012.12.037
- 309 **Starling RC**. Advanced heart failure: Transplantation. LVADs and beyond. *Cleveland Clinic Journal of Medicine* 2013 Jan; 80(1):33-40. DOI: 10.3949/ccjm.80gr.12003.
- 310 Fukamachi K, Shiose A, Massiello A, Horvath DJ, Golding LA, Lee S, **Starling RC**. Preload sensitivity in cardiac assist devices. *Annals of Thoracic Surgery* 2013 Jan; 95(1):373-380. DOI: 10.1016/j.athoracsur.2012.07.077, Epub 2012 Dec 25.
- 311 Moazami N, Fukamachi K, Kobayashi M, Smedira NG, Hoercher KJ, Massiello A, Lee S, Horvath DJ, **Starling RC**. Axial and centrifugal continuous-flow rotary pumps: A translation from pump mechanics to clinical practice. *The Journal of Heart and Lung Transplantation* 2013 Jan; 32(1):1-11. DOI: 10.1016/j.healun.2012.10.001.
- 312 Acker MA, Pagani FD, Stough WG, Mann DL, Jessup M, Kormos R, Slaughter MS, Baldwin T, Stevenson L, Aaronson KD, Miller L, Naftel D, Yancy C, Rogers J, Teuteberg J, **Starling RC**, Griffith B, Boyce S, Westaby S, Blume E, Wearden P, Higgins R, Mack M. Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. *Circulation: Heart Failure* 2013 Jan; 6(1):e1-e11. DOI: 10.1161/HHF.0b013e318279f6b5, Epub 2012 Nov 12.
- 313 Acker MA, Pagani FD, Stough WG, Mann DL, Jessup M, Kormos R, Slaughter MS, Baldwin T, Stevenson L, Aaronson KD, Miller L, Naftel D, Yancy C, Rogers J, Teuteberg J, **Starling RC**, Griffith B, Boyce S, Westaby S, Blume E, Wearden P, Higgins R, Mack M. Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: Executive summary. *Circulation: Heart Failure* 2013 Jan; 6(1):145-150, DOI: 10.1161/HHF.0b013e318279f55d, Epub 2012 Nov 12.
- 314 Nagarajan V, Cauthen CA, **Starling RC**, Tang WH. Prognosis of morbid obesity patients with advanced heart failure. *Congestive Heart Failure* 2013; 19:160-164.
- 315 **Starling RC**, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, Lytle BW, Smedira NG. Unexpected abrupt increase in left ventricular assist device thrombosis. *New England Journal of Medicine* 2014 Jan 2; 370(1):33-40. DOI: 10.1056/NEJMoa1313385, Epub 2013 Nov 27.
- 316 Oliveira G, Matthias D, Naftel D, Myers S, Yuan Y, Tang WH, Gonzalez-Stawinski G, Young J, Taylor D, **Starling RC**. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support. *Journal of the American College of Cardiology* 2014 Jan 28; 63(3):240-248. DOI: 10.1016.
- 317 Najjar SS, Slaughter MS, Pagani FD, **Starling RC**, McGee EC, Eckman P, Tatroles AJ, Moazami N, Kormos RL, Hathaway DR, Najarian KB, Bhat G, Aaronson KD, Boyce SW; HVAD Bridge to Transplant ADVANCE Trial Investigators. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant

and continued access protocol trial. *The Journal of Heart and Lung Transplantation* 2014 Jan; 33(1):23-34, DOI:10.1016.

- 318 Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, Acharya D, Cantor R, **Starling RC**, Naftel D, Kirklin J. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support: Data from the INTERMACS registry. *Circulation: Heart Failure* 2014 Mar 1; 7(2):300-309. DOI: 10.1161/CIRCHEARTFAILURE.113.000721, Epub 2014 Jan 17.
- 319 Triposkiadis FK, Butler J, Karayannis G, **Starling RC**, Filippatos G, Wolski K, Parissis J, Parisi C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. *International Journal of Cardiology* 2014 Mar 1; 172(1):115-121. DOI: 10.1016/j.ijcard.2013.12.276, Epub 2014 Jan 10.
- 320 Toma M, Ezekowitz JA, Bakal JA, O'Connor CM, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K, Armstrong PW, **Starling RC**. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. *European Journal of Heart Fail.* 2014 Mar;16(3):334-41. DOI: 10.1002/ejhf.19. Epub 2013 Dec 14.
- 321 Kalavrouziotis D, Tong MZ, **Starling RC**, Massiello A, Soltesz E, Smedira NG, Fryc R, Heatley G, Farrar DJ, Moazami N. Percutaneous lead dysfunction in the HeartMate II Left Ventricular Assist Device. *Annals of Thoracic Surgery* 2014 Apr; 97(4):1373-1378, DOI: 10.1016/j.athoracsur.2013.11.039, Epub 2014 Feb 1.
- 322 Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, **Starling RC**, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Shahzad K, Hiller D, Yee J, Valentine HA; for the MAGE Study Group. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. *Transplantation* 2014 Jan 31; (Epub ahead of print).
- 323 Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, O'Connor CM, **Starling RC**, Butler J. High sensitivity C-reactive protein in acute heart failure: Insights from the ASCEND-HF trial. *Journal of Cardiac Failure* 2014 May; 20(5):319-326, DOI: 10.1016/j.cardfail.2014.02.002, Epub 2014 Feb 12.
- 324 Porepa LF, **Starling RC**. Destination therapy with left ventricular assist devices: for whom and when? *Canadian Journal of Cardiology* 2014 Mar; 30(3):296-303.
- 325 Cantillon DJ, Saliba WI, Wazni OM, Kanj M, **Starling RC**, Tang WH, Wilkoff BL. Low cardiac output associated with ventricular tachy arrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). *The Journal of Heart and Lung Transplantation* 2014 Mar; 33(3):318-320.
- 326 **Starling RC**, Blackstone EH, Smedira NG. Increase in left ventricular assist device thrombosis. *New England Journal of Medicine* 2014 Apr 10; 370(15):1465-6. DOI: 10.1056/NEJMc1401768.
- 327 Kobashigawa J, Zuckermann A, Macdonald P, LePrince P, Esmailian F, Luu M, Mancini D, Patel J, Razi R, Reichenspurner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F, **Starling RC**. Consensus Conference participants. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *The Journal of Heart and Lung Transplantation*. 2014 Apr; 33(4):327-40. DOI: 10.1016/j.healun.2014.02.027. Epub 2014 Mar 5. PubMed PMID: 24661451.
- 328 Higgins RS, Brown RN, Chang PP, **Starling RC**, Ewald GA, Tallaj JA, Kirklin JK, George JF. A multi-institutional study of malignancies after heart transplantation and a comparison with the general United States population. *The Journal of Heart and Lung Transplantation* 2014 May; 33(5):478-85. DOI: 10.1016/j.healun.2014.01.862. Epub 2014 Jan 28.
- 329 Bennett MK, Sweet WE, Baicker-McKee S, Looney E, Karohl K, Mountis M, Tang WH, **Starling RC**, Moravec CS. S100A1 in human heart failure: lack of recovery following left ventricular assist device support. *Circulation: Heart Failure* 2014 Jul; 7(4):612-8. DOI:10.1161/CIRCHEARTFAILURE.113.000849. Epub 2014 May 19.

- 330 Agarwal S, Parashar A, Kapadia SR, Tuzcu EM, Modi D, **Starling RC**, Oliveira GH. Long-term mortality after cardiac allograft vasculopathy: implications of percutaneous intervention. *Journal of the American College of Cardiology Heart Failure*. 2014 Jun;2(3):281-8. DOI: 10.1016/j.jchf.2014.01.003.
- 331 Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, Acharya D, Cantor R, **Starling RC**, Naftel D, Kirklin J. Response to letter regarding article, "Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support: Data from the Interagency Registry for Mechanically Assisted Circulatory Support". *Circulation: Heart Failure* 2014 Jul;7(4):696. DOI: 10.1161/CIRCHEARTFAILURE.114.001345.
- 332 Mihaljevic T, Planinc M, Williams SJ, Gillinov AM, Sabik JF 3rd, Svensson LG, **Starling RC**, Smedira NG, Blackstone EH. Less invasive versus conventional heart valve surgery in patients with severe heart failure. *The Journal of Thoracic and Cardiovascular Surgery*. 2014 Jul;148(1):161-167.e6. DOI: 10.1016/j.jtcvs.2013.08.029. Epub 2013 Oct 11.
- 333 Reynard AK, Butler RS, McKee MG, **Starling RC**, Gorodeski EZ. Frequency of depression and anxiety before and after insertion of a continuous flow left ventricular assist device. *The American Journal of Cardiology* 2014 Aug 1; 114(3):433-40. DOI: 10.1016/j.amjcard.2014.05.015. Epub 2014 May 17.
- 334 Hsich EM, **Starling RC**, Blackstone EH, Singh TP, Young JB, Gorodeski EZ, Taylor DO, Schold JD. Does the UNOS heart transplant allocation system favor men over women? *Journal of the American College of Cardiology Heart Failure*. 2014 Aug; 2(4):347-55. DOI: 10.1016/j.jchf.2014.03.008. Epub 2014 Jul 9.
- 335 Cavalcante JL, Marwick TH, Hachamovitch R, Popovic ZB, Aldweib N, **Starling RC**, Desai MY, Flamm SD, Kwon DH. Is there a role for diastolic function assessment in era of delayed enhancement cardiac magnetic resonance imaging?: a multimodality imaging study in patients with advanced ischemic cardiomyopathy. *American Heart Journal* 2014 Aug; 168(2):220-8.e1. DOI: 10.1016/j.ahj.2014.04.004. Epub 2014 Apr 16.
- 336 McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; **PARADIGM-HF Investigators and Committees**. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *New England Journal of Medicine*. 2014 Sep 11;371(11):993-1004. DOI: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. PubMed PMID: 25176015.
- 337 Groh M, Masciocco G, Kirchner E, Kristen A, Pellegrini C, Varnous S, Bortman G, Rosenberg M, Brucato A, Waterworth P, Bonacina E, Facchetti F, Calabrese L, Gregorini G, Scali JJ, **Starling R**, Frigerio M, D'Armini AM, Guillemin L. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *The Journal of Heart and Lung Transplantation* 2014 Aug;33(8):842-50. DOI: 10.1016/j.healun.2014.02.023. Epub 2014 Feb 24. PubMed PMID: 24709271.
- 338 Van Deursen VM, Hernandez AF, Stebbins A, Hasselblad V, Ezekowitz JA, Califf RM, Gottlieb SS, O'Connor CM, **Starling RC**, Tang WH, McMurray JJ, Dickstein K, Voors AA. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). *Circulation*. 2014 Sep 16;130(12):958-65. DOI: 10.1161/CIRCULATIONAHA.113.003046. Epub 2014 Jul 29.
- 339 Moazami N, Dembitsky WP, Adamson R, Steffen RJ, Soltesz EG, **Starling RC**, Fukamachi K. Does pulsatility matter in the era of continuous-flow blood pumps? *The Journal of Heart and Lung Transplantation* 2014 Sep 28. S1053-2498(14)01347-3. DOI: 10.1016/j.healun.2014.09.012.
- 340 Steffen RJ, Halbreiner MS, Zhang L, Fukamachi K, Soltesz EG, **Starling RC**, Moazami N. Mechanical circulatory support for the right ventricle in the setting of a left ventricular assist device. *Expert Review of Medical Devices* 2014 Nov; 11(6):587-593, DOI: 10.1586/17434440.2014.940316, Epub 2014 Jul 14.
- 341 Van Diepen S, Podder M, Hernandez AF, Westerhout CM, Armstrong PW, McMurray JJ, Eapen ZJ, Califf RM, **Starling RC**, O'Connor CM, Ezekowitz JA. Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. *International Journal of Cardiology* 2014 Nov 4;177(3):840-846. DOI: 10.1016/j.ijcard.2014.11.007.

- 342 Patel PA, Heizer G, O'Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, Armstrong PW, Hasselblad V, Mills RM, McMurray JJ, **Starling RC**, Tang WH, Califf RM, Hernandez AF. Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality: Findings From ASCEND-HF. *Circulation Heart Failure*. 2014 Nov;7(6):918-25. DOI: 10.1161/CIRCHEARTFAILURE.113.000872. Epub 2014 Oct 3.
- 343 Dhillon A, Sweet W, Popovic ZB, Smedira NG, Thamarasan M, Lytle BW, Tan C, **Starling RC**, Lever HM, Moravec CS, Desai MY. Association of noninvasively measured left ventricular mechanics with in vitro muscle contractile performance: a prospective study in hypertrophic cardiomyopathy patients. *Journal of the American Heart Association* 2014 Nov 11;3(6):e001269. DOI: 10.1161/JAHA.114.001269.
- 344 Rickard J, Cheng A, Spragg D, Cantillon D, Baranowski B, Varma N, **Starling RC**, Wilkoff BL, Tang WH. A Clinical Prediction Rule to Identify Advanced Heart Failure Patients with Heightened Risk for Early Demise Following Cardiac Resynchronization Therapy. *Journal of Cardiovascular Electrophysiology* 2014; 25(3):278-282.
- 345 Halbreiner MS, Cruz V, **Starling R**, Smedira N, Moravec C, Moazami N Myocardial recovery: A focus on the impact of left ventricular assist devices. *Expert Review of Cardiovascular Therapy* 2014; 12:589-600.
- 346 **Starling R**, Helme D, Nodulman JA, Bryan AD, Buller DB, Donohew RL, Woodall WG. Testing a Risky Sex Behavior Intervention Pilot Website for Adolescents. *California Journal of Health Promotion*. 2014 Dec;12(3):24-34.
- 347 DeVore AD, Hasselblad V, Mentz RJ, O'Connor CM, Armstrong PW, McMurray JJ, Ezekowitz JA, Tang WH, **Starling RC**, Voors AA, Califf RM, Hernandez AF. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. *European Journal of Heart Failure*. 2015 Mar;17(3):340-6. DOI: 10.1002/ejhf.235. Epub 2015 Jan 23.
- 348 Rogers JG, Boyle AJ, O'Connell JB, Horstmanshof DA, Haas DC, Slaughter MS, Park SJ, Farrar DJ, **Starling RC**. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. *American Heart Journal*. 2015 Feb;169(2):205-210.e20. DOI: 10.1016/j.ahj.2014.11.004. Epub 2014 Nov 11.
- 349 **Starling RC**. Left Ventricular Assist Devices Ramp Studies: Truth or Consequences? *Journal of the American College of Cardiology - Heart Fail*. 2015 Mar 3. pii: S2213-1779(15)00020-7. DOI: 10.1016/j.jchf.2015.01.002. [Epub ahead of print] No abstract available.
- 350 **Starling RC**, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS; CTOT-05 consortium. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. *American Journal of Transplantation*. 2015 Aug 10. DOI:10.1111/ajt.13422. [Epub ahead of print] PubMed PMID: 26260101.
- 351 Loyaga-Rendon RY, Acharya D, Pamboukian SV, Tallaj JA, Cantor R, **Starling RC**, Naftel D, Kirklin J. Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory Support. *Circulation Heart Failure*. 2015 Aug 6. CIRCHEARTFAILURE.115.002321. [Epub ahead of print] PubMed PMID: 26251182.
- 352 Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, **Starling RC**, Testani JM, Tang WH. Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. *Journal of the American College of Cardiology*. 2015 Aug 11;66(6):659-66. DOI: 10.1016/j.jacc.2015.06.007. PubMed PMID: 26248993.
- 353 Verbrugge FH, Dupont M, Finucan M, Gabi A, Hawwa N, Mullens W, Taylor DO, Young JB, **Starling RC**, Tang WH. Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. *European Journal of Heart Failure*. 2015 Jul 24. DOI: 10.1002/ejhf.324. [Epub ahead of print] PubMed PMID: 26213182.
- 354 Sunagawa G, Byram N, Karimov JH, Horvath DJ, Moazami N, **Starling RC**, Fukamachi K. In vitro hemodynamic

characterization of HeartMate II at 6000 rpm: Implications for weaning and recovery. *The Journal of Thoracic and Cardiovascular Surgery*. 2015 Aug; 150(2):343-8. DOI: 10.1016/j.jtcvs.2015.04.015. Epub 2015 Apr 8. PubMed PMID: 26204865.

- 355 Tong MZ, Smedira NG, Soltesz EG, **Starling RC**, Koval CE, Porepa L, Moazami N. Outcomes of Heart Transplant After Left Ventricular Assist Device Specific and Related Infection. *Annals of Thoracic Surgery*. 2015 Jul 15. S0003-4975(15)00671-2. DOI: 10.1016/j.athoracsur.2015.04.047. [Epub ahead of print] PubMed PMID: 26188972.
- 356 **Starling RC**, Krum H, Bril S, Tsintzos SI, Rogers T, Hudnall JH, Martin DO. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. *Journal of the American College of Cardiology Heart Failure*. 2015 Jul;3(7):565-72. DOI: 10.1016/j.jchf.2015.03.001. Epub 2015 Jun 10. PubMed PMID: 26071616.
- 357 Grodin JL, Drazner MH, Dupont M, Mullens W, Taylor DO, **Starling RC**, Tang WH. A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. *American Heart Journal* 2015 Jun;169(6):806-12. DOI: 10.1016/j.ahj.2015.02.017. Epub 2015 Feb 28. PubMed PMID: 26027618; PubMed Central PMCID: PMC4451570.
- 358 Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, **Starling RC**, Hernandez AF; **NHLBI Heart Failure Clinical Research Network**. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. *Circulation*. 2015 May 19;131(20):1763-71. DOI: 10.1161/CIRCULATIONAHA.114.014536. Epub 2015 Apr 14. PubMed PMID: 25986447; PubMed Central PMCID: PMC4438785.
- 359 Grodin JL, Mullens W, Dupont M, Wu Y, Taylor DO, **Starling RC**, Tang WH. Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. *European Journal of Heart Failure*. 2015 Jul;17(7):689-96. DOI: 10.1002/ejhf.268. Epub 2015 Apr 28. PubMed PMID: 25924078.
- 360 De S, Popović ZB, Verhaert D, Dresing T, Wilkoff B, **Starling R**, Tang WH, Thomas JD, Grimm RA. Comparison of left ventricular torsion and strain with biventricular pacing in patients with underlying right bundle branch block versus those with left bundle branch block. *The American Journal of Cardiology*. 2015 Apr 1;115(7):918-23. DOI: 10.1016/j.amjcard.2015.01.018. Epub 2015 Jan 15. PubMed PMID: 25779616.
- 361 Wehbe E, Patarroyo M, Taliercio JJ, **Starling RC**, Nally JV Jr, Tang WH, Demirjian S. Renal failure requiring dialysis complicating slow continuous ultrafiltration in acute heart failure: importance of systolic perfusion pressure. *Journal of Cardiac Failure*. 2015 Feb;21(2):108-15. DOI: 10.1016/j.cardfail.2014.10.005. Epub 2014 Oct 15. PubMed PMID: 25463414.
- 362 Rigolli M, Rossi A, Quintana M, Klein AL, Yu CM, Ghio S, Dini FL, Prior D, Troughton RW, Temporelli PL, Poppe KK, Doughty RN, Whalley GA; **MeERGE Collaborators**. The prognostic impact of diastolic dysfunction in patients with chronic heart failure and post-acute myocardial infarction: Can age-stratified E/A ratio alone predict survival? *International Journal of Cardiology*. 2015 Feb 15;181:362-8. DOI: 10.1016/j.ijcard.2014.12.051. Epub 2014 Dec 23. PubMed PMID: 25555281.
- 363 Chirakarnjanakorn S, **Starling RC**, Popović ZB, Griffin BP, Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: Diagnostic accuracy and predictors of outcomes. *The Journal of Heart and Lung Transplantation*. 2015 May;34(5):710-7. DOI: 10.1016/j.healun.2014.11.019. Epub 2014 Nov 17. PubMed PMID: 25682552.
- 364 Tang WH, Dupont M, Hernandez AF, Voors AA, Hsu AP, Felker GM, Butler J, Metra M, Anker SD, Troughton RW, Gottlieb SS, McMurray JJ, Armstrong PW, Massie BM, Califf RM, O'Connor CM, **Starling RC**. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. *Journal of the American College of Cardiology Heart Failure*. 2015 Jan;3(1):40-9. DOI: 10.1016/j.jchf.2014.06.014. Epub 2014 Nov 11. PubMed PMID: 25453534.

- 365 McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Bělohávek J, Böhm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, **Starling RC**, Vinereanu D, Teerlink JR, Wong R; PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. *European Heart Journal*. 2015 Feb 14;36(7):434-9. PubMed PMID: 25416329.
- 366 Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, González-Medina A, Hagège AA, Huang J, Katova T, Kiatchosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, **Starling RC**, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*. 2015 Jan 6;131(1):54-61. DOI: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17. PubMed PMID: 25403646.
- 367 Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, **Starling RC**, Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. *The American Journal of Cardiology*. 2015 Jan 1;115(1):57-61. DOI: 10.1016/j.amjcard.2014.10.008. Epub 2014 Oct 13. PubMed PMID: 25456873.
- 368 Hurst TE, Moazami N, **Starling RC**. Left ventricular assist device thrombosis in the setting of left ventricular recovery. *The Journal of Heart and Lung Transplantation*. 2015 Apr;34(4):622-3. DOI:10.1016/j.healun.2014.12.019. Epub 2014 Dec 24. No abstract available. PubMed PMID: 25708130.
- 369 Halbreiner MS, Soltesz E, **Starling R**, Moazami N. Current practice in patient selecting for long-term mechanical circulatory support. *Current Heart Failure Reports*. 2015 Apr;12(2):120-9. DOI: 10.1007/s11897-014-0243-3. PubMed PMID: 25433835.
- 370 Khazanie P, Heizer GM, Hasselblad V, Armstrong PW, Califf RM, Ezekowitz J, Dickstein K, Levy WC, McMurray JJ, Metra M, Tang WH, Teerlink JR, Voors AA, O'Connor CM, Hernandez AF, **Starling R**. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. *American Heart Journal*. 2015 Aug;170(2):290-7. DOI: 10.1016/j.ahj.2015.04.006. Epub 2015 Apr 11. PMID: 26299226.
- 371 ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, **Starling RC**, van der Meer P, O'Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WH, Voors AA. Diuretic response in acute heart failure-an analysis from ASCEND-HF. *American Heart Journal*. 2015 Aug;170(2):313-21. DOI: 10.1016/j.ahj.2015.05.003. Epub 2015 May 9. PMID: 26299229.
- 372 Abualnaja S, Podder M, Hernandez AF, McMurray JJ, **Starling RC**, O'Connor CM, Califf RM, Armstrong PW, Ezekowitz JA. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. *Journal of the American Heart Association*. 2015 Aug 24;4(8):e002092. DOI: 10.1161/JAHA.115.002092. PMID: 26304935.
- 373 **Starling RC**. Sacubitril-valsartan and the evolution of heart failure care. *Cleveland Clinic Journal of Medicine*. 2015 Oct;82(10):702-704. DOI: 10.3949/ccjm.82a.15121. No abstract available. PubMed PMID: 26469828.
- 374 Grodin JL, Perez AL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Califf RM, **Starling RC**, O'Connor CM, Tang WH. Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *Journal of the American College of Cardiology Heart Failure*. 2015 Oct;3(10):777-85. DOI: 10.1016/j.jchf.2015.06.006. PMID: 26449997.
- 375 Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, Rame E, Acker M, Kormos RL,

- Salerno C, Schleeter TP, Goldstein DJ, Shin J, **Starling RC**, Wozniak T, Malik AS, Silvestry S, Ewald GA, Jorde UP, Naka Y, Birks E, Najarian KB, Hathaway DR, Aaronson KD; ADVANCE Trial Investigators. The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. *Journal of the American College of Cardiology Heart Failure*. 2015 Oct;3(10):818-28. DOI: 10.1016/j.jchf.2015.05.011. PMID: 26450000.
- 376 Ambrosy AP, Hernandez AF, Armstrong PW, Butler J, Dunning A, Ezekowitz JA, Felker GM, Greene SJ, Kaul P, McMurray JJ, Metra M, O'Connor CM, Reed SD, Schulte PJ, **Starling RC**, Wilson Tang WH, Voors AA, Mentz RJ. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. *European Journal of Heart Failure*. 2015 Oct 14. DOI: 10.1002/ejhf.420. [Epub ahead of print] PMID: 26467269.
- 377 Rosenthal JL, **Starling RC**. Coagulopathy in Mechanical Circulatory Support: A Fine Balance. *Current Cardiology Reports*. 2015 Dec;17(12):114. DOI: 10.1007/s11886-015-0670-0. PMID: 26482757.
- 378 Estep JD, **Starling RC**, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O'Connell JB, Boyle AJ, Farrar DJ, Rogers JG; ROADMAP Study Investigators. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. *Journal of the American College of Cardiology*. 2015 Oct 20;66(16):1747-61. DOI: 10.1016/j.jacc.2015.07.075. PMID: 26483097.
- 379 Cavalcante JL, Marek J, Sheppard R, **Starling RC**, Mather PJ, Alexis JD, Narula J, McNamara DM, Gorcsan J 3rd. Diastolic function improvement is associated with favourable outcomes in patients with acute non-ischaemic cardiomyopathy: insights from the multicentre IMAC-2 trial†. *European Heart Journal Cardiovascular Imaging*. 2015 Nov 30. jev311. [Epub ahead of print] PMID: 26628616.
- 380 Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, O'Connor CM, **Starling RC**. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. *Journal of the American College of Cardiology Heart Failure*. 2015 Nov 25. S2213-1779(15)00648-4. DOI: 10.1016/j.jchf.2015.07.015. [Epub ahead of print] PMID: 26656144.
- 381 Perez AL, Grodin JL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, **Starling RC**, O'Connor CM, Tang WH. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. *European Journal of Heart Failure*. 2015 Dec 14. DOI: 10.1002/ejhf.456. [Epub ahead of print] PMID: 26663359.
- 382 Smedira NG, Blackstone EH, Ehrlinger J, Thuita L, Pierce CD, Moazami N, **Starling RC**. Current risks of HeartMate II pump thrombosis: Non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. *The Journal of Heart and Lung Transplantation*. 2015 Dec;34(12):1527-34. DOI: 10.1016/j.healun.2015.10.027. PMID: 26681122.
- 383 Samsky MD, Dunning A, DeVore AD, Schulte PJ, **Starling RC**, Wilson Tang WH, Armstrong PW, Ezekowitz JA, Butler J, McMurray JJ, Teerlink JR, Voors AA, Metra M, Mentz RJ, O'Connor CM, Patel CB, Hernandez AF. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. *European Journal of Heart Failure*. 2015 Dec 28. DOI: 10.1002/ejhf.440. [Epub ahead of print] PMID: 26707029.
- 384 Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, **Starling RC**, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. *Circulation Heart Failure* 2016 Jan;9(1). e002560. DOI: 10.1161/CIRCHEARTFAILURE.115.002560. PMID: 26754626.
- 385 Wong YW, Mentz RJ, Felker GM, Ezekowitz J, Pieper K, Heizer G, Hasselblad V, Metra M, O'Connor CM, Armstrong PW, **Starling RC**, Hernandez AF. Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. *European Journal of Heart Failure*. 2016 Jan 27. DOI: 10.1002/ejhf.487. [Epub ahead of print]. PMID: 26817735.

- 386 **Starling RC**. Augmenting outcomes in advanced heart failure: a lot to learn. *European Journal of Heart Failure*. 2016 Jan 28. DOI: 10.1002/ejhf.488. [Epub ahead of print] No abstract available. PMID: 26821768.
- 387 Verbrugge FH, Grodin JL, Mullens W, Taylor DO, **Starling RC**, Tang WH. Transient Hyponatremia during Hospitalization for Acute Heart Failure. *The American Journal of Medicine*. 2016 Jan 30. S0002-9343(16)30079-1. DOI: 10.1016/j.amjmed.2016.01.016. [Epub ahead of print]. PMID: 26836387.
- 388 Sunagawa G, Byram N, Karimov JH, Horvath DJ, Moazami N, **Starling RC**, Fukamachi K. The Contribution to Hemodynamics Even at Very Low Pump Speeds in the HVAD. *Annals of Thoracic Surgery* 2016 Feb 22. S0003-4975(15)01987-6. DOI: 10.1016/j.athoracsur.2015.12.002. [Epub ahead of print]. PMID: 26912300.
- 389 Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, **Starling RC**, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circulation Heart Failure*. 2016 Mar;9(3):e002744. DOI: 10.1161/CIRCHEARTFAILURE.115.002744. PMID: 26915374.
- 390 **Starling RC**. Cardiac Myosin Activators for the Treatment of Heart Failure: Stop Now or Push Ahead? *Journal of the American College of Cardiology*. 2016 Mar 29;67(12):1456-8. DOI: 10.1016/j.jacc.2016.01.038. No abstract available. PMID: 27012406.
Ezekowitz JA, Podder M, Hernandez AF, Armstrong PW, **Starling RC**, O'Connor CM, Califf RM. Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). *British Medical Journal Open*. 2016 Mar 17;6(3):e010201. DOI: 10.1136/bmjopen-2015-010201. PMID: 26988350.
- 391 Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, **Starling RC**, Mann DL. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. *Journal of the American College of Cardiology*. 2016 Mar 29. S0735-1097(16)32404-4. DOI: 10.1016/j.jacc.2016.03.525. [Epub ahead of print]. PMID: 27058909.
- 392 Nagarajan V, Hernandez AV, Cauthen CA, **Starling RC**, Tang WH. Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. *Am Heart J*. 2017 Jan;183:35-39. DOI: 10.1016/j.ahj.2016.09.008.
- 393 Grodin JL, Sun JL, Anstrom KJ, Chen HH, **Starling RC**, Testani JM, Tang WH. Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). *Am J Cardiol*. 2017 Jan 1;119(1):78-83. DOI: 10.1016/j.amjcard.2016.09.014.
- 394 **Starling RC**, Young JB. Tolvaptan in Acute Heart Failure: Time to Move On. *J Am Coll Cardiol*. 2016 Sep 15. S0735-1097(16)35324-4. DOI: 10.1016/j.jacc.2016.09.005.
- 395 Kitai T, Grodin JL, Mentz RJ, Hernandez AF, Butler J, Metra M, McMurray JJ, Armstrong PW, **Starling RC**, O'Connor CM, Swedberg K, Tang WH. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. *Eur J Heart Fail*. 2016 Sep 16. DOI: 10.1002/ejhf.629.
- 396 Vest AR, Kennel PJ, Maldonado D, Young JB, Mountis MM, Naka Y, Colombo PC, Mancini DM, **Starling RC**, Schulze PC. Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation. *Circ Heart Fail*. 2016 Sep;9(9). e002881. DOI: 10.1161/CIRCHEARTFAILURE.115.002881.
- 397 Javaheri A, Molina M, Zamani P, Rodrigues A, Novak E, Chambers S, Stutman P, Maslanek W, Williams M, Lilly SM, Heeger P, Sayegh MH, Chandraker A, Briscoe DM, Daly KP, **Starling R**, Ikle D, Christie J, Rame JE, Goldberg LR, Billheimer J, Rader DJ. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. *J Heart Lung Transplant*. 2016 Nov;35(11):1295-1302. DOI: 10.1016/j.healun.2016.06.022.

- 398 Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, **Starling R**, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. *JAMA*. 2016 Aug 2;316(5):500-8. DOI: 10.1001/jama.2016.10260.
- 399 Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJ, Solomon SD; PARADIGM-HF Investigators... Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. *J Am Coll Cardiol*. 2016 Jul 19;68(3):241-8. DOI: 10.1016/j.jacc.2016.04.047.
- 400 Lander BS, Patel K, Blackstone EH, Nordseth T, **Starling RC**, Gorodeski EZ. Post-acute Care Trajectories in the First Year Following Hospital Discharge After Left Ventricular Assist Device Implantation. *J Am Med Dir Assoc*. 2016 Oct 1;17(10):908-12. DOI: 10.1016/j.jamda.2016.05.024.
- 401 Triposkiadis F, Giamouzis G, Parissis J, **Starling RC**, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co-morbidities in heart failure. *Eur J Heart Fail*. 2016 Jul;18(7):744-58. DOI: 10.1002/ejhf.600.
- 402 Hsich EM, Rogers JG, McNamara DM, Taylor DO, **Starling RC**, Blackstone EH, Schold JD. Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? *JACC Heart Fail*. 2016 Sep;4(9):689-97. DOI: 10.1016/j.jchf.2016.03.010.
- 403 Metra M, Mentz RJ, Hernandez AF, Heizer GM, Armstrong PW, Clausell N, Corbalan R, Costanzo MR, Dickstein K, Dunlap ME, Ezekowitz JA, Howlett JG, Komajda M, Krum H, Lombardi C, Fonarow GC, McMurray JJ, Nieminen MS, Swedberg K, Voors AA, **Starling RC**, Teerlink JR, O'Connor CM. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). *Am J Cardiol*. 2016 Jun 1;117(11):1771-8. DOI:10.1016/j.amjcard.2016.03.002.
- 404 Gurvitz M, Burns KM, Brindis R, Broberg CS, Daniels CJ, Fuller SM, Honein MA, Khairy P, Kuehl KS, Landzberg MJ, Mahle WT, Mann DL, Marelli A, Newburger JW, Pearson GD, **Starling RC**, Tringali GR, Valente AM, Wu JC, Califf NHLBI/ACHA Working Group. *J Am Coll Cardiol*. 2016 Apr 26;67(16):1956-64. DOI:10.1016/j.jacc.2016.01.062.
- 405 Samsky MD, Dunning A, DeVore AD, Schulte PJ, **Starling RC**, Tang WH, Armstrong PW, Ezekowitz JA, Butler J, McMurray JJ, Teerlink JR, Voors AA, Metra M, Mentz RJ, O'Connor CM, Patel CB, Hernandez AF. Liver Function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. *Eur J Heart Fail*. 2016 Apr;18(4):424-32. doi: 10.1002/ejhf.440. Epub 2015 Dec 28.
- 406 Perez AL, Grodin JL, Wu Y, Hernandez AF, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, **Starling RC**, O'Connor CM, Tang WH. Increased Mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. *Eur J Heart Fail*. 2016 Mar;18(3):290-7. DOI:10.1002/ejhf.456.
- 407 Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, O'Connor CM, **Starling RC**. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. *JACC Heart Fail*. 2016 Jan;4(1):68-77. DOI:10.1016/j.jchf.2015.07.015.
- 408 Cavalcante JL, Marek J, Sheppard R, **Starling RC**, Mather PJ, Alexis JD, Narula J, McNamara DM, Gorcsan J 3rd. Diastolic function improvement is associated with favourable outcomes in patients with acute non-ischaemic cardiomyopathy: insights from the multicentre IMAC-2 trial. *Eur Heart J Cardiovasc Imaging*. 2016 Sep;17(9):1027-35. DOI: 10.1093/ehjci/jev311.
- 409 Ambrosy AP, Hernandez AF, Armstrong PW, Butler J, Dunning A, Ezekowitz JA,

Felker GM, Greene SJ, Kaul P, McMurray JJ, Metra M, O'Connor CM, Reed SD, Schulte PJ, **Starling RC**, Tang WH, Voors AA, Mentz RJ. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2016 Mar;18(3):306-13. DOI:10.1002/ejhf.420.

- 410 **Starling RC**, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS; CTOT-05 consortium.. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. *Am J Transplant*. 2016 Jan;16(1):121-36. DOI:10.1111/ajt.13422. PubMed PMID: 26260101.
- 411 Karimov JH, Zhen-Yu Tong M, Byram N, Sunagawa G, Dessoffy R, Moazami N, **Starling RC**, Fukamachi K. The axial continuous-flow blood pump: Bench evaluation of changes in flow associated with changes of inflow cannula angle. *J Heart Lung Transplant*. 2016 Sep 29. S1053-2498(16)30332-1. DOI:10.1016/j.healun.2016.09.004.
- 412 Greene SJ, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, Ezekowitz JA, **Starling RC**, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, O'Connor CM, Mentz RJ. Influence of Clinical Trial Site Enrollment on Patient Characteristics Protocol Completion, and End Points: Insights from the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *Circ Heart Fail*. 2016 Sep;9(9). e002986. DOI:10.1161/CIRCHEARTFAILURE.116.002986.
- 413 Buller DB, Woodall WG, Saltz R, **Starling R**. Pseudo-Underage Assessment of Compliance With Identification Regulations at Retail Marijuana Outlets in Colorado. *J Stud Alcohol Drugs*. 2016 Nov;77(6):868-872. PMID: 27797687
- 414 Karimov JH, Zhen-Yu Tong M, Byram N, Sunagawa G, Dessoffy R, Moazami N, **Starling RC**, Fukamachi K. Bench evaluation of changes in flow associated with changes of inflow cannula angle. *J Heart Lung Transplant*. 2017 Jan;36(1):106-112. doi: 10.1016/j.healun.2016.09.004. Epub 2016 Sep 29.
- 415 Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, **Starling RC**, Teerlink JR, Voors AA, Mentz RJ. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. *JACC Heart Fail*. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012. PMID: 28034373
- 416 Nagatomo Y, McNamara DM, Alexis JD, Cooper LT, Dec GW, Pauly DF, Sheppard R, **MYOC**, Tang WH; Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β 1-Adrenergic Receptors. IMAC-2 Investigators. *J Am Coll Cardiol*. 2017 Feb 28;69(8):968-977. doi: 10.1016/j.jacc.2016.11.067. PMID: 28231950
- 417 Naga Prasad SV, Gupta MK, Duan ZH, Surampudi VS, Liu CG, Kotwal A, Moravec CS, **Starling RC**, Perez DM, Sen S, Wu Q, Plow EF, Karnik S. PLoS One. A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. 2017 Mar 22;12(3):e0170456. doi: 10.1371/journal.pone.0170456. eCollection 2017. PMID: 28329018
- 418 Raslan IR, Brown P, Westerhout CM, Ezekowitz JA, Hernandez AF, **Starling RC**, O'Connor C, McAlister FA, Rowe BH, Armstrong PW, van Diepen S. Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. *Am Heart J*. 2017 Jun;188:127-135. doi: 10.1016/j.ahj.2017.03.014. Epub 2017 Mar 25. PMID: 28577668
- 419 Yamasaki H, Lustgarten D, Cerkenik J, Birnie D, Gasparini M, Lee KL, Sekiguchi Y, Varma N, Lemke B, **Starling RC**, Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter? Aonuma K. *Int J Cardiol*. 2017 Aug 1;240:297-301. doi: 10.1016/j.ijcard.2017.04.036. Epub 2017 Apr 12. PMID: 28416247
- 420 Frontera JA, **Starling R**, Cho SM, Nowacki AS, Uchino K, Hussain MS, Mountis M, Moazami N. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. *J Heart Lung Transplant*. 2017 Jun;36(6):673-683. doi: 10.1016/j.healun.2016.12.010. Epub 2016 Dec 23. PMID: 28110971

- 421 Perez AL, Kittipibul V, Tang WHW, **Starling RC**. Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap. *JACC Heart Fail*. 2017 Jun;5(6):460-463. doi: 10.1016/j.jchf.2017.03.007. Review. No abstract available.
- 422 Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, **Starling RC**, Teerlink JR, Voors AA, O'Connor CM, Mentz RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. *J Am Coll Cardiol*. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043. PMID: 28641792
- 423 Stehlik J, Estep JD, Selzman CH, Rogers JG, Spertus JA, Shah KB, Chuang J, Farrar DJ, **Starling RC**; ROADMAP Study Investigators. Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). *Circ Heart Fail*. 2017 Jun;10(6). pii: e003910. doi: 10.1161/CIRCHEARTFAILURE.116.003910.
- 424 Barakat AF, Sperry BW, **Starling RC**, Mentias A, Popovic ZB, Griffin BP, Desai MY. Prognostic Utility of Right Ventricular Free Wall Strain in Low Risk Patients After Orthotopic Heart Transplantation. *Am J Cardiol*. 2017 Jun 1;119(11):1890-1896. doi: 10.1016/j.amjcard.2017.03.003. Epub 2017 Mar 15. PMID: 28390683
- 425 Aksut B, **Starling R**, Kapadia S. Stable coronary artery disease and left ventricular dysfunction: The role of revascularization. *Catheter Cardiovasc Interv*. 2017 Jul 14. doi: 10.1002/ccd.27175. [Epub ahead of print] PMID: 28707392
- 426 Steffen RJ, Blackstone EH, Smedira NG, Soltesz EG, Hoercher KJ, Thuita L, **Starling RC**, Mountis M, Moazami N. Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation. *Ann Thorac Surg*. 2017 Nov;104(5):1569-1576. doi: 10.1016/j.athoracsur.2017.03.066. Epub 2017 Jun 24. PubMed PMID: 28651783.
- 427 Sperry BW, Perez AL, Alvarez PA, Kendall K, Gorodeski EZ, **Starling RC**. Medicaid Insurance and Psychosocial Status in Patients Evaluated for Heart Transplantation. *J Am Coll Cardiol*. 2017 Nov 28;70(21):2727-2728. doi: 10.1016/j.jacc.2017.09.1097. PubMed PMID: 29169481.
- 428 Rice CJ, Cho SM, Zhang LQ, Hassett C, **Starling RC**, Uchino K. The Management of Acute Ischemic Strokes and the Prevalence of Large Vessel Occlusion in Left Ventricular Assist Device. *Cerebrovasc Dis*. 2018;46(5-6):213-217. doi: 10.1159/000495080. Epub 2018 Dec 4. Review. PubMed PMID: 30513514.
- 429 Xanthopoulos A, **Starling RC**, Triposkiadis F. Mitral Valve Stenosis: Still a Clinical Challenge? *Cardiology*. 2018;140(1):45-46. doi: 10.1159/000487664. Epub 2018 May 17. PubMed PMID: 29772580.
- 430 Grodin JL, Mullens W, Dupont M, Taylor DO, McKie PM, **Starling RC**, Testani JM, Tang WHW. Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. *Int J Cardiol*. 2018 Feb 1;252:112-116. doi: 10.1016/j.ijcard.2017.11.024. PubMed PMID: 29249420.
- 431 Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, **Starling RC**, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020. Epub 2017 Oct 29. PubMed PMID: 29082629; PubMed Central PMCID: PMC5826892.
- 432 Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, O'Connor CM, Teerlink JR,

- Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. *Eur J Heart Fail.* 2018 Mar;20(3):525-532. doi: 10.1002/ejhf.1078. Epub 2017 Dec 20. PubMed PMID: 29266564.
- 433 Xanthopoulos A, Tryposkiadis K, Giamouzis G, Konstantinou D, Giannakoulas G, Karvounis H, Kattan MW, Skoularigis J, Parissis J, Starling RC, Triposkiadis F. Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure. *Eur J Heart Fail.* 2018 Mar;20(3):614-616. doi: 10.1002/ejhf.1132. Epub 2017 Dec 22. PubMed PMID: 29271552.
- 434 Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. *JACC Heart Fail.* 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7. PubMed PMID: 29525328.
- 435 Kobashigawa J, Colvin M, Potena L, Dragun D, Crespo-Leiro MG, Delgado JF, Olymbios M, Parameshwar J, Patel J, Reed E, Reinsmoen N, Rodriguez ER, Ross H, Starling RC, Tyan D, Urschel S, Zuckermann A. The management of antibodies in heart transplantation: An ISHLT consensus document. *J Heart Lung Transplant.* 2018 May;37(5):537-547. doi: 10.1016/j.healun.2018.01.1291. Epub 2018 Jan 31. PubMed PMID: 29452978.
- 436 Shah KB, Starling RC, Rogers JG, Horstmanshof DA, Long JW, Kasirajan V, Stehlik J, Chuang J, Farrar DJ, Estep JD; ROADMAP Investigators. Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. *J Heart Lung Transplant.* 2018 Jun;37(6):706-714. doi: 10.1016/j.healun.2017.12.003. Epub 2017 Dec 7. PubMed PMID: 29275844.
437. Verma AK, Sun JL, Hernandez A, Teerlink JR, Schulte PJ, Ezekowitz J, Voors A, Starling R, Armstrong P, O'Conner CM, Mentz RJ. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. *Clin Cardiol.* 2018 Jul;41(7):945-952. doi: 10.1002/clc.22981. Epub 2018 Jul 17. PubMed PMID: 29781109; PubMed Central PMCID: PMC6103846.
- 438 Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinckam K, Askar M, Chandraker A, Chang PP, Colvin M, Demetris AJ, Diamond JM, Dipchand AI, Fairchild RL, Ford ML, Friedewald J, Gill RG, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine DJ, Levitsky J, Mengel M, Milford E, Newell KA, O'Leary JG, Palmer S, Randhawa P, Smith J, Snyder L, Starling RC, Sweet S, Taner T, Taylor CJ, Woodle S, Zeevi A, Nickerson P. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. *Am J Transplant.* 2018 Jul;18(7):1604-1614. doi: 10.1111/ajt.14752. Epub 2018 May 22. PubMed PMID: 29603613.
- 439 Xanthopoulos A, Triposkiadis F, Starling RC. Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. *Trends Cardiovasc Med.* 2018 Aug;28(6):392-400. doi: 10.1016/j.tcm.2018.01.001. Epub 2018 Jan 9. Review. PubMed PMID: 29471985.
- 440 D'Addio F, Vergani A, Potena L, Maestroni A, Uselli V, Ben Nasr M, Bassi R, Tezza S, Dellepiane S, El Essawy B, Iacone M, Iacovoni A, Borgese L, Liu K, Visner G, Dhe-Paganon S, Corradi D, Abdi R, Starling RC, Folli F, Zuccotti GV, Sayegh MH, Heeger PS, Chandraker A, Grigioni F, Fiorina P. P2X7R mutation

disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. *J Clin Invest*. 2018 Aug 1;128(8):3490-3503. doi: 10.1172/JCI94524. Epub 2018 Jul 16. PubMed PMID: 30010623; PubMed Central PMCID: PMC6063506.

- 441 Grodin JL, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Hernandez AF, O'Connor C, Starling RC, Tang WHW. Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. *J Card Fail*. 2018 Aug;24(8):512-519. doi: 10.1016/j.cardfail.2018.06.008. PubMed PMID: 30012361.
- 442 Blackstone EH, Rajeswaran J, Cruz VB, Hsich EM, Koprivanac M, Smedira NG, Hoercher KJ, Thuita L, Starling RC. Continuously Updated Estimation of Heart Transplant Waitlist Mortality. *J Am Coll Cardiol*. 2018 Aug 7;72(6):650-659. doi: 10.1016/j.jacc.2018.05.045. PubMed PMID: 30071995; PubMed Central PMCID: PMC6298792.
- 443 Halkar M, Nowacki AS, Kendall K, Efeovbokhan N, Gorodeski EZ, Moazami N, Starling RC, Young JB, Lee S, Tang WHW. Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. *Prog Transplant*. 2018 Sep;28(3):220-225. doi: 10.1177/1526924818781559. Epub 2018 Jun 7. PubMed PMID: 29879864.
- 444 Joyce E, Howell EH, Senapati A, Starling RC, Gorodeski EZ. Prospective assessment of combined handgrip strength and Mini-Cog identifies hospitalized heart failure patients at increased post-hospitalization risk. *ESC Heart Fail*. 2018 Oct;5(5):948-952. doi: 10.1002/ehf2.12300. Epub 2018 Jun 12. PubMed PMID: 29893487; PubMed Central PMCID: PMC6165927.
- 445 Cho SM, Lee T, Starling RC, Thompson NR, Uchino K. The Impact of Infection and Elevated INR in LVAD-Associated Intracranial Hemorrhage: A Case-Crossover Study. *ASAIO J*. 2018 Oct 9. doi: 10.1097/MAT.0000000000000887. [Epub ahead of print] PubMed PMID: 30312211.
- 446 Stehlik J, Armstrong B, Baran DA, Bridges ND, Chandraker A, Gordon R, De Marco T, Givertz MM, Heroux A, Iklé D, Hunt J, Kfoury AG, Madsen JC, Morrison Y, Feller E, Pinney S, Tripathi S, Heeger PS, Starling RC. Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. *Am J Transplant*. 2018 Dec 14. doi: 10.1111/ajt.15218. [Epub ahead of print] PubMed PMID: 30549425.
- 447 Sperry BW, Ikram A, Alvarez PA, Perez AL, Kendall K, Gorodeski EZ, Starling RC. Standardized Psychosocial Assessment Before Left Ventricular Assist Device Implantation. *Circ Heart Fail*. 2019 Jan;12(1):e005377. doi: 10.1161/CIRCHEARTFAILURE.118.005377. PubMed PMID: 30621509.
- 448 Cho SM, Hassett C, Rice CJ, Starling R, Katzan I, Uchino K. What Causes LVAD-Associated Ischemic Stroke? Surgery, Pump Thrombosis, Antithrombotics, and Infection. *ASAIO J*. 2019 Jan 3. doi: 10.1097/MAT.0000000000000901. [Epub ahead of print] PubMed PMID: 30507850.
- 449 Writing Group Members, Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P; Rating Panel Members, Dehmer GJ, Doherty JU, Schoenhagen P, Bashore TM, Bhave NM, Calnon DA, Carabello B, Conte J, Dickfeld T, Edmundowicz D, Ferrari VA, Hall ME, Ghoshhajra B, Mehrotra P, Naqvi TZ, Reece TB, Starling RC, Szerlip M, Tzou WS, Wong JB; Appropriate Use Criteria Task Force, Doherty JU, Dehmer GJ, Bailey SR, Bhave NM, Brown AS, Daugherty SL, Dean LS, Desai MY, Duvernoy CS, Gillam LD, Hendel RC, Kramer CM, Lindsay BD, Manning WJ, Patel MR, Sachdeva R, Wann LS, Winchester DE, Wolk MJ. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019

appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Thorac Cardiovasc Surg*. 2019 Jan 7. pii: S0022-5223(18)33502-5. doi: 10.1016/j.jtcvs.2018.12.061. [Epub ahead of print] PubMed PMID: 30635178.

- 450 Kittipibul V, Xanthopoulos A, Hurst TE, Fukamachi K, Blackstone EH, Soltesz E, Starling RC. Clinical Courses of HeartMate II Left Ventricular Assist Device Thrombosis. *ASAIO J*. 2019 Jan 24. doi: 10.1097/MAT.0000000000000952. [Epub ahead of print] PubMed PMID: 30688690.
- 451 Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart Failure and Liver Disease: Cardiohepatic Interactions. *JACC Heart Fail*. 2019 Feb;7(2):87-97. doi: 10.1016/j.jchf.2018.10.007. Epub 2018 Dec 12. Review. PubMed PMID: 30553904.
- 452 Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P, Dehmer GJ, Doherty JU, Schoenhagen P, Bashore TM, Bhave NM, Calnon DA, Carabello B, Conte J, Dickfeld T, Edmundowicz D, Ferrari VA, Hall ME, Ghoshhajra B, Mehrotra P, Naqvi TZ, Reece TB, Starling RC, Szerlip M, Tzou WS, Wong JB. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2019 Feb 5;73(4):488-516. doi: 10.1016/j.jacc.2018.10.038. Epub 2019 Jan 7. PubMed PMID: 30630640.
- 453 Valentine CM, Cox DA, Deering TF, Starling RC. What Should I Do?: Maintenance of Certification for All Cardiologists in 2019 and Beyond. *J Am Coll Cardiol*. 2019 Feb 5;73(4):517-520. doi: 10.1016/j.jacc.2018.12.024. PubMed PMID: 30704581.
- 454 Writing Group Members, Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P; Rating Panel Members, Dehmer GJ, Doherty JU, Schoenhagen P, Bashore TM, Bhave NM, Calnon DA, Carabello B, Conte J, Dickfeld T, Edmundowicz D, Ferrari VA, Hall ME, Ghoshhajra B, Mehrotra P, Naqvi TZ, Reece TB, Starling RC, Szerlip M, Tzou WS, Wong JB; Appropriate Use Criteria Task Force, Doherty JU, Dehmer GJ, Bailey SR, Bhave NM, Brown AS, Daugherty SL, Dean LS, Desai MY, Duvernoy CS, Gillam LD, Hendel RC, Kramer CM, Lindsay BD, Manning WJ, Patel MR, Sachdeva R, Wann LS, Winchester DE, Wolk MJ. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Am Soc Echocardiogr*. 2019 Feb 7. pii: S0894-7317(19)30008-2. doi: 10.1016/j.echo.2019.01.008. [Epub ahead of print] PubMed PMID: 30744922.

- 455 Cho SM, Moazami N, Katz S, Starling R, Frontera JA. Reversal and Resumption of Antithrombotic Therapy in LVAD- Associated Intracranial Hemorrhage. *Ann Thorac Surg.* 2019 Feb 11. pii: S0003-4975(19)30193-6. doi:10.1016/j.athoracsur.2019.01.016. [Epub ahead of print] PubMed PMID: 30763560.

Edited Books, Monographs or Journal Volumes

- 1 Randall C. Starling, MD, MPH. *The Cleveland Clinic Guide to Heart Failure*, 2009. Kaplan Publishing, New York.

Book Chapters Published or In Press

1. **Starling RC**, Unverferth DV. "Value of Endomyocardial Biopsy: Indications and Applications." In: Zipes DP, Rowlands DJ, eds. *Progress in Cardiology*, 33-41, 1989.
2. **Starling RC**. "Cardiac Transplantation." In: Mazzaferri E, Bowen J, eds. *Contemporary Internal Medicine*, Volume II, New York: Plenum Publishing Company, Aug 1989.
3. Bornstein RA, Hammer DF, **Starling RC**, Stang JM, Lewis RP, Magorien RD. "Neuropsychological Impairment in Candidates before and after Cardiac Transplantation." In: Willner AE, Rodewald G, eds. *Impact of Cardiac Surgery on the Quality of Life*, New York: Plenum Press, 1990: 231-235.
4. Young JB, Haas GJ, **Starling RC**. "Heart and Circulatory Failure." *American College of Cardiology Adult Clinical Cardiology Self-Assessment Program*, 1997 (ACCSAP 1997-98).
5. **Starling RC**. "Interview: Partial Left Ventriculectomy." *Audio Journal of Cardiovascular Medicine*, 1997;3:1.
6. Young JB, Haas GJ, **Starling RC**. "Managing Heart Failure with Cardiac Transplantation, Ventricular Assist Devices, and Cardiomyoplasty." In: Poole-Wilson P, Colucci W, Chatterjee K, Massie B, eds. *Heart Failure: Scientific Principles and Clinical Practice*, New York: Churchill Livingstone, 1997:827-851.
7. **Starling RC**. "The Health Care Impact of Heart Failure." In: Topol EJ, ed. *Textbook of Cardiovascular Medicine*, Lippincott-Raven, 1997:2205-2214.
8. **Starling RC**. "As Demand for Heart Transplantation Grows, so do Alternatives." *Heartline*, 1997;27(1):3-4.
9. **Starling RC**. "Patient Selection for Ventricular remodeling Surgery: Evolving Criteria and Outcomes." *ACCEL* Aug 1997;29(8).
10. **Starling RC**. "Economics of Heart Transplantation." In: Norman DJ, Suki WN, eds. *Primer on Transplantation*, American Society of Transplant Physicians, Thorofare, New Jersey, 1998:405-407.
11. **Starling RC**. "The Health Care Impact of Heart Failure." In: Topol EJ, ed. *Comprehensive Cardiovascular Medicine*, Volume 1, Lippincott-Raven, Philadelphia, 1998:2579-2588.
12. McCarthy PM, Kasirajan RC, **Starling RC**, Smedira NG, Young JB. "Ventriculectomy." In: Rose EA and Stevenson LW, eds. *Management of End-Stage Heart Disease*, Lippincott-Raven, Philadelphia, 1998:251-254.
14. **Starling RC**, Young JB. "Surgical Therapy for Dilated Cardiomyopathy." *Cardiology Clinics*, Nov 1998; 16(4):727-737.
15. McCarthy PM, **Starling RC**, Wong J, Scalia GM, Buda T, Vargo RL, Goormastic M, Thomas JD, Smedira NG, Young JB. "Should the Surgical Technique of the Left Ventricular Volume Reduction be Modified (reply)." *The Journal of Thoracic and Cardiovascular Surgery* 1998; 116:881.

16. **Starling RC.** "Left Ventricular Reduction." Best of 71st Scientific Sessions of American Heart Association Annual Meeting (audiocassette and CD); (Rockpointe Broadcasting; Washington, District of Columbia) Dallas, Texas. Nov 10, 1998.
17. Young JB, Haas GJ, **Starling RC.** "Heart and Circulatory Failure." American College of Cardiology Adult Clinical Cardiology Self-Assessment Program (ACCSAP 1999-2000).
18. Kaplon RJ, McCarthy PM, **Starling RC.** "Reduction Ventriculography: The Cleveland Clinic Experience." In: Franco KL, Verrier ED, eds. Advanced Therapy in Cardiac Surgery, Hamilton: B. C. Decker, 1999:369-374.
19. **Starling RC.** "The Diagnosis and Treatment of Heart Failure: A Special Report." Heart Advisor and the Cleveland Clinic. Rothman J, ed. Torstar Publications, Stratford, 1999.
20. Yamani MH, McCarthy PM, **Starling RC.** "Surgical Treatment of Chronic Congestive Heart Failure." In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure, Lippincott Williams and Wilkins, New York, 2000:767-784.
21. Yamani MH, **Starling RC.** "Long-Term Management Issues in Heart Transplantation." In: Norman DJ, Turka LA, eds. Primer on Transplantation, 2nd edition, American Society of Transplantation, Mount Laurel, New Jersey, 2001:375-381.
22. **Starling RC,** ed. "Heart and Circulatory Failure." American College of Cardiology Adult Clinical Cardiology Self-Assessment Program (ACCSAP2002).
23. **Starling RC.** "The Health Care Impact of Heart Failure." In: Topol EJ, ed. Comprehensive Cardiovascular Medicine, Volume 1, 2nd edition, Philadelphia, PA: Lippincott, Williams and Wilkins, 2002:1807-1817.
24. **Starling RC,** McCarthy PM, Yamani HM. "Surgical Treatment of Chronic Congestive Heart Failure." In: Mann DL, ed. Heart Failure: A Companion to Braunwald's Heart Disease, 1st edition, Saunders (Elsevier), 2003:717-736.
25. **Starling RC,** O'Neill JO. "Focus on Heart Failure." American College of Cardiology Adult Clinical Cardiology Self-Assessment Program, 2003 (ACCSAP 2003-2004).
26. Peacock WF, Allegra J, Ander D, Collins S, Diercks D, Emerman C, Kirk JD, **Starling RC,** Silver M, Summers R. "Management of Acute Decompensated Heart Failure in the Emergency Department." Congestive Heart Failure. 2003 Sept/Oct; 1(S):3-18.
27. O'Neill JO, **Starling RC.** "Surgical Remodeling in Ischemic Cardiomyopathy." Current Treatment Options in Cardiovascular Medicine. 2003; 5:311-319.
28. **Starling RC.** Improving Care of Chronic Heart Failure: Advances from Drugs to Devices. *Cleveland Clinic Journal of Medicine*, 2003; 70:141-146.
29. **Starling RC.** "Heart Failure: Advances in Prevention and Treatment." 2003 Annual Report. Englander Communications LLC, Greenwich, 2003.
30. Chuang, H, **Starling RC.** "Medical Treatment of Heart Failure." In: Griffin BP, Rimmerman CM, Topol EJ, eds. The Cleveland Clinic Cardiology Board Review, 1st edition, Philadelphia, PA: Lippincott, Williams and Wilkins, Philadelphia, 2006.
31. **Starling RC.** "Global Pandemic of Heart Failure." In: Topol EJ, ed. Textbook of Cardiovascular Medicine, 3rd edition, Philadelphia, PA: Lippincott Williams & Wilkins, 2007:1330-1338.
32. Smedira NG, Hoercher KJ, **Starling RC.** "Surgical Approaches for Heart Failure." In: Topol EJ, ed. Textbook of Cardiovascular Medicine, 3rd edition, Philadelphia, PA: Lippincott, Williams & Wilkins, 2007: 1442-1450.
33. **Starling RC.** Chapter 1: "Epidemiology of Heart Failure: Progression to Pandemic?" In: McCarthy PM, Young

JB, eds. Heart Failure: A Combined Medical and Surgical Approach, Blackwell Publishing, 2007:1-8.

34. Hsich E, **Starling RC**. “Neurohormonal Activation in Heart Failure: Aldosterone Antagonists.” In: Yancy CW, Young JB, eds. Therapeutic Strategies in Heart Failure, 1st edition, Clinical Publishing, Oxford, 2008:81-91.
35. **Starling RC**. Editor, Chapter 17: “Heart Failure.” Adult Clinical Cardiology Self-Assessment Program, Version 7, American College of Cardiology Foundation, Mar 2009:17.1.1-17.10.22.
36. **Starling RC**. Chapter 17.1: “Epidemiology, Etiology, and Public Health Implications of Heart Failure.” Adult Clinical Cardiology Self-Assessment Program, Version 7, American College of Cardiology Foundation, Mar 2009:17.1.1-17.1.13.
37. **Starling RC**, Gorodeski EZ. Chapter 2: “Potential Population for Long Term Use of Left Ventricular Assist Devices.” Mechanical Circulatory Support: A Companion to Braunwald’s Heart Disease, Elsevier Saunders, 2011:11-21.
38. **Starling RC**, Gorodeski EZ. “The Potential Population for Chronic Use of Left Ventricular Assist Devices.” In: Kormos RL, Miller LW, eds. Mechanical Circulatory Support: A Companion to Braunwald’s Heart Disease. Philadelphia, PA: Elsevier/ Saunders, 2012:11-21.
39. **Starling RC**. Section V, Chapter 41: “Surgical Treatment of Chronic Congestive Heart Failure.” In: Mann DL, Felker GM, eds. Heart Failure: A Companion to Braunwald’s Heart Disease, 3rd edition, Elsevier/Saunders, 2015.
40. Moazami N, **Starling RC**. “Complications of Long-Term Mechanical Circulatory Support.” Focused Review for Braunwald’s Heart Disease, 10th edition, Philadelphia, Elsevier, 2015.
41. Joyce E, **Starling RC**. “Mechanical Circulatory Support Devices. European Society of Cardiology Textbook of Cardiovascular Medicine. 3rd Edition. A. John Camm (Editor), Thomas F. Lüscher (Editor), Gerald Maurer (Editor), Patrick W. Serruys (Editor). Oxford University Press, 2019

Abstracts

1. **Starling RC**, Khabbaza EJ, Unverferth DV, Johnson JD. Digoxin compromises the effectiveness of calcium channel blockers as vasodilators in isolated human coronary arteries. *Clinical Research*, 1987;35.
2. **Starling RC**, Khabbaza EJ, Unverferth DV, Johnson JD. Magnesium relaxes isolated porcine coronary arteries by calcium channel blockade. *Circulation. Part II* 1987;76:245.
3. **Starling RC**, Baker PB, Galbraith TA, Myerowitz PD, Unverferth DV. Hemodynamics at rest and during supine bicycle exercise in cyclosporine treated orthotopic heart transplant recipients. *Clinical Research*, 1988;36.
4. **Starling RC**, O'Dorisio TM, Galbraith TA, Myerowitz PD, Unverferth DV. Atrial natriuretic peptide pre and post supine bicycle exercise in orthotopic heart transplant recipients. *Clinical Research*, 1988;36.
5. Li Q, **Starling RC**, Myerowitz PD, Galbraith TA, Wimsatt DK, Hohl CM, Biagi BA, Stokes BT, Altschuld R.A. Isolation and characterization of human ventricular cardiomyocytes in end stage failure. *Clinical Research*, 1988;36.
6. **Starling RC**, Binkley PF, Van Fossen DB, Myerowitz PD, Altschuld RA, Hammer DF. Biochemical analysis of human myocardium in cardiac transplant recipients. *Clinical Research*, 1988;36:829.
7. **Starling RC**, O'Dorisio TM, Myerowitz PD, Galbraith TA, DeVol RA. Preserved atrial natriuretic peptide secretory function in denervated cardiac transplant recipients. *Journal of the American College of Cardiology*, 1989;13.
8. Li Q, Biagi B, **Starling RC**, Hohl C, Altschuld R, Stokes B. Characteristics of calcium transients and electrophysiology in human ventricular myocytes. *Biophysical Journal*, 1989;55.

9. O'Connell JB, Dec GW, Billingham ME, Goldenberg IF, **Starling RC**, Mudge GH, Augustine SM, Constanzo-Nordin MR, Hess ML, Hosenpud JD, Icenogle TB, Menlove RL, Mason JW. Results of cardiac transplantation in active myocarditis. *The Journal of Heart and Lung Transplantation*, 1989; 8.
10. Hammer DF, **Starling RC**, Myerowitz PD, Kelley RE, Altschuld RA. ATP and total adenine nucleotide depletion in failing human myocardium. *Journal of Molecular and Cellular Cardiology*, 1989;(SII)21.
11. **Starling RC**, Haas GJ, Hammer DF, Scott MW, Myerowitz PD, Cody RJ. Progressive left ventricular hypertrophy in cardiac transplant recipients. *Circulation*, 1987; 80:537.
12. **Starling RC**, Binkley PF, Hammer DF, Galbraith TA, Howanitz P, Murray KD, Lowe P, Watson K, Myerowitz PD. Cold preservation, adenine nucleotide content, and cardiac performance after heart transplantation. *Journal of Heart Transplantation*, 1990; 9:70.
13. **Starling RC**, Working Group of Transplant Cardiologists. Efficacy of induction and non-induction immunosuppression in cardiac transplantation. *Journal of Heart Transplantation*, 1990; 9:61.
14. Shaffer P, Binkley P, **Starling RC**, Myerowitz PD, Olsen J. Decreased myocardial utilization of radio labeled fatty acid in cardiac allograft rejection. *Journal of the American College of Cardiology*, 1990; 15.
15. **Starling RC**, Hammer DF, Myerowitz PD, Galbraith TA, Watson K, Binkley PF. Exercise performance and pressure volume relationships after cardiac transplantation. *Clinical Research*, 1990; 38:37.
16. Farhat AZ, Binkley PF, Hammer DF, Myerowitz PD, **Starling RC**. Effect of recipient atrial contraction timing on left ventricular filling in transplanted hearts. *Clinical Research*, 1990; 38.
17. **Starling RC**, Johnson DB, Leesman CJ, Baker PB. Histologic assessment of dilated cardiomyopathy: Limitations of right ventricular endomyocardial biopsy. *Clinical Research*, 1990; 38.
18. Hammer DF, Myerowitz PD, Galbraith TA, **Starling RC**. Biventricular depletion of high energy phosphate content in dilated cardiomyopathy. *Clinical Research*, 1990; 38.
19. Binkley PF, **Starling RC**, Hammer DF, Leier CV. The dobutamine dependent patient: Successful weaning with hydralazine. *Clinical Research*, 1990; 38.
20. **Starling RC**, Johnson DB, Hammer DF, Unverferth DV, Baker PB. Progressive myocardial interstitial fibrosis: The consequence of longstanding dilated cardiomyopathy. *Clinical Research*, 1990; 38.
21. **Starling RC**, Hammer DF, Wooding-Scott M, Binkley PF. A comparison of thermodilution versus radio nuclide assessment of ejection fraction in cardiac transplant recipients. *Clinical Research*, 1990; 38:88.
22. Myocarditis Treatment Trial Investigators. Cardiac structure and function in biopsy proven myocarditis: An echocardiographic substudy of the myocarditis treatment trial. *Journal of the American College of Cardiology*, 1991; 17(SA).
23. **Starling RC**, Hammer DF, Myerowitz PD, Galbraith TA, Binkley PF. Exercise performance and pressure volume relationships after cardiac transplantation. *The Journal of Heart and Lung Transplantation*, 1991; 10:177.
24. Myocarditis Treatment Trial Investigators. Incidence and clinical characteristics of myocarditis. *Circulation*, 1991; 84:II-2.
25. **Starling RC**, Watson KM, Galbraith TA, Howanitz EP, Murray KD, Cody RJ, Myerowitz PD. Reversible functional and biochemical changes in the human donor heart. *Circulation*, 1991; 84:II-488.
26. Bourge RC, Naftel DC, Constanzo-Nordin M, Kirklin JK, Young J, and the Transplant Cardiologists' Research Database Group. Risk factors for death after cardiac transplantation: A multi-institutional study. *The Journal of Heart and Lung Transplantation* 1992; 11:II-191.

27. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, and the Transplant Cardiologists' Research Database Group. Infection following cardiac transplantation: A multi-institutional analysis. *The Journal of Heart and Lung Transplantation* 1992; 11:II-192.
28. Kobashigawa J, Naftel DC, Bourge RC, Kirklin JK, Ventura HO, and the Transplant Cardiologists' Research Database Group. Acute rejection after cardiac transplantation: A multi-institutional analysis. *The Journal of Heart and Lung Transplantation* 1992; 11:II-192.
29. **Starling RC**, Johnson DB, Leesman CJ, Baker PB. Histologic assessment of dilated cardiomyopathy: Limitations of right ventricular endomyocardial biopsy. *Journal of the American College of Cardiology* 1992; 19.
30. Estrada-Quintero T, Murali S, Uretsky BJ, Armitage JM, **Starling RC**, Kormos RL, Hardesty RL, Griffith BP. Hemodynamics, renal function and allograft coronary disease in cardiac transplant patient's immunosuppressed with FK-506. *Journal of the American College of Cardiology* 1992; 19.
31. Gheorghiade M, Sueta CA, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, **Starling RC**, Butman SM, Grossman S, and the Epoprostenol Multicenter Research Group. Multicenter randomized trial of epoprostenol in patients with severe heart failure. *Journal of the American College of Cardiology* 1992; 19.
32. **Starling RC**, VanFossen DB, Kelley RE, Hammer DF. Lack of correlation between ejection fraction and myocardial ATP in cardiomyopathy. *Journal of the American College of Cardiology* 1993; 19.
33. Binkley PF, Khot U, Haas GJ, Reeder DD, Nunziata E, Myerowitz PD, **Starling RC**. Preservation of beat-beat blood pressure variability despite abnormal heart rate variability following cardiac transplantation. *Clinical Research* 1992; 40.
34. Boudoulas H, **Starling RC**, Haas GJ, Sparks L, Myerowitz PD, Wooley CR. Left atrial volume and function in orthotopic heart transplantation. *Circulation* 1992; 86:I-770.
35. Jarcho J, Naftel DC, Shroyer TW, Kirklin JK, Bourge RC, Barr ML, Pitts DG, **Starling RC** and the Transplant Cardiologists Research Database (TCRD) Group, University of Alabama, Birmingham. Does HLA mismatch affect the incidence of rejection after cardiac transplantation: A multi-institutional study. *The Journal of Heart and Lung Transplantation* 1993; 12:50.
36. Armstrong AT, Strauch AR, **Starling RC**. A prospective study of coronary arterioles in human transplanted hearts examined with quantitative morphometric analysis and immunocytochemical labeling. *Clinical Research* 1994.
37. Armstrong AT, Strauch AR, **Starling RC**. Quantitative morphometric analysis of coronary arterioles in human transplanted hearts. *Clinical Research* 1994.
38. Binkley PF, Khot UN, Haas GJ, **Starling RC**, Nunziata E. Contrasting patterns of heart rate and blood pressure variability in congestive heart failure: Evidence for abnormal oscillatory blood pressure control in the setting of ventricular dysfunction. *Circulation* 1994; 90:I-539.
39. Khot UN, **Starling RC**, Haas GJ, Myerowitz PD. Restoration of diurnal blood pressure variability after cardiac transplantation. *Circulation* 1994; 90:I-540.
40. Armstrong AT, Strauch AR, **Starling RC**. Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. Proceedings of the National Meeting of the American Society of Transplant Physicians May 16, 1995.
41. **Starling RC**, Haas GJ. Simplified assessment of pulmonary hypertension in heart transplant candidates. *Journal of the American College of Cardiology* 1996 Feb; 27(S1)144A.
42. **Starling RC**, Goormastic M, Leier CV, Wagoner L, Walsh T, Bohnengel A, for the Ohio Solid Organ Transplant Consortium. Maturation of heart transplantation in Ohio: Evolving outcomes and changing economics. Proceedings of the National Meeting of the American Society of Transplant Physicians May 28, 1996.

43. McCarthy PM, **Starling RC**, Smedira NG, Buda TM, Scalia GM, Young JB. Partial left ventriculectomy with valve repair as an alternative to cardiac transplantation. *The Journal of Heart and Lung Transplantation* 1997; 16.
44. Cook DJ, Sano Y, McCarthy PM, Smedira NG, Massad M, Hurley J, McCarthy JF, Ratliff NR, Young JB, **Starling RC**, Hoercher K, Vargo R, Stewart RW. Post-transplant flow cytometry crossmatching and patient survival in heart transplant recipients. *The Journal of Heart and Lung Transplantation* 1997; 16: I84.
45. **Starling RC**, Young JB, Scalia GM, Thomas JD, Vargo RL, Buda TM, Smedira NG, McCarthy PM. Preliminary observations with ventricular remodeling surgery for refractory congestive heart failure. *Journal of the American College of Cardiology* 1997; 29.
46. Scalia GM, McCarthy PM, **Starling RC**, Vargo RL, Buda TM, Thomas JD. Intra-operative echocardiography in left ventricular remodeling surgery. *Journal of the American College of Cardiology* 1997; 29.
47. Binkley PF, Ahmed S, **Starling RC**, Haas GH, Nunziata E, Cody RJ, Leier CV. Altered autonomic balance with Carvedilol in congestive heart failure does not result from increase in baroreflex gain. *Journal of the American College of Cardiology* 1997; 29.
48. **Starling RC**, Young JB, Buda TM, Vargo RL, Smedira NG, McCarthy PM. Patient selection for ventricular remodeling surgery: Evolving criteria and outcomes. *Journal of the American College of Cardiology* 1997; 29.
49. Scalia GM, McCarthy PM, **Starling RC**, Morehead AJ, Vargo RL, Buda TM, Thomas JD. Mitral valve morphology and function before and after left ventricular remodeling surgery. *Journal of the American College of Cardiology* 1997; 29.
50. McCarthy JM, McCarthy PM, Massad MG, Cook DJ, Kasirajan V, Smedira NG, Goormastic M, Ratliff NB, Young JB, **Starling RC**, Vargo R, Hoercher K, Stewart R. Risk factors for death after a heart transplant: Does single center experience correlate with multi-center registries? *The Annals of Thoracic Surgery* 1997; 65:1574-1579.
51. Avery R, Mossad S, Pelegrin D, McCarthy P, Stewart R, Longworth D, Hobbs R, **Starling RC**, Young JB and the Department of Infectious Disease. Prophylaxis of primary cytomegalovirus infection and disease after heart transplantation: Does adding cytomegalovirus immune globulin to ganciclovir help? Presented at the American Society of Transplant Physicians 16th Annual Meeting and Scientific Sessions 1997; 155:282.
52. Cook DJ, Sano Y, McCarthy PM, Massad M, Smedira N, Hurley J, McCarthy JF, Ratliff NR, Young JB, **Starling RC**, Hobbs R, Hoercher K, Vargo R, Stewart RW. A relationship between post-transplant flow cytometry crossmatch (fcxm) results and vascular rejection in cardiac transplant recipients. Presented at the American Society of Transplant Physicians 16th Annual Meeting and Scientific Sessions 1997; 166:327.
53. McCarthy JM, Cook DJ, Koo A, Massad M, Stewart RW, Ratliff NB, Smedira NB, Goormastic M, Young JB, **Starling RC**, Vargo R, Hoercher K, McCarthy PM. Plasma exchange as a treatment modality in HLA sensitized cardiac allograft recipients. Presented at the American Society of Transplant Physicians 16th Annual Meeting and Scientific Sessions 1997; 166:328.
54. Hoercher K, **Starling RC**, Young JB, McCarthy PM, Stewart RW, Goormastic M. Heart transplantation in the older recipient: Excellent survival but at what cost? Presented at the American Society of Transplant Physicians 16th Annual Meeting and Scientific Sessions 1997; 240:621.
55. McCarthy PM, **Starling RC**, Wong J, Scalia GM, Buda T, Vargo RL, Goormastic M, Thomas JD, Smedira NG, Young JB. Early results with partial left ventriculectomy. Presented at the 77th Annual Meeting of the American Association of Thoracic Surgeons, May 1997.
56. McCarthy PM, Smedira NG, Vargo RL, Goormastic M, **Starling RC**, Young JB. One-hundred HeartMate LVAD patients: Evolving concepts and technology. Western Thoracic Surgical Association 23rd Annual Meeting, Jun 25-28, 1997.

57. Fukamachi K, McCarthy M, Smedira NG, Vargo RL, **Starling RC**, Young JB. Risk factors for perioperative RV failure after implantable LVAD insertion. *Circulation* 1997;96:1299.
58. Wong J, Garcia MJ, **Starling RC**, Buda T, Vargo RL, Scalia GM, McCarthy PM, Thomas JD. Alterations in left ventricular wall stress after partial left ventriculectomy surgery. *Circulation* 1997;96:1344.
59. James KB, **Starling RC**, Sapp SK, Donovan C, Vargo RL, McCarthy PM. Economic comparison of two surgical therapies for heart failure: Ventricular remodeling vs. cardiac transplantation. *Circulation* 1997;96:1368.
60. Kapadia SR, Ziada KM, Crowe TD, Young JB, **Starling RC**. Development and progression of transplant vasculopathy: Serial intravascular ultrasound study. *Journal of the American College of Cardiology* 1998;31.
61. Chung MK, **Starling RC**, Buda TM, Schweikert RA, Ko D, Tchou P, Smedira NG, Young JB, McCarthy PM. Significant risk for ventricular arrhythmias remains after partial left ventriculectomy. *Journal of the American College of Cardiology* 1998;31(S1):293.
62. **Starling RC**, Young JB, Buda TM, Smedira NG, Goormastic M, McCarthy PM. Intermediate results of partial left ventriculectomy for dilated cardiomyopathy. *Journal of the American College of Cardiology* 1998;31(S1):376.
63. Park MH, Young JB, Hobbs RE, Haas GJ, Goormastic M, Boparai N, **Starling RC**. The use of home inotropic therapy for patients awaiting cardiac transplant: Analysis of a nationwide survey among U.S. cardiac transplant centers. *The Journal of Heart and Lung Transplantation* 1998;17:43.
64. Scott RL, Ratliff NB, **Starling RC**, Young JB. Recurrence of giant cell myocarditis in cardiac allograft. *The Journal of Heart and Lung Transplantation* 1998;17:47.
65. Park MH, Young JB, Tuzcu EM, **Starling RC**, Kapadia S, O'Malley KJ, Cook DJ. Anti-donor HLA antibodies associated with allograft arteriopathy detected using intravascular ultrasound. *Transplantation* 1998;65:102.
66. Cook DJ, McCarthy JF, McCarthy PM, Massad M, Sano Y, O'Malley KJ, Smedira N, Goormastic M, Ratliff NR, Young JB, **Starling RC**, Hoercher K, Stewart RW. Early versus late onset vascular rejection in cardiac transplantation. *Transplantation* 1998;65:102.
67. Park MH, Young JB, Stewart RW, Ratliff NB, McCarthy PM, Smedira NG, Pelegri D, **Starling RC**. The efficacy of oral steroid pulse for the treatment of asymptomatic moderate cardiac allograft rejection. *Transplantation* 1998;65:178.
68. Chung MK, **Starling RC**, Buda TM, Jaeger FJ, Schweikert RA, Young JB, Smedira NG, McCarthy PM. Inducibility of ventricular tachycardia after left ventricular remodeling surgery. *Circulation* 1998;68:1164.
69. Fukamachi K, McCarthy PM, Smedira NG, Buda TM, Wong J, **Starling RC**, Young JB. Effects of partial left ventriculectomy on left ventricular performance: One year follow-up. *Circulation* 1998;68:11201.
70. Cook DJ, Bishay S, Raspovic JF, McCarthy PM, **Starling RC**, Young JB, Smedira NG. The impact of HLA sensitization and donor cause of death in heart transplantation. *The Journal of Heart and Lung Transplantation* 1999;18:38.
71. Sheffield CD, Smedira NG, Hoercher K, Goormastic M, McCarthy PM, **Starling RC**, Young JB, Barnes D. Hepatitis C virus (HCV) positive donor hearts: Impact on morbidity and mortality. *The Journal of Heart and Lung Transplantation* 1999;18:39.
72. Marullo AGM, McCarthy PM, Smedira NG, Buda TM, Shiota T, **Starling RC**, Young JB. Left ventricular reconstruction using the Dor procedure for ischemic aneurysm or akinetic dilatation. *The Journal of Heart and Lung Transplantation* 1999;18:42.
73. Pathak A, Park MH, **Starling RC**, Young JB. Hemodynamic guided inotropic tailoring does not appear to impact long-term survival among patients requiring chronic home inotropic therapy. *The Journal of Heart and Lung Transplantation* 1999;18:43.

74. Smedira NG, Sheffield CD, Hoercher K, Goormastic M, McCarthy PM, **Starling RC**, Young JB. Gender mismatch is not associated with reduced survival after heart transplantation. *The Journal of Heart and Lung Transplantation* 1999; 18:44.
75. Hoercher K, Young JB, **Starling RC**, Price LL, Banbury M, Smedira NG, McCarthy PM. Should advanced recipient age be contraindicated in cardiac transplantation? Continued analysis of a single center experience. *The Journal of Heart and Lung Transplantation* 1999; 18:45.
76. Park MH, Pathak A, **Starling RC**, Young JB. Failure to wean from parenteral inotropes: A strong predictor for early mortality among patients with end-stage heart disease. *The Journal of Heart and Lung Transplantation* 1999; 18:47.
77. Kapadia SR, Ziada KM, Ozduran V, Magyar WA, Young JB, **Starling RC**, Nissen SE, Tuzcu EM. Does single vessel intravascular ultrasound imaging adequately reflect the prevalence and severity of transplant vasculopathy? *Journal of the American College of Cardiology* 1999; 33.
78. Avery RK, Mawhorter SD, **Starling RC**, McCarthy PM, Smedira NG, Goormastic M, Pelegrin D, Majercik M, Hobbs RE, Hoercher K, Cook D, Young JB. Hypogammaglobulinemia in heart transplant recipients treated with tacrolimus, mycophenolate and prednisone. *Transplantation* 1999; 67.
79. Yamani MH, Khubchehre C, Young JB, VanLente F, Smedira NG, McCarthy PM, **Starling RC**. Is the therapeutic efficacy of mycophenolate mofetil in the treatment of cardiac allograft rejection related to blood level? *Transplantation* 1999; 67:74.
80. Bishay ES, Cook DJ, Abou El Fettouh H, **Starling RC**, Young JB, Smedira NG, McCarthy PM. The impact of transplantation across a positive crossmatch and donor cause of death in heart transplantation. *Transplantation* 1999; 67.
81. Hoercher K, Goormastic M, McCarthy PM, **Starling RC**, Young JB. Gender mismatch is not associated with reduced survival after heart transplantation. *The Journal of Heart and Lung Transplantation* 1999; 18:44.
82. Matsumiya G, McCarthy PM, Smedira NG, Hoercher K, Schmitt S, **Starling RC**, Young JB. Is it safe to utilize hearts from donors with positive blood cultures? *The Journal of Heart and Lung Transplantation* 1999; 18:79.
83. Hague K, Minal OA, Cosgrove D, **Starling RC**, Yamani M, Schilz R. Epoprostenol salvage in MR induced severe PH. Presented at the 1999 International Conference of American Thoracic Society; San Diego, California. *American Journal of Respiratory and Critical Care Medicine* 1999; 159.
84. McNamara DM, **Starling RC**, Dec, GW, Loh E, Torre-Amione G, Gass A, Janosko KM, Tokarczyk T, Holubkov R, Feldman AM. Intervention in myocarditis and acute cardiomyopathy with immune globulin: Results from the randomized placebo controlled IMAC trial. *Circulation* 1999; 100.
85. McCarthy PM, Bishay EB, Hoercher KJ, Blackstone E, Young JB, **Starling RC**, Smedira NG, Lytle BW, Cosgrove DM. Mitral valve surgery for cardiomyopathy: Late outcomes and effect on rehospitalizations for heart failure. *Circulation* 1999; 100: I514.
86. McCarthy PM, Young JB, **Starling RC**, Blackstone E, Smedira NG, Buda T, Goormastic M, Navia JL, Hoercher KJ. Anterior infarct exclusion surgery for ischemic cardiomyopathy. *Circulation* 1999; 100: I514.
87. **Starling RC**, McCarthy PM, Hoercher KJ, Buda T, Goormastic M, Young JG. Partial left ventriculectomy for dilated cardiomyopathy: A viable option for end stage heart failure? *Circulation* 1999; 100: I801.
88. McCarthy JF, Cook DJ, Smedira NG, O'Malley KJ, Massad MG, Sano Y, Young JB, **Starling RC**, Ratliff NB, McCarthy PM. Vascular rejection in cardiac transplantation. *Transplantation Proceedings* 1999; 31:160.
89. Jimenez J, Kapadia SR, Yamani MH, Platt L, **Starling RC**, Young JB, Nissen SE, Tuzcu EM. Cellular rejection and rate of progression of transplant vasculopathy: A three year serial intravascular ultrasound study. *Journal of*

the American College of Cardiology 2000;35.

90. Tayara W, **Starling RC**, Young JB, Wazni O, Jubran FJ, Smedira NG, McCarthy PM. Improved survival following acute myocardial infarction complicated by cardiogenic shock with LVAD / transplant support: A study comparing aggressive intervention with conservative treatment. *Journal of the American College of Cardiology* 2000;35.
91. Chung MK, Schweikert RA, Firstenberg M, Buda T, Natale A, Jaeger FJ, Niebauer MJ, Tchou PJ, **Starling RC**, Young JB, Smedira NG, McCarthy PM. Inducibility of ventricular tachycardia after Dor procedures. *Journal of the American College of Cardiology* 2000;35.
92. Jimenez J, Bishay ES, Tayara W, Morales A, Cook DJ, Ratliff NB, **Starling RC**, Young JB. Post-transplant HLA antibodies in cellular rejection in heart transplantation. *Transplantation* 2000;69.
93. Hoercher KJ, **Starling RC**, Young JB, Bishay ES, Price LL, McCarthy PM. An economic analysis of older recipient age and its impact on the cost of cardiac transplantation. *Transplantation* 2000;69.
94. Hoercher KJ, **Starling RC**, Young JB, Smedira NG, Banbury M, Goormastic M, McCarthy PM. Use of left ventricular support as a bridge to transplantation: Impact of age on survival. *Transplantation* 2000;69.
95. Avery RK, Mossad SB, Young JB, Goormastic M, **Starling RC**, Hoercher KJ, Hobbs RE, Pelegrin D, Mawhorter SD, McCarthy PM. Long-term outcomes in heart transplant recipients who received ganciclovir prophylaxis: impact of CMV and CMV serostatus on rejection, allograft vasculopathy and survival. *Transplantation* 2000;69.
96. Saliba WI, Helou J, McCarthy PM, Hoercher KJ, **Starling RC**, Smedira NG, Banbury M, Price L, Young JB, Wilkoff BL. Improved survival with early pacemaker implantation following cardiac transplantation. *Pace* 2000; 23:702.
97. **Starling RC**, McCarthy PM, Fukamachi K, Takagaki M, Ochiai Y, Tabata T, Cordon L, Shiota T, Young JB, Schweich CJ. Device based left ventricular shape change immediately improves ventricular function in a canine heart failure model. *European Journal of Heart Failure* 2000; 2:(II)86.
98. Yamani MH, **Starling RC**, Avery RK, Mawhorter SD, Goormastic M, McCarthy PM, Young JB. Relationship of hypogammaglobulinemia to acute cellular rejection and infection following cardiac transplantation: Importance of IgG level monitoring. *The Journal of Heart and Lung Transplantation* 2000; 19:89.
99. Cook DJ, Bishay E, **Starling RC**, Young JB, Smedira NG, McCarthy PM. The crossmatch in cardiac transplantation: Relative risks. *The Journal of Heart and Lung Transplantation* 2000; 19:39.
100. McNamara DM, **Starling RC**, Dec GW, Loh E, Torre-Amione G, Tokarczk TR, Janosko KM, Holubkov R. Plasma cytokines in acute cardiomyopathy: Evolution over time, correlations with functional studies and potential role in recovery. *Circulation* 2000; 102:II-415.
101. Yamani MH, McMahon JT, Young J, **Starling RC**, Cook D, Tuzcu M, McCarthy P, Ratliff NB. A novel method based on computerized scoring of rejection for the prediction of coronary vasculopathy validated by intravascular ultrasound. *The Journal of Heart and Lung Transplantation* 2001; 20:150.
102. Yamani MH, Masri S, Ratliff NB, Young JB, **Starling RC**, Tuzcu M, McCarthy P, Bond M. The role of vitronectin receptor and tissue factor in the pathogenesis of transplant coronary vasculopathy. *The Journal of Heart and Lung Transplantation* 2001; 20:185.
103. Jimenez J, Rosario A, Morales A, Tayara W, Abdo A, Young J, McCarthy P, **Starling R**, Cook D. Risk factors and outcome in patients with hemodynamically unstable rejection after heart transplantation. *The Journal of Heart and Lung Transplantation* 2001; 20:193.
104. Abdo AS, Cook DJ, McCarthy JF, Bishay ES, Kumpati GS, **Starling RC**, Young JB, Koo AP, Smedira NG, McCarthy PM. Plasma exchange before and after cardiac transplantation. *The Journal of Heart and Lung Transplantation* 2001; 20:194.

105. Hoercher K, McCarthy PM, Young J, Smedira NG, **Starling RC**, Banbury MK. Heart transplantation in the older recipient: Has the time come to reconsider our selection policies? *The Journal of Heart and Lung Transplantation* 2001;20:204.
106. Hoercher K, McCarthy PM, Smedira N, Banbury MK, **Starling RC**, Buda TM, Goormastic M, Roberts SR, Young J. Hospital transfer of patients for LVAD bridge to transplant: Is timing really critical to success? *The Journal of Heart and Lung Transplantation* 2001;20:209.
107. Kumpati GS, Cook DJ, Blackstone EH, White J, Abdo A, Young JB, **Starling RC**, Smedira NG, McCarthy PM. Evolution and significance of HLA allosensitization during ventricular assist device support. *The Journal of Heart and Lung Transplantation* 2001;20:210-211.
108. Yamani MH, Cook D, **Starling RC**, Ratliff NB, McMahon JT, Abdo A, Tuzcu M, McCarthy P, Young JB. Myocardial ischemic injury following heart transplantation is associated with decreased risk of acute cellular rejection in the absence of humoral rejection. *The Journal of Heart and Lung Transplantation* 2001;20:238.
109. Roberts SR, Hoercher K, McCarthy PM, Smedira NG, Banbury MK, Goormastic M, **Starling RC**, Young J. The internal cardiac defibrillator for VT on LVAD support. *The Journal of Heart and Lung Transplantation* 2001;20:239.
110. Cook DJ, Blackstone EH, White J, Abdo AS, Young JB, **Starling RC**, Smedira NG, McCarthy PM. HLA allosensitization during ventricular assist device support can be predicted and is related to decreased transplant survival. *American Journal of Transplantation* 2001;1:1178.
111. Abdo AS, Cook DJ, McCarthy JF, Bishay ES, Kumpati GS, **Starling RC**, Young JB, Yamani MH, Smedira NG, McCarthy PM. Sensitivity of the flow cytometry crossmatch in heart transplantation. *American Journal of Transplantation* 2001;1:1215.
112. Yamani MH, Avery R, Mawhorter S, Young JB, McNeill A, Ratliff NB, McCarthy PM, **Starling RC**. Severe hypogammaglobulinemia following heart transplantation: Impact of pre-emptive use of immunoglobulin replacement (cytogram) on infection and rejection outcomes. *American Journal of Transplantation* 2001;1:1280.
113. Hoercher KJ, McCarthy PM, Banbury MK, Young JB, **Starling RC**. Advanced recipient age as a risk factor for morbidity following cardiac transplantation: Does single center experience correlate with multicenter registries? *American Journal of Transplantation* 2001;1:1325.
114. Yamani MH, Abdo AS, Young JB, **Starling RC**, Ratliff NB, Avery R, Tuzcu M, McCarthy PM, Cook DJ. HLA-cytomegalovirus (CMV) interaction in relation to rejection and vasculopathy following human heart transplantation. *American Journal of Transplantation* 2001;1:1431.
115. Masri SC, Yamani MH, Ratliff NB, Almasan A, Fink M, Young JB, **Starling RC**, Bond M. Apoptosis in cardiac allograft rejection and its response to treatment. *The Journal of Heart and Lung Transplantation* 2001;20:227.
116. Fahmi N, Yamani MH, **Starling RC**, Ratliff NB, Young JB, Fairchild R. Expression of chemokine genes during acute rejection of human cardiac allografts. *American Journal of Transplantation* 2001;1:259.
117. Yamani MH, Ratliff NB, **Starling RC**, McCarthy PM, Young JB. Acute vascular rejection is associated with tissue factor generation and increased expression of integrin $\alpha v \beta 3$. *European Journal of Heart Failure* 2001;3:S77.
118. Yamani MH, Masri S, Ratliff NB, **Starling RC**, McCarthy PM, Young JB. Myocardial ischemic injury is associated with up-regulation of integrin $\alpha v \beta 3$ and induction of the metalloproteinase system. *European Journal of Heart Failure* 2001;3:S81.
119. Ferri C, Properzi G, Tomassoni G, Santucci A, Young JB, **Starling RC**, Ratliff NB, Tuzcu EM, McCarthy PM, Yamani MH. Myocardial endothelin-1 expression following heart transplantation. *American Journal of Hypertension* 2001;14:63A.

120. Kelly L, Bennett R, Arroyo L, **Starling RC**, Young JB, Yamani MH. The use of beta blockers in status II heart transplant candidates may eliminate the need for heart transplantation. *Journal of Cardiac Failure* 2001;7:92.
121. McCarthy PM, Young JB, Hoercher KJ, Smedira NG, Secic M, **Starling RC**. Surgical LV reconstruction for end-stage heart disease: Outcomes and effects on NYHA class and hospitalization for heart failure. *Circulation* 2001; 104:II-358.
122. Bennett R, Mahon NG, Hoercher K, Smedira NG, Young JB, McCarthy PM, **Starling RC**. Disposition of patients referred for cardiac transplantation to a tertiary specialized heart failure center in contemporary clinical practice. *Journal of the American College of Cardiology* 2002; 39 (S1):145A.
123. Khot UN, Singh B, Buda T, Smedira NG, McCarthy PM, Yeager M, Young JB, **Starling RC**. Abnormal diurnal pattern of blood pressure in patients with left ventricular assist devices. *Journal of the American College of Cardiology* 2002; 39(S1):154A-155A.
124. Haji SA, Yamani MH, **Starling RC**, Schoenhagen P, Kapadia S, Crowe TD, Ratliff NB, Young JB, Tuzcu EM. Shrinkage of allograft vessels early after transplantation is independent of plaque progression and associated with myocardial fibrosis: A serial histological and volumetric intravascular ultrasound study. *Journal of the American College of Cardiology* 2002; 39(S1):188A.
125. Casey DM, **Starling RC**, Tuzcu M. Outcomes of percutaneous intervention in cardiac allograft vasculopathy. *Journal of the American College of Cardiology* 2002; 39(S1):189A.
126. Yen MH, Pilkington G, Ratliff N, McCarthy PM, Young JB, **Starling RC**, Chisolm GM, Penn MS. Tissue factor expression is increased in cardiac transplant recipients who develop cardiac transplant arteriopathy. *Journal of the American College of Cardiology* 2002; 39(S1):202A.
127. Eisen H, Dorent R, Mancini D, Valantine H, Vigano M, **Starling R**, Lind J, Bernhardt P, Abeywickrama K, the RAD B253 Study Group. Safety and efficacy of Everolimus (RAD) as part of a triple immunosuppressive regimen in *de novo* cardiac transplant recipients: Six-month analysis. *The Journal of Heart and Lung Transplantation* 2002; 21:55.
128. Tuzcu EM, Schoenhagen P, **Starling RC**, Hobbs RE, Dorent R, Pulpon L, Simonsen S, Taylor DO, Hill J, Kobashigawa J, Abeywickrama KH, Popovich J, Magyar W, Crowe TD, Nissen SE. Impact of Everolimus on allograft vasculopathy the SDZ RAD/heart intravascular ultrasound study. *The Journal of Heart and Lung Transplantation* 2002; 21:68.
129. Yamani MH, Tuzcu EM, **Starling RC**, Ratliff NB, Yu Y, Geoffrey V, Powell K, Masri CS, McCarthy PM, Young JB. Peritransplant myocardial ischemic injury is associated with up-regulation of vitronectin receptor, matrix metalloproteinase induction, and subsequent development of coronary vasculopathy. *The Journal of Heart and Lung Transplantation* 2002; 21:73-74.
130. Haji SA, Yamani MH, **Starling RC**, Schoenhagen P, Kapadia SR, Crowe TD, Young JB, Tuzcu EM. Regression of donor-transmitted atherosclerosis. Evidence from serial intravascular ultrasound imaging. *The Journal of Heart and Lung Transplantation* 2002; 21:88.
131. Haji SA, Yamani MH, **Starling RC**, Schoenhagen P, Crowe TD, Young JB, Tuzcu EM. Shrinkage of allograft arteries occurs frequently after transplantation and is accompanied with plaque shrinkage. *The Journal of Heart and Lung Transplantation* 2002; 21:91-92.
132. Yen MH, Pilkington G, Ratliff NB, McCarthy PM, Young JB, **Starling RC**, Chisolm GM, Penn MS. Tissue factor expression is increased in cardiac transplant recipients who develop cardiac transplant arteriopathy. *The Journal of Heart and Lung Transplantation* 2002; 21:113.
133. Cook DJ, Abdo AS, Young JB, **Starling RC**, Yamani M, Smedira NG, McCarthy PM. HLA alloantibodies and time of death in cardiac transplantation. *The Journal of Heart and Lung Transplantation* 2002; 21:169.

134. Fahmy N, Yamani HM, **Starling RC**, Ratliff NB, Young JB, Novick AC, Fairchild RL. Induction of rantes is a positive indicator of human acute cardiac allograft rejection. *American Journal of Transplantation* 2002; 2:III-219.
135. Haji SA, Tuzcu EM, **Starling RC**, Young JB, Ratliff NB, Cook DJ, Avery R, Mawhorter S, Yamani HM. Donor or recipient hepatitis B infection accelerates allograft vasculopathy: A serial intravascular ultrasound study. *American Journal of Transplantation* 2002; 2:III-247.
136. Tang WHW, Lee MJ, Gupta R, Young JB, **Starling RC**, Francis GS. Point-of-care plasma B-type natriuretic peptide assay in clinical practice: A single center experience. *Journal of Cardiac Failure* 2002; 8.
137. Haji SA, **Starling RC**, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, Cook DJ, Ratliff NB, McCarthy PM, Young JB, Yamani HM. Donor hepatitis C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. *Circulation* 2002; 106:II-324-325.
138. Hoercher KJ, **Starling RC**, McCarthy PM, Blackstone EH, Young JB. Partial left ventriculectomy: Lessons learned and future implications for surgical trials. *Circulation* 2002; 106:II-418.
139. Haji SA, **Starling RC**, Yamani HM, Schoenhagen P, Tsunoda T, Badak O, Crowe TD, Young JB, Tuzcu EM. Defining allograft vasculopathy using volumetric intravascular ultrasound analysis. *Circulation* 2002; 106:II-587.
140. Sachar R, Kapadia SR, Ziada KM, Feng J, Crowe TD, Hobbs RE, **Starling RC**, Nissen SE, Tuzcu ME. Intimal thickness one year after cardiac transplantation predicts long-term angiographic outcomes: A serial intravascular ultrasound study. *Circulation* 2002; 106:II-587.
141. Jian XQ, Shiota T, McCarthy PM, Greenberg NL, Gibbons J, Hoercher KJ, Smedira NG, **Starling RC**, Young JB, Thomas JD. The impact of left ventricular reconstruction on left ventricular remodeling in patients with ischemic cardiomyopathy: One year real-time 3D echo followup study. *Circulation* 2002; 106:II-607-608.
142. Fahmy N, Yamani HM, **Starling RC**, Ratliff NB, Young JB, Novick AC, Fairchild RL. An update on chemokine genes and receptor expression during acute rejection of human cardiac allografts. *American Journal of Transplantation* 2002; 2:III-219.
143. Yamani MH, **Starling RC**, Tuzcu EM, Haji SA, Cook DJ, Abdo AS, Ratliff NB, Yousufuddin MM, McCarthy PM, Young JB. Donor intracranial bleeding is associated with advanced transplant coronary vasculopathy: Evidence from intravascular ultrasound. *The Journal of Heart and Lung Transplantation* 2003; (S76)22.
144. McNeill AM, Abdo AS, Cook DJ, **Starling RC**, Ratliff NB, McCarthy PM, Young JB, Yamani MH. Donor intracranial hemorrhage is associated with graft dysfunction and poorer survival following heart transplantation. *The Journal of Heart and Lung Transplantation* 2003; 22(S):S112-S113.
145. **Starling RC**, Hare J, Renlund D, Mancini D, Mayer HW, Schmidli H. Everolimus dose recommendations in de novo heart transplantation – TDM simulations. *The Journal of Heart and Lung Transplantation* 2003; (S140)22.
146. Yousufuddin M, **Starling RC**, Tuzcu EM, Haji S, Ratliff NB, Cooke DJ, Abdo A, McCarthy PM, Young JB, Yamani MH. Cardiac angiotensin II receptors predict allograft vasculopathy in heart transplant recipients. *The Journal of Heart and Lung Transplantation* 2003; (S165)22.
147. Yamani MH, Cook DJ, Abdo AS, Yousufuddin M, **Starling RC**, Yu Y, Tuzcu EM, Ratliff NB, Paul P, McCarthy PM, Young JB. Donor intracranial bleeding is associated with up-regulation of the angiotensin receptor. *The Journal of Heart and Lung Transplantation* 2003; (S212)22.
148. Tang WHW, Girod JP, Lee MJ, **Starling RC**, Young JB, Francis GS. Prevalence and clinical characteristics of patients with chronic systolic heart failure and normal plasma levels of B-type natriuretic peptide. *Journal of the American College of Cardiology* 2003; 41(S1):221A.
149. Yousufuddin M, **Starling RC**, Tuzcu EM, Abdo A, Paul P, Haji S, Ratliff NB, Cook DJ, Saad Y, Karnik S, McCarthy PM, Young JB, Yamani MH. Circulating and tissue angiotensin II type 1 receptors from perioperation

through one-year of transplantation: A potential molecular mechanism for cardiac allograft vasculopathy. *Journal of the American College of Cardiology* 2003;41:542A-543A.

150. Hare J, **Starling RC**, Renlund D, Mancini D, Mayer HW, Schmidli H. Therapeutic drug monitoring of Everolimus may be beneficial in de novo heart transplantation. *American Journal of Transplantation* 2003;3(5):167.
151. Fahmy N, Yamani MH, **Starling RC**, Ratliff NB, Young JB, McCarthy PM, Novick AC, Fairchild RL. Higher chemokine gene expression during late vs early acute rejection episodes in human heart grafts. *American Journal of Transplantation* 2003;3(5):197.
152. Fahmy N, Yamani MH, **Starling RC**, Ratliff NB, Young JB, McCarthy PM, Novick AC, Fairchild RL. Expression of MCP-1 as a marker of acute rejection in human cardiac transplantation. *American Journal of Transplantation* 2003;3(5):385.
153. Kobashigawa JA, **Starling RC**, Mehra MR., Bhat G, Kormos RL, Barr ML. Impact of ongoing post cardiac transplant risk factors on outcomes: A multicenter study. *American Journal of Transplantation* 2003;3(5):457.
154. Fahmy N, Yamani MH, **Starling RC**, Ratliff NB, Young JB, McCarthy PM, Novick AC, Fairchild RL. Increased chemokine gene expression in human heart grafts following ischemia. *American Journal of Transplantation* 2003;3(5):525.
155. O'Neill JO, McRae AT, Taylor DO, Ng K, Yamani MH, **Starling RC**. Time dependent decline in plasma brain natriuretic peptide levels occurs independent of rejection after orthotopic cardiac transplantation. *American Journal of Transplantation* 2003;3(5):528.
156. Mawhorter S, Nasrallah M, **Starling RC**, Brakeman J, Bennett R, McCarthy PM, Young JB. Assessment of an accelerated hepatitis B vaccination protocol in congestive heart failure and left ventricular assist device patients awaiting heart transplantation. *American Journal of Transplantation* 2003;3(5):528.
157. Lee MJ, Tang MHW, Girod JP, **Starling RC**, Young JB, Francis GS. Using B-type natriuretic peptide (BNP) in ambulatory patients with chronic heart failure and concomitant chronic renal insufficiency. *European Journal of Heart Failure* 2003;9(5) (S1):S31.
158. Maybaum S, Frazier OH, **Starling RC**, Miller L, Murali S, Aaronson KD, Margulies K, McRee S, Torre G, on behalf of the LVAD Working Group. Cardiac recovery during 30 days of support with a left ventricular assist device. Preliminary results from the LVAD Working Group. *Journal of the American College of Cardiology* 2003;41(S1):165A-166A.
159. Tang WHW, Girod JP, Lee MJ, **Starling RC**, Young JB, Francis GS. Prevalence and clinical characteristics of patients with chronic systolic heart failure and normal plasma levels of B-type natriuretic peptide. *Journal of the American College of Cardiology* 2003;41(S1):221A.
160. Yousufuddin M, **Starling RC**, Tuzcu EM, Abdo A, Paul P, Haji S, Ratliff NB, Cook DJ, Saad Y, Karnik S, McCarthy PM, Young JB, Yamani MH. Circulating and tissue angiotensin II type 1 receptors from perioperation through one-year of transplantation: A potential molecular mechanism for cardiac allograft vasculopathy. *Journal of the American College of Cardiology* 2003;41:542A-543A.
161. Yamani MH, **Starling RC**, Tuzcu EM, Cook DJ, Powell K, Ratliff NB, Yu Y, McCarthy PM, Young JB. Donor intracranial bleeding is associated with activation of the metalloproteinase system and subsequent development of allograft vasculopathy. *Circulation* 2003;e131-e134.
162. Zhang L, Sun JP, Garcia MJ, Taylor DO, **Starling RC**, Smedira NG, Banbury MK, Thomas JD, Stewart WJ. Right ventricular dysfunction occurs commonly after orthotopic heart transplantation. *Journal of the American Society of Echocardiography* 2003;16:564.
163. Zhang L, Sun JP, Garcia MJ, Taylor, DO, **Starling RC**, Smedira NG, Banbury MK, Thomas JD, Stewart WJ. Evaluation of right ventricular function after orthotopic heart transplantation: Short -term follow-up. *Journal of the American Society of Echocardiography* 2003.

164. Maybaum S, Frazier OH, **Starling RC**, Miller L, Aaronson K, Murali S, Margulies K, McRee SC, Torre G. Cardiac recovery during support with a left ventricular assist device: Results from the LVAD working group. *Journal of Cardiac Failure* 2003;5(SIII).
165. Torre-Amione G, Frazier OH, **Starling RC**, Miller L, Aaronson K, Murali S, Margulies K, McRee S, Maybaum S. Cellular regression of fibrosis and hypertrophy following chronic LVAD support does not translate into sustained improvements in contractile function: Results from the LVAD working group. *Journal of Cardiac Failure* 2003; 5(SIII).
166. O'Neill JO, Bott-Silverman CE, McRae AT III, Troughton RW, Ng K, **Starling RC**, Young JB. Can B-type natriuretic peptide levels be a surrogate marker for invasive hemodynamics during management of heart failure? *Journal of Cardiac Failure* 2003;5(SIII).
167. O'Neill JO, McCarthy PM, Brunken RC, Buda T, Hoercher K, Young JB, **Starling RC**. High prevalence of regional abnormalities in dilated cardiomyopathy. *Journal of Cardiac Failure* 2003;5(SIII).
168. O'Neill JO, Brunken RC, McCarthy PM, Buda T, Hoercher K, Young JB, **Starling RC**. QRS duration correlates with scar content in dilated cardiomyopathy. *Journal of Cardiac Failure* 2003;5(SIII).
169. Lee MJ, Tang WHW, **Starling RC**, Young JB, Francis GS. Using plasma B-type natriuretic peptide levels to monitor ambulatory patients with chronic heart failure and concomitant renal insufficiency. *Journal of Cardiac Failure* 2003;5(SIII).
170. Abdo AS, Cook DJ, **Starling RC**, Paul P, Yamani HM, Apgar J, Tuzcu EM. The impact of the ACE insertion polymorphism on the outcome of heart transplantation. *Journal of Cardiac Failure* 2003;5(SIII).
171. Yamani HM, **Starling RC**, McNeill A, Cook DJ, Ratliff NB, Abdo A, Dempsey J, Hobbs RE, Rincon G, Bott-Silverman CE, McCarthy PM, Young JB. Peri-transplant graft dysfunction is associated with ischemic injury/fibrosis and adverse long-term outcome. *Journal of Cardiac Failure* 2003;5(SIII).
172. Borowski AG, Troughton RW, Yeager ML, Thomas JD, Griffin BP, Garcia MJ, **Starling RC**, McCarthy PM, Grande-Allen KJ. Persistent mitral regurgitation in turndown echo evaluations of LVAD patients. *Journal of Cardiac Failure* 2003;5(SIII).
173. Hoercher KJ, Lee R, McCarthy PM, Feng J, Young JB, **Starling RC**, Blackstone EH. Preoperative QRS widening and ventricular dysrhythmia predict adverse outcomes following LV reconstruction for ischemic cardiomyopathy. *Journal of Cardiac Failure* 2003;5 (SIII).
174. Yamani HM, **Starling RC**, Tuzcu EM, McNeill AM, Abdo AS, Cook DJ, Ratliff NB, McCarthy PM, Young JB. The impact of donor spontaneous intracerebral hemorrhage on left ventricular function and remodeling following heart transplantation. *Journal of Cardiac Failure* 2003;5(SIII).
175. Hail MD, Heery AM, O'Neill JO, Khaykin Y, Chung MK, Young JB, McCarthy PM, **Starling RC**. Cost effectiveness of implantable defibrillators following left ventricular reconstruction surgery in patients with ischemic cardiomyopathy. *Journal of Cardiac Failure* 2003;5(SIII).
176. Higginbotham MB, **Starling RC**, Wagoner L, Coman J, Kennett J, Lowes B, Wolfel G. Cardiac resynchronization therapy improves functional status in heart failure patients: Results from the COMPANION exercise performance sub-study. *Journal of Cardiac Failure* 2003;5(SIII).
177. O'Neill JO, McRae AT III, Ng K, **Starling RC**. A time dependent decline in plasma brain natriuretic peptide levels occurs independent of rejection after orthotopic cardiac transplantation. *Journal of the American Society of Transplant* 2003.
178. O'Neill JO, Bott-Silverman CE, McRae AT III, Troughton RW, Ng K, **Starling RC**, Young JB. Can B-type natriuretic peptide levels be a surrogate marker for invasive hemodynamics during management of heart failure? *Circulation* 2003, in press.

179. Khaykin Y, O'Neill JO, Hail M, Vargo P, Young JB, McCarthy PM, **Starling RC**, Smedira NB, Chung M. Are EP studies still useful in the post-MADIT II era? *European Journal of Cardiology* 2003, in press.
180. Erine SK, Yamani MH, **Starling RC**, Young JB, Crowe TD, Hobbs RE, Bott-Silverman C, Rincon G, Feng J, McCarthy PM, Nissen SE, Tuzcu EM. The effect of combined angiotensin converting enzyme inhibition and calcium antagonist on allograft coronary vasculopathy validated by intravascular ultrasound. *Circulation* 2003; 108(SIV):329-330.
181. Yamani MH, **Starling RB**, Tuzcu EM, Cook DJ, Abdo A, Paul P, Ratliff NB, Yu Y, McCarthy PM, Young JB. Donor intracerebral hemorrhage is associated with up-regulation of the vitronectin receptor ($\alpha v\beta 3$). *Circulation* 2003; 108(SIV):331.
182. O'Neill JO, Bott-Silverman C, McRae AT III, Troughton RW, Ng K, **Starling RC**, Young JB. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. *Circulation* 2003; 108(SIV):557.
183. Troughton RW, Prior DL, Pereira JJ, Fogarty AM, Morehead A, Martin M, **Starling RC**, Young JB, Thomas JD, Klein AL. New echocardiographic indices of diastolic function have significant prognostic value in systolic heart failure: Preliminary results from the ADEPT study. *Circulation* 2003; 108(SIV):593.
184. Erinc SK, Yamani MH, **Starling RC**, Young JB, Crowe TD, Hobbs RC, Bott-Silverman C, Rincon G, Feng J, McCarthy PM, Nissen SE, Tuzcu EM. The effects of combined angiotensin converting enzyme inhibition and calcium antagonist on allograft coronary vasculopathy validated by intravascular ultrasound. *Circulation* 2003; 108(SIV):329-330.
185. Yamani MH, **Starling RC**, Tuzcu EM, Cook DJ, Abdo A, Paul P, Ratliff NB, Yu Y, McCarthy PM, Young JB. Donor intracerebral hemorrhage is associated with up-regulation of the vitronectin receptor ($\alpha v\beta 3$). *Circulation* 2003; 108(SIV):331.
186. O'Neill JO, Bott-Silverman C, McRae AT III, Troughton RW, Ng K, **Starling RC**, Young JB. B-type natriuretic peptide levels are not a surrogate marker for invasive haemodynamics during management of patients with severe heart failure. *Circulation* 2003; 108(SIV):557.
187. Hoercher KJ, Gonzalez-Stawinski GV, Taylor DO, McCarthy PM, Young JB, **Starling RC**. Cardiac transplantation at the Cleveland Clinic. In: Cecka JM, Terasaki PI, eds. *Clinical Transplants* 2003, Los Angeles, UCLA tissue typing Laboratory, 267-274.
188. Yamani MH, Lauer MS, **Starling RC**, Pothier CE, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, McNeil A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. *American Journal of Transplantation* 2004 Feb; 4:257-261.
189. Shah AN, **Starling R**, Dec GW, Torre-Amione G, Gass A, London B, Mcnamara DM, for the IMAC Investigators. Effect of the Beta1Ser49Gly polymorphism on outcomes in recent onset cardiomyopathy: Results from the IMAC trial. *Journal of the American College of Cardiology* 2004; 43(S1):163A.
190. Maybaum S, Frazier OH, **Starling R**, Miller L, Murali S, Aaronson K, Margulies K, Xydas S, McRee S, Torre G. Cardiac recovery during left ventricular assist device support: Results from the LVAD working group. *Journal of the American College of Cardiology* 2004; 43(S1):233A.
191. Ng K, Kedia N, **Starling R**, Wilkoff B, Tchou P, Martin D, Grimm R. Benefit of biventricular pacing in subsets of patients with heart failure. *Journal of the American College of Cardiology* 2004; 43(S1):237A.
192. Yamani MH, **Starling RC**, Tuzcu EM, Cook D, Paul P, Ratliff NB, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Correlation between angiotensin II receptor subtype 1 and vitronectin receptor in cardiac transplantation. *Journal of the American College of Cardiology* 2004; 43(S1):193A.

193. O'Neill JO, McRae III AT, Troughton RW, Ng K, Taylor DO, Yamani MH, Young JB, **Starling RC**. Brain natriuretic peptide levels correspond with diastolic function following orthotopic heart transplantation. *Journal of the American College of Cardiology* 2004; 43(S1):194A.
194. Schenk S, Popovic ZB, McCarthy PM, Ochiai Y, **Starling RC**, Navia JL, Ootaki Y, Kamohara K, Thomas JD, Fukamachi K. Optimal preload adjustment of right ventricular power allows for single beat estimation of contractility. *Journal of the American College of Cardiology* 2004; 43(S1):219A.
195. Hoercher KJ, Lee R, McCarthy PM, Feng J, Young JB, **Starling RC**, Blackstone EH. Preoperative QRS widening and ventricular dysrhythmia predict adverse outcomes following left ventricular reconstruction for ischemic cardiomyopathy. *Journal of the American College of Cardiology* 2004; 43(S1):271A.
196. Eisen H, Kobashigawa J, **Starling RC**, Cretin N, Jaffe J, Murphy J. Twenty-four-month safety results of a randomized, multicenter, double-blind study of Everolimus vs azathioprine in de novo heart transplant recipients. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
197. Gonzalez-Stawinski GV, McCarthy PM, Cook DJ, Atik F, Parrino PE, Hoercher K, Taylor DO, **Starling RC**, Yamani MH, Young JB. Left ventricular assist devices in the development of post transplant vasculopathy. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
198. Tuzcu EM, Kobashigawa JA, Eisen HJ, **Starling RC**, Crowe T, Abeywickrama K, Jaffe J. Favorable effect of Everolimus on cardiac allograft vasculopathy is maintained through 24 months. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
199. Erinc SK, Yamani MH, **Starling RC**, Young JB, Crowe T, Cook DJ, Hobbs R, Bott-Silverman C, Rincon G, McCarthy PM, Tuzcu EM. Influence of donor gender on allograft coronary vasculopathy: Evidence from intravascular ultrasound. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
200. Gonzalez-Stawinski GV, McCarthy PM, Hoercher K, Feng J, Beyer EA, McGee E, Parrino PE, Taylor DO, **Starling RC**, Young JB. Outcomes in elderly patients receiving orthotopic heart transplants. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
201. **Starling RC**, Kobashigawa J, Eisen H, Jaffe J, Li Y. Risk factors for acute rejection and vasculopathy among 634 patients treated with Everolimus or azathioprine. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
202. Poggio E, Roddy M, Clemente M, Riley J, **Starling R**, McCarthy P, Young J, Gus B, Yamani M, Heeger PS. Anti-donor immunity in cardiac allograft recipients with and without transplant vasculopathy (TV). Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
203. Kobashigawa JA, Tobis JM, **Starling RC**, Tuzcu ME, Mehra MR, Yeung A, Valantine H, Smith A, Anzai H, Oeser BT, Abeywickrama K, Murphy J, Cretin N. Multi-center intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. Presented at the Fifth Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation May 15-19, 2004.
204. Shah T, Yamani MH, McNeill A, Avery RK, Mawhorter S, Saber S, Cook DJ, Buda T, Yeager M, Hobbs RE, Taylor D, Young JB, Smedira N, **Starling RC**. The impact of hypogammaglobulinemia on infections in patients with ventricular assist devices. *Journal of the American College of Cardiology* 2005 Feb; 45:11A.
205. Yamani MH, Cook DJ, Yu Y, Tuzcu EM, Ratliff NB, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Smedira N, **Starling RC**. Peritransplant ischemic injury triggers mobilization of stem cells to allografts following heart transplantation. *Journal of the American College of Cardiology* 2005 Feb; 45:16A.

206. Tang WHW, Troughton RW, Nash P, Bhavnani S, Francis GS, **Starling RC**, Richards AM, Yandle T, Klein AL. Reduction of natriuretic peptides in obese patients with systolic heart failure is independent of peptide types and echocardiographic indices of myocardial performance: Analysis from ADEPT neurohormonal substudy. *Journal of the American College of Cardiology* 2005 Feb; 45:140A.
207. Angheloiu GO, Yamani MH, **Starling RC**, Young JB. Elevated troponin T is associated with increased left ventricular end-diastolic pressure and electrocardiographic left ventricular hypertrophy in congestive heart failure patients with no coronary artery disease. *Journal of the American College of Cardiology* 2005 Feb; 45:145A.
208. Mezu UL, Philip K, Francis GS, **Starling RC**, Taylor DO, Tang WHW. The impact of baseline glomerular filtration rate on the incidence of worsening renal failure in patients admitted for acute decompensated heart failure. *Journal of the American College of Cardiology* 2005 Feb; 45:170A.
209. Khan M, Jais P, Cummings JE, Sanders P, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Belden W, Wazni O, Wang P, Al-Ahmad A, Beheiry S, Pisano E, Santarelli P, **Starling R**, Russo AD, Pelargonio G, Brachmann J, Gunther J, Bonso A, Raviele A, Haissaguerre M, Natale A. Randomized controlled trial of pulmonary vein antrum isolation vs. AV node ablation with bi-ventricular pacing for treatment of atrial fibrillation in patients with congestive heart failure (PABA CHF). *Circulation* 2005; 112(SII):394.
210. Yamani MH, Rodriguez R, Cook DJ, Wholgemuth J, McNeill A, Zhou L, Taylor DO, Hobbs R, Young JB, Smedira N, **Starling RC**. Transplant vasculopathy is associated with increased AlloMap gene expression score. *Circulation* 2005; 112(SII):457.
211. Yamani MH, Rodriguez R, Cook DJ, McNeill A, Yu Y, Taylor DO, Hobbs R, Zhou L, Tuzcu EM, Young JB, Smedira N, **Starling RC**. Recurrent cardiac allograft rejection is associated with increased myocardial expression of angiotensin II receptor subtype-1. *Circulation* 2005; 112(SII):544.
212. Sweet WE, Urich MG, Banbury M, Navia J, Young JB, **Starling RC**, Smedira NG, Moravec CS. Beta 2 adrenergic receptors play a greater role in the failing human heart following LVAD support. *Circulation* 2005; 112(SII):591.
213. Tang WHW, Borowski AG, Juno C, Tong W, Troughton RW, Martin MG, Kassimatis K, Agler D, **Starling RC**, Jasper SE, Whitman CM, Grimm R, Klein AL. Limitations of bundle branch block (BBB) in assessing intra-ventricular delay in unselected patients with chronic heart failure (CHF): An ADEPT ancillary study. *Circulation* 2005; 112(SII):756.
214. Khan MN, Jais P, Cummings JE, Sanders P, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Wazni O, Wang P, Al-Ahmad A, Beheiry S, Pisano E, Santarelli P, **Starling RC**, Schweikert RA, Dello Russo A, Pelargonio G, Brachmann J, Gunther J, Bonso A, Raviele A, Haissaguerre M, Natale A. Progression of atrial fibrillation in the pulmonary vein antrum isolation vs. AV node ablation with bi-ventricular pacing for treatment of atrial fibrillation in patients with congestive heart failure trial (PABA CHF). *Heart Rhythm* May 2006; 3(SV):S36.
215. Baranowski B, Civello KC, Wilkoff BL, **Starling RC**, Grimm RA. Lack of echocardiographic evidence of dyssynchrony predicts poor relative survival following cardiac resynchronization therapy (CRT). *Heart Rhythm* May 2006; 3(SV):S69.
216. Gupta S, Cook DJ, Sharma M, Gonzales-Stawinski G, Taylor D, Yamani M, Rodriguez ER, **Starling RC**, Smedira N. HLA sensitization at the time of diagnosis of vascular rejection in heart transplantation. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
217. Baris N, Sipahi I, **Starling RC**, Hobbs R, Kapadia SR, Tuzcu EM. Increase in TIMI frame count in the first year after transplantation is associated with increased long-term mortality in patients with cardiac transplantation: A serial angiography study. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
218. Deng MC, Cadeiras M, Lim WK, Baron HM, Marboe CC, **Starling RC**, Eisen H, Hunt SA, Kobashigawa J, Mehra MR, Pauli D, Murali S, Wohlgemuth J, Klingler T, Dedrick R, Califano A. Reconstructing the CREB-Network

from 285 leukocyte-arrays in CARGO yields insight into transcription factor function during quiescence and rejection. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.

219. Gonzalez-Stawinski GV, Ludrosky K, Taylor DO, Navia JL, Banbury MK, Yamani MH, Hoercher K, Yeager M, **Starling RC**, Smedira NG. One hundred days or more bridged on a ventricular assist device and the effects on outcomes following heart transplantation. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
220. Gonzalez-Stawinski GV, Tan CD, Smedira NG, **Starling RC**, Yamani MH, Rodriguez ER. Regulators of complement activation in antibody mediated cardiac allograft rejection. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
221. Shabari RF, Yamani MH, Tang W, Taylor DO, Rodriguez ER, Cook DJ, Colosimo PJ, Maynard C, Wohlgenuth J, Smedira N, **Starling RC**. Single center experience with a genomic-based noninvasive strategy for the follow-up of cardiac transplant recipients. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
222. Sopko NA, Shea KJ, Ludrosky K, Hoercher K, Smedira NG, Navia JL, Taylor DO, Yamani MH, **Starling RC**, Gonzalez-Stawinski GV. Functional cardiac abnormalities in heart donors and their impact following heart transplantation. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
223. Shea KJ, Sopko NA, Ludrosky K, Colosimo P, Reese JR, Hoercher K, Smedira NG, Navia JL, Taylor DO, Yamani MH, **Starling RC**, Gonzalez-Stawinski GV. Heart donors with high risk social behavior: Is it risky business? Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
224. Avery RK, Mossad SB, Mawhorter SD, Schmitt SK, Budev M, Lard ML, **Starling RC**, Colosimo PJ, Fung J, Corey R, Krishnamurthi V, Flechner S, Yen-Lieberman B. Reduction of late CMV after prophylaxis by a combined prophylaxis/preemptive therapy program in high-risk transplant recipients. Presented at the World Transplant Congress, Boston, Massachusetts, Jul 22-27, 2006.
225. Chow CH, Aktas MK, Jaber WA, Tang WH, **Starling RC**, Taylor DO, Yamani MH. Modulation of NBP response in relation to myocardial scarring on PET scan in patients with acute congestive heart failure exacerbation. Presented at Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, Sep 10-13, 2006.
226. Tong W, Van Lente F, Troughton RW, Francis GS, **Starling RC**, Klein AL, Tang WH. Relation of Cystatin C to natriuretic peptide, creatinine clearance, and prognosis in patients with chronic systolic heart failure. Presented at Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, Sep 10-13, 2006.
227. Narayan SB, Avery R, Mawhorter S, Cook DJ, Kelly L, Hobbs R, **Starling RC**, Taylor DO, Yamani MH. Hypogammaglobulinemia in congestive heart failure patients: prevalence and impact on infection outcome. Presented at Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, Sep 10-13, 2006.
228. Tang WH, Mezu UL, Taylor DO, **Starling RC**. Cardiac power index predicts need for inotropic support but not worsening renal function in patients admitted for acute decompensated heart failure. Presented at Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, Sep 10-13, 2006.
229. Teuteberg J, Janosko KM, **Starling RC**, Torre-Amione G, Dec GW, McTiernan C, McNamara DM. Gender differences in myocardial histology and gene expression in recent onset cardiomyopathy: Implications for recovery. Presented at Heart Failure Society of America 10th Annual Scientific Meeting, Seattle, Washington, Sep 10-13, 2006.
230. Mehra M, Kobashigawa J, Deng MC, Klingler T, Lal P, Rosenberg S, Uber P, **Starling RC**, Baron H, Wohlgenuth J, Eisen H. The role of IL1R2 and FLT3 gene expression in cardiac allograft rejection: A precise measure of corticosteroid effect? Presented at American Heart Association Scientific Sessions, Chicago, Illinois, Nov 12-15, 2006.

231. Angheloiu GO, Rahaby M, **Starling RC**, Yamani MH, Young JB. Myocardial degradation as indicated by elevated Troponin T in nonischemic congestive heart failure is predictive of adverse events, including conversion from predominantly diastolic to systolic left ventricular dysfunction. Presented at American Heart Association Scientific Sessions, Chicago, Illinois, Nov 12-15, 2006.
232. Cooper LT, Hare JM, Tazelaar HD, **Starling RC**, Deng MC, Menon S, Mullen GM. A prospective treatment trial of immunosuppression for giant cell myocarditis. Presented at American Heart Association Scientific Sessions, Chicago, Illinois, Nov 12-15, 2006.
233. Tang, WH, Tong W, Van Lente F, Troughton RW, Francis GS, **Starling RC**, Klein AL. Relation of Cystatin C to natriuretic peptide creatinine clearance, and prognosis in patients with chronic systolic heart failure. Presented at American Heart Association Scientific Sessions, Chicago, Illinois, Nov 12-15, 2006.
234. O'Neill JO, **Starling RC**, Smedira NG, White R, Buda T, Lytle BW. Left ventricular reconstruction improves left ventricular geometry and systolic function as assessed by cardiac magnetic resonance imaging. Presented at American College of Cardiology 56th Annual Scientific Session, New Orleans, Louisiana, Mar 2007.
235. **Starling RC**, Jessup M, Oh J, Sabbah HN, Acker MA, Mann DL, Kubo SH. Long term benefits of the CorCapTM Cardiac Support Device on left ventricular (LV) remodeling: 3 year results. Presented at American College of Cardiology 56th Annual Scientific Session, New Orleans, Louisiana, Mar 2007.
236. Taylor DO, Brown RN, Jessup ML, **Starling RC**, Aaronson KD, Rayburn BK, Czerr J, Naftel DC, Kirklin JK, Cardiac Transplant Research Database. Progress in heart transplantation: Riskier patients yet better outcomes: A 15-year multi-institutional study. Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
237. Magyar D, Smedira NG, Hoercher KJ, Navia JL, Mihaljevic T, Taylor DO, **Starling RC**, Gonzalez-Stawinski GV. Outcomes of female heart transplant recipients bridged to transplantation with a ventricular assist device. Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
238. Mehra MR, **Starling RC**, Lal PG, Woodward RG, Dedrick RL, Rosenberg S. Gene expression and prediction of early cardiac allograft rejection: Discovery of a gene-based corticosteroid efficacy measure. Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
239. Mehra M, Deng MC, **Starling RC**, Murali S, Pauly D, Lal P, Cadeiras M, Baron H, Rosenberg S, Eisen H. Does induction therapy influence the utility of gene expression testing for cardiac allograft rejection? Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
240. Hunt J, Bedánová H, **Starling RC**, Rabágo G, Banner NR, Kobashigawa J, Keogh A, Kormos R, Mehra M, Wahlers T, Noeldeke J. Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
241. Sharma MS, Hoercher KJ, **Starling RC**, Alster JM, Deglurkar I, Blackstone EH, Gonzalez-Stawinski GV, Smedira NG. Seeing the future: Strategic decision support for heart transplant. Presented at International Society for Heart and Lung Transplantation Scientific Sessions, San Francisco, California, Apr 2007.
242. Keslar K, Rodriguez ER, Tan CD, **Starling RC**, Heeger PS. Complement gene expression in human heart biopsies correlates with histologic grade of injury. Presented at American Transplant Congress, San Francisco, California, May 2007.
243. Usmani A, Yamani MH, Narayan SB, Yen-Lieberman B, Haire C, Hobbs R, **Starling RC**, Smedira N, Taylor DO. Immunosuppression management guided by immune cell function assay (ImmunKnowTM) in heart transplant recipients. Poster Board—Session: P59-11. Presented at the American Transplant Congress, May 5—9, 2007. *American Journal of Transplantation*; 7(SII): 423, 1072.

244. Zahr F, Ootaki Y, **Starling RC**, Smedira N, Yamani M, Fukamachi K. Preoperative risk factors for mortality after biventricular assist device implantation. Presented at Heart Failure Society of America Annual Scientific Meeting, Washington, DC, Sep 16-19, 2007.
245. Narayan SB, Ayache M, Chung MK, Haire C, Taylor DO, **Starling RC**, Yamani MH. The prevalence of atrial fibrillation in patients with congestive heart failure and hypogammaglobulinemia. Presented at Heart Failure Society of America Annual Scientific Meeting, Washington, DC, Sep 16-19, 2007.
246. Skouri HN, Mullens W, Abrahams Z, **Starling RC**, Taylor DO, Tang WHW. Lower pulmonary capacitance portends poorer survival in patients with advanced heart failure. Presented at Heart Failure Society of America Annual Scientific Meeting, Washington, DC, Sep 16-19, 2007.
247. Morrison J, Moravec CS, Tang WHW, Southard J, Southard L, **Starling RC**, Prasad SVN. Abstract 772: Calcitonin-gene related peptide receptor regulation in human heart failure. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
248. Halley CM, Kwon DH, Carrigan TP, Setser R, Schoenhagen P, **Starling RC**, Flamm SD, Desai MD. Abstract 1979: Association of renal dysfunction, myocardial fibrosis and survival in patients with severe left ventricular dysfunction: A delayed hyperenhancement MRI Study. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
249. Yamani MH, Haire C, Taylor DO, Young JB, **Starling RC**. Abstract 2093: Myocardial upregulation of mRNA angiotensin II receptor subtype 1 (AGTR1) at one year of heart transplantation is associated with worse long-term clinical outcome including skin cancer. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
250. Thomas NC, Tanabe M, **Starling RC**, Markham DW, McNamara DM, Gorcsan J. Abstract 2182: Left ventricular dyssynchrony in acute onset cardiomyopathy. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
251. Moon KW, Sipahi I, Nicholls SJ, Schoenhagen P, Kalidindi SR, Kapadia SR, **Starling RC**, Hobbs RE, Erinc K, Magyar WA, Nissen SE, Tuzcu EM. Abstract 2886: Angiotensin-converting enzyme inhibitors attenuate age-related progression of cardiac allograft vasculopathy - A serial volumetric intravascular ultrasound study. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
252. Angheloiu F, Wright DM, **Starling RC**, Dec GW, Torre-Amione G, Alexis J, Sheppard R, Mann D, McTiernan C, McNamara DM. Abstract 2915: Circulating fas in subjects with acute cardiomyopathy and myocarditis: Results from IMAC 1. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
253. **Starling RC**, Cooper LT, Dec GW, Boehmer J, Liu P, Pauly D, Gorcsan J, Tanabe M, Kip K, McNamara DM. Abstract 3002: Left ventricular diameter predicts recovery in acute cardiomyopathy: Results of the IMAC 2 trial. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
254. Kwon DH, Halley C, Carrigan T, Setser R, Schoenhagen P, **Starling RC**, Flamm S, Desai M. Abstract 3098: Left ventricular delayed hyper-enhancement further risk stratifies patients with severe systolic dysfunction regardless of the presence of coronary artery disease: A cardiac MRI study. Presented at the American Heart Association Annual Scientific Sessions, Orlando, Florida, Nov 3-7, 2007.
255. Kwon DH, Halley C, Carrigan TP, Setser R, Zysek V, Popovic Z, Schoenhagen P, **Starling RC**, Flamm SD, Desai MY. Abstract 812-7: Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with severe systolic dysfunction: A delayed hyper-enhancement MRI study. *JACC* Mar 2008; 51(10 Suppl. A):A161.
256. Tanaka H, Tanabe M, **Starling RC**, McNamara DM, Gorcsan III J. Abstract 1016-14: Association of left ventricular diastolic dysfunction with dyssynchrony in acute onset cardiomyopathy. *JACC* Mar 2008; 1(10 Suppl. A):A56.

257. Ching-Chiew Wong R, Dumont CA, Austin BA, Kwon DH, Flamm SD, Thomas JD, **Starling RC**, Desai MY. Abstract 1023-38: Relation of ventricular-vascular coupling to exercise capacity in ischemic cardiomyopathy: A cardiac multi-modality imaging study. *JACC* Mar 2008; 51(10 Suppl. A):A71.
258. Mullens W, Tong W, Skouri HN, Abrahams Z, Taylor DO, **Starling RC**, Tang WH Wilson. Abstract 1019-142: Impact of impaired pulmonary arterial capacitance on the incidence of renal insufficiency in advanced heart failure. *JACC* Mar 2008; 51(10 Suppl. A):A252.
259. Moon K-W, Nicholls SJ, Sipahi I, Schoenhagen P, Kapadia SR, **Starling RC**, Hobbs RE, Magyar WA, Nissen SE, Tuzcu EM. Abstract 1030-32: Does the presence of the metabolic syndrome accelerate progression of cardiac allograft vasculopathy? A serial volumetric intravascular ultrasound study. *JACC* Mar 2008; 51(10 Suppl. A):A79.
260. Pham MS, Deng MC, Teuteberg JJ, Kfoury AG, **Starling RC**, Anderson A, Cappola TP, Kao AC, Cotts WG, Bogaev RC, Baran DA, Ewald GA, Baron H, Valentine HA. Invasive monitoring attenuation through gene expression (IMAGE) trial: Current enrollment and study prognosis. *American Journal of Transplantation* 2009.
261. Cantillon DF, Tarakji KG, HU T, Smedira NG, **Starling RC**, Wilkoff BL, Saliba W. Long-term outcomes or pacemaker-requiring bradyarrhythmias after cardiac transplantation: Analysis of the UNOS registry. *Circulation* 2009.
262. Verhaert D, Grimm RA, Putawangkoon C, Wilkoff BL, **Starling RC**, Tang WHW, Thomas JD, Popovic ZB. Extended echocardiographic follow-up in patients undergoing cardiac resynchronization therapy. *Circulation* 2009.
263. Giamouzis G, Butler J, **Starling RC**, Economou D, Karayannis G, Parisi C, Rovithis D, Nastis I, Kiridis T, Tsaknakis T, Skoularigis J, Triposkiadis F. Dopamine prevents worsening of renal function and hypokalemia during hospitalization for acute decompensated heart failure. *Circulation* 2009.
264. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsieh E. **Starling RC**. Application of the Seattle heart failure model in patients presented to a heart transplant committee. *Circulation* 2009.
265. Austin B, Flamm S, Rodriguez R, Tan C, Tang WHW, Taylor DO, **Starling RC**, Desai MY. Accuracy of delayed hyper-enhancement cardiac magnetic resonance imaging in patients with endomyocardial biopsy positive amyloidosis: A multimodality imaging study. *Circulation* 2009.
266. Giamouzis G, Butler J, **Starling RC**, Karayannis G, Rovithis D, Parisi C, Nastas J, Tsaknakis T, Skoularigis J, Triposkiadis F. The renal effects of low-dose dopamine infusion in elderly patients hospitalized for acute decompensated heart failure. *Journal of Cardiac Failure*, Aug 2010; 16(8S).
267. Giamouzis G, Butler J, **Starling RC**, Karayannis G, Rovithis D, Parisi C, Nastas J, Tsaknakis T, Skoularigis J, Triposkiadis F. Beta-blocker pretreatment does not affect the renoprotective effects of low dose dopamine in patients with acute decompensated heart failure. *Journal of Cardiac Failure* Aug 2010; 16(8S).
268. **Starling RC**, Cooper L, Boehmer J, Torre-Amione G, Pauly D, Wittstein I, Zucker M, Narula J, McNamara D. Beta blockers, myocardial recovery and outcomes in recent onset cardiomyopathy: Results of IMAC2. *Journal of Cardiac Failure* Aug 2010; 16(8S).
269. Sweet WE, Perpar J, Schomisch SJ, **Starling RC**, Moravec CS. Altered expression of glycogen synthase kinase -3 beta at different stages of remodeling and reverse remodeling of the human heart. *Journal of Cardiac Failure* Aug 2010; 16(8S).
270. Toma M, Gonzalez-Stawinski GV, Halley C, Gorodeski EZ, Smedira NG, **Starling RC**, Mountis MM. BMI and survival in patients treated with a continuous flow left ventricular assist device as bridge to transplant: A single center experience. *Journal of Cardiac Failure* Aug 2010; 16(8S).
271. Lewis A, Popovic Z, Kwon D, Halley C, Schoenhagen P, Flamm S, Griffin B, **Starling RC**, Desai M. Left ventricular scarring and aortic stiffness are better predictors of mortality than ejection fraction, sphericity and

volumes in severe ischemic cardiomyopathy: A cardiac magnetic resonance study. *European Heart Journal*. ESC Congress, Stockholm, Sweden, Aug 28 – Sep 01, 2010.

272. Giamouzis G, Butler J, **Starling RC**, Karayannis G, Rovithis D, Parisis C, Nastas J, Tsaknakis T, Skoularigis J, Triposkiadis F, Giamouzis G. Beta-blocker pretreatment does not affect the renoprotective effects of low-dose dopamine in patients with acute decompensated heart failure. *Journal of Cardiac Failure CT*. 14th Annual Scientific Meeting of the Heart-Failure Society of America, San Diego, California, Sep 12-15, 2010.
273. Toma M, Gonzalez-Stawinski GV, Halley C, Gorodeski EZ, Smedira NG, **Starling RC**, Mountis MM. BMI and survival in patients treated with a continuous flow left ventricular assist device as bridge to transplant: A single center experience. *Journal of Cardiac Failure*. 14th Annual Scientific Meeting of the Heart-Failure Society of America, San Diego, California, Sep 12-15, 2010.
274. **Starling RC**, Cooper L, Boehmer J, Torre-Amione G, Pauly D, Wittstein I, Zucker M, Narula J, McNamara D. Beta blockers, myocardial recovery and outcomes in recent onset cardiomyopathy: Results of IMAC2. *Journal of Cardiac Failure*. 14th Annual Scientific Meeting of the Heart-Failure Society of America, San Diego, California, Sep 12-15, 2010.
275. Giamouzis G, Butler J, **Starling RC**, Karayannis G, Rovithis D, Parisis C, Nastas J, Tsaknakis T, Skoularigis J, Triposkiadis F. The renal effects of low-dose dopamine infusion in elderly patients hospitalized for acute decompensated heart failure. *Journal of Cardiac Failure*. 14th Annual Scientific Meeting of the Heart Failure Society of America, San Diego, California, Sep 12-15, 2010.
276. Sweet WE, Perpar J, Schomisch SJ, **Starling RC**, Moravec CS. Altered expression of glycogen synthase kinase-3 beta at different stages of remodeling and reverse remodeling of the human heart. *Journal of Cardiac Failure*. 14th Annual Scientific Meeting of the Heart-Failure Society of America, San Francisco, California, Sep 12-15, 2010.
277. Brozzi NA, Wang J, Smedira NG, Navia JL, Taylor D, **Starling RC**, Gonzalez-Stawinski GV. Impact of ventricular assist device associated infections in patients bridged to transplantation: Long term results after heart transplantation. Presented at 21st Century Treatment of Heart Failure, Cleveland Clinic, Cleveland Ohio, Oct 21-22, 2010.
278. Frank D, Baumann M, Liebenstein M, Bolwell G, Sweet W, Tang W, **Starling RC**, Young, JB, McKee M, Moravec C. Biofeedback in heart failure patients awaiting transplantation. Presented at 21st Century Treatment of Heart Failure, Cleveland Clinic, Cleveland, Ohio, Oct 21-22, 2010.
279. Sweet WE, Perpar J, Schomish SJ, **Starling RC**, Moravec CS. Altered expression of glycogen synthase kinase – 3 beta at different stages of remodeling and reverse remodeling of the human heart. Presented at 21st Century Treatment of Heart Failure, Cleveland Clinic, Cleveland, Ohio, Oct 21-22, 2010.
280. Hernandez AF, O'Connor CM, **Starling RC**, Armstrong PW, Dickstein K, Gennivovs D, Hasselblad V, Heizer GM, Komajda M, Massie B, McMurray JJ, Nieminen M, Reist CJ, Rouleau JL, Swedberg K, Califf RM. Acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). *Circulation*. American Heart Association Scientific Sessions 2010 on Resuscitation Science Symposium, Chicago, Illinois, Nov 13-17, 2010.
281. Rogers JG, Tatroles AJ, Park SJ, Steidley DE, Horstmanshof DA, Pae WE, **Starling RC**, Farrar DJ, Slaughter MS, and for the HeartMate II Clinical Investigators. Outcomes of mechanical circulatory support for destination therapy in NYHA class IIIB patients. *Circulation* Nov 23, 2010; 122:A13124.
282. **Starling RC**, Stehlik J, Nicholls S, Ilke D, Chandraker A, Teresa F, Baran D, Wolski K, Mfarrej B, Ahmad U, Sayegh M, Heeger P. Incidence of coronary artery vasculopathy has decreased with modern immunosuppression: Insights from clinical trials in organ transplantation. *Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society of Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
283. Toma M, Dorogi A, Gonzalez-Stawinski GV, Smedira NG, **Starling RC**, Mountis MM. Temporal trends in body mass index after implantation with continuous flow LVAD. *Journal of Heart and Lung Transplantation*. 31st

Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.

284. Lee S, Mountis MM, **Starling RC**, Taylor DO. Post-cardiac transplant survival of status 1A patients is related to level of support: An analysis of OPTN/UNOS data. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Session on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
285. Ewald GA, Tuteberg JJ, Pham MX, Wolters H, Baran DA, **Starling RC**, Kfoury AG, Cappola TP, Kao A, Anderson AS, Cotts WG, Bogaev RC, Scheel J, Yee JP, Deng MC, Valentine HA. Tricuspid regurgitation following orthotopic heart transplantation (OHT): MultiCenter experience from the IMAGE trial. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
286. Pham MX, Wolters H, Baran DA, **Starling RC**, Teuteberg JJ, Kfoury AG, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Bogaev RC, Shahzad K, Yee JP, Valentine HA. Incidence and predictors of late rejection after cardiac transplantation. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Session on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
287. Deng MC, Wolters H, Shahzad K, Pham MX, Teuteberg JJ, Kfoury AG, **Starling RC**, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Klingler T, Baron H, Yee J, Valentine HA. Personalized clinical rejection surveillance after cardiac transplantation by longitudinal gene expression profiling. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
288. Budge D, Brunisholz KD, Wolters H, Valentine HA, Pham MX, Teuteberg JT, Deng MC, **Starling RC**, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Yee J, Kfoury AG. Do longitudinal stable lower AlloMap® scores portend better outcomes after heart transplantation? *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
289. Pauly D, **Starling RC**, Kobashigawa J, Wang S, Cantin B, Keogh A, Lehmkuhl H, Hirt S, Lopez P, Dong G, Cines M, Jiang H, Eisen H. Heart transplant recipients treated with Everolimus have less increase in intimal thickness vs MMF, irrespective of lipid values. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
290. Eisen H, Pauly D, **Starling RC**, Lehmkuhl H, Ross H, Kfoury A, Wang S, Cantin B, Van Bakel A, Zuckerman A, Lopez P, Dong G, Panis C, Jiang H, Cornu-Artis C, Kobashigawa J. Everolimus with reduced CsA vs MMF with standard CsA exposure in de novo heart transplant recipients: 12 month efficacy and safety analysis. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
291. Kobashigawa J, Pauly D, Ross H, Wang S, Cantin B, Burton J, Keogh A, Eisen H, Lopez P, Dong G, Jiang H, Cines M, **Starling RC**. Reduction of cardiac allograft vasculopathy with Everolimus over mycophenolate mofetil: Intravascular ultrasound results of a randomized multicenter trial. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
292. Bonde P, Dew MA, Meyer D, Tallaj JJ, Martin T, Hollifield KA, Slaughter M, **Starling RC**, Kormos RL. National trends in readmission (REA) rates following ventricular assist device (LVAD) Therapy. *The Journal of Heart and Lung Transplantation*. 31st Annual Meeting and Scientific Sessions on International Society for Heart and Lung Transplantation, San Diego, California, Apr 13-16, 2011.
293. Lee S, Thuita L, Rajeswaran J, Kamdar F, Taylor D, **Starling RC**, John R. Changing patterns and regional differences in the use of ventricular assist devices as a bridge-to-transplant: An analysis of UNOS data. Gordon Research Conference - Assisted Circulation, Waterville Valley, New Hampshire, Jun 2011.

294. Dupont M, Oliveira GH, Naftel DC, Yuan Y, Meyers SL, Schmuhl D, Buda T, Mountis M, Smedira N, Tang WHW, Gonzalez-Stawinski G, **Starling RC**. Anthracycline-induced cardiomyopathy patients treated with ventricular assist devices frequently need biventricular support. Data from the INTERMACS registry. *Circulation* 2011.
295. Gonzalez-Stawinski GV, Mountis M, Thuita L, Shafii A, Halley C, Navia JL, Smedira NG, **Starling RC**, Hoercher K, Blackstone EH. The effect of evolving left ventricular assist device technology on post-implant adverse events. American Association for Thoracic Surgery 2011.
296. Frank DL, Baumann M, Liebenstein M, Khorshid L, Bolwell GJ, Kiffer J, Tang WH, Young JB, **Starling RC**, McKee MG, Moravec CS. Biofeedback training in patients with advanced heart failure. Poster presentation at 2011 Heart Failure Society of America Annual Scientific Sessions, Boston, Massachusetts 2011. *Journal of Cardiac Failure* 2011;S91.
297. Patarroyo M, Simbaqueba C, **Starling RC**, Taylor DO, Tang WH. MELD score at the time of surgery does not predict post-operative outcomes in orthotopic heart transplantation. Poster presentation at 2011 Heart Failure Society of America Annual Scientific Sessions, Boston, Massachusetts 2011. *Journal of Cardiac Failure* 2011; 17(8 supplement):S76.
298. Tang WH, Felker GM, Hernandez AF, Gottlieb S, Voors AA, Butler J, Metra M, Anker S, Troughton RW, Hsu A, Massie B, Califf RC, O'Connor CM, **Starling RC**. Baseline cystatin C is associated with short-term adverse events in acute heart failure but does not predict treatment effects with nesiritide therapy: Data from the ASCEND-HF study. Poster presentation at 2011 American Heart Association Scientific Sessions [Abstract 13339], Orlando Florida 2011. *Circulation* 2011; 124:A13339.
299. Felker GM, Tang WH, Hernandez AF, Armstrong P, Dickstein K, Butler J, Metra M, Anker S, Troughton RW, **Starling RC**, Califf RC, O'Connor CM. High sensitivity Troponin I in acute decompensated heart failure: Data from the ASCEND HF study. Oral presentation at 2011 American Heart Association Scientific Sessions. [Abstract 13262], Orlando, Florida, 2011. *Circulation* 2011; 124:A13262.
300. Kwon D, Hachamovich R, Asamoto L, Adeniyi A, Popovic Z, **Starling RC**, Desai, M, Flamm S, Marwick T, Cleveland Clinic, Cleveland, Ohio. Impact on scar burden on gender differences in survival after implantable cardioverter defibrillator implantation in patients with severe ischemic cardiomyopathy. *JACC* Mar 27, 2012; (SA)59:13.
301. Bennett MK, Sweet W, Tang WHW, Mountis M, **Starling RC**, Moravec CM. Cleveland Clinic, Cleveland, Ohio. Calcium cycling protein S100A1 does not recover following continuous flow left ventricular assist device support of the failing human heart. *JACC* Mar 27, 2012; 59:13(SA).
302. Smedira N, **Starling RC**. Unplanned hospital readmissions following Heartmate II implantation: frequency, risk factors, and impact on survival. *JACC* Mar 27, 2012; 59:13(SA).
303. Frank DL, Baumann M, Liebenstein M, Khorshid L, Bolwell GJ, Grossman EF, Kiffer J, Tang WHW, Young J, **Starling RC**, McKee MG, Moravec C. Biofeedback training in patients with advanced heart failure. *JACC* Mar 27, 2012; 59:13(SA).
304. Lee S, Vargas L, Santosh R, Halley C, Sun Z, Mountis M, Gonzalez-Stawinski G, Smedira N, Fukamachi K, **Starling RC**. Performance of the right ventricular failure risk score in patients supported with a left ventricular assist device. *JACC* Mar 27, 2012; 59:13(SA).
305. Zubin E, Reed S, Li Y, Armstrong P, **Starling RC**, McMurray J, Massie B, Sweedberg K, Ezekowitz J, Fonarow G, Teerlink J, Metra M, Whellan D, O'Connor C, Califf R, Hernandez A. Do countries of hospitals with longer stays have lower readmission rates: Findings from the ASCEND HF trial. *JACC* Mar 27, 2012; 59:13(SA).
306. Asamoto L, Hachamovitch R, Popovic Z, **Starling RC**, Flamm S, Marwick T, Kwon D. Infarct heterogeneity is an independent and incremental predictor of mortality in patients with severe ischemic cardiomyopathy. *JACC* Mar 27, 2012; 59:13(SA).

307. Kwon D, Hachamovitch R, Asamoto L, Popovic Z, **Starling RC**, Desai M, Flamm S, Marwick T. End systolic volume and scar burden predict gender differences in survival in patients with severe ischemic cardiomyopathy undergoing revascularization. *JACC* Mar 27, 2012; 59:13 (SA).
308. Dhillon AS, Sweet W, Popovic Z, Smedira N, Lytle B, **Starling RC**, Lever H, Moravec C, Desia M. Association of noninvasively measured left ventricular mechanics with in-vitro muscle performance: a prospective study of hypertrophic cardiomyopathy patients undergoing surgical myectomy. *JACC* Mar 27, 2012; 59:13(SA).
309. Oliveira GH, Mathias D, Naftel DC, Yuan Y, Meyers SL, Schmuhl D, Mountis MM, Smedira N, Tang WHW, Gonzalez-Stawinski G, Taylor DO, **Starling RC**. Outcomes of patients with anthracycline cardiomyopathy treated with mechanical circulatory support: Data from the INTERMACS registry. *The Journal of Heart and Lung Transplantation* Apr 2012; 31:4S.
310. Kobashigawa J, Pauly D, Kfoury A, Ross H, Wang SS, Cantin B, VanBakel A, **Starling RC**, Hirt S, Dong G, Panis C, Lopez P, Eisen H. Multicenter randomized trial of Everolimus vs. mycophenolate mofetil in heart transplantation: Final 24 month analysis of efficacy and safety. *The Journal of Heart and Lung Transplantation* Apr 2012; 31:4S.
311. Cotts, WG, Deng MC, Elashoff B, Pham MX, Teuteberg JJ, Kfoury AG, **Starling RC**, Cappola TP, Kao A, Anderson AS, Ewald GA, Baran DA, Bogaev RC, Stosor V, Yee JP, Valentine HA. Correlation of cytomegalovirus (CVM) serologic status of heart transplant recipients to gene-expression profiling scores and clinical outcomes: Results from the IMAGE multicenter study. *The Journal of Heart and Lung Transplantation* Apr 2012; 31:4S.
312. Askar M, Zhang A, Klingman L, Mastroianni M, Nowacki A, Reville P, Gatto J, Bakdash S, Smedira N, **Starling RC**, Gonzalez-Stawinski G. Higher incidence of class II human leukocyte antigen (HLA)-allosensitization in patients supported with pulsatile ventricular assist devices (VAD). *The Journal of Heart and Lung Transplantation* Apr 2012; 31:4S.
313. Lee S, Vargas L, Rao S, Halley C, Sun Z, Mountis MM, Gonzalez-Stawinski G, Smedira NG, Fukamachi K, **Starling RC**. Performance of the right ventricular failure risk score in patients supported with a left ventricular assist device. *The Journal of Heart and Lung Transplantation* Apr 2012; 31:4S.
314. Dupont M, Mullens W, Taylor DO, **Starling RC**, Tang WH. Treatment of decompensated left-sided heart failure lowers right ventricular pulsatile load and increases the pulmonary arterial time constant. Oral presentation at the 2012 European Society of Cardiology Congress [Abstract 509], Munich Germany. *European Heart Journal* Sep 2012; 33: S45-46.
315. Nagarajan V, Cauthen C, **Starling RC**, Tang WH. Impaired cell-mediated immunity portends poor prognosis in advanced heart failure. Poster presentation at the 2012 Heart Failure Society of America Annual Scientific Session, [Abstract 269], Seattle, Washington 2012. *Journal of Cardiac Failure* Sep 2012; 18(S8):S83.
316. Nagarajan V, Cauthen C, **Starling RC**, Tang WH. Cardio-hepatic dysfunction predicts mortality in stage D HF patients. Accepted for poster presentation at the 2012 Heart Failure Society of America Annual Scientific Session, [Abstract 285], Seattle, Washington 2012. *Journal of Cardiac Failure* Sep 2012; 18(S8):S87-88.
317. Cauthen C, Nagarajan V, **Starling RC**, Tang WH. Elevated serum cobalamin (B12) levels identify a sicker population of patients with advanced heart failure. Poster presentation at the 2012 Heart Failure Society of America Annual Scientific Session, [Abstract 256], Seattle, Washington 2012. *Journal of Cardiac Failure* Sep 2012; 18(S8): S79.
318. Schneeberger DL, Reynard AK, Bolwell GJ, Grossman EF, Kiffer J, Tang WHW, Young JB, **Starling RC**, McKee MG, Moravec CS. Biofeedback training in patients with advanced heart failure. *Journal of Cardiac Failure* Aug 2012; 18(S1):S19.
319. Hsich E, **Starling RC**, Blackstone EH, Taylor DO, Schold JD. Sex differences in mortality on waiting list for heart transplantation. *Journal of Cardiac Failure* Aug 2012; 18(S8):S39.

320. Cauthen CA, Nagarajan V, **Starling RC**, Tang WHW. Elevated serum cobalamin (B12) levels identify a sicker population of patients with advanced heart failure. *Journal of Cardiac Failure* Aug 2012; 18(8S):S79.
321. Nagarajan V, Cauthen CA, **Starling RC**, Tan WHW. Impaired cell-mediated immunity portends poor prognosis in advanced heart failure. *Journal of Cardiac Failure* Aug 2012; 18(8S):S83.
322. Nagarajan V, Cauthen CA, **Starling RC**, Tan WHW. Cardio-hepatic dysfunction predicts mortality in stage D HF patients. *Journal of Cardiac Failure* Aug 2012; 18(8S):S87-S88.
323. Shrestha K, Troughton R, Borowski A, **Starling RC**, Klein A, Tang WHW. Carvedilol versus metoprolol succinate do not differ in determining improvement in myocardial performance, reverse remodeling, and long-term outcome in chronic systolic heart failure. *Journal of Cardiac Failure* Aug 2013; 19:8S.
324. Moravec C, Sweet W, French J, Schneeberger D, McKee M, Tang WHW, **Starling RC**. Differential regulation of muscarinic cholinergic receptors in human heart failure and reverse remodeling. *Journal of Cardiac Failure* Aug 2013; 19:8S.
325. Sweet W, Bennett M, Karohl K, Moazami N, **Starling RC**, Moravec CS. Recovery of SERCA protein following LVAD support: Heartmate vs Heartmate II. *Journal of Cardiac Failure* Aug 2013; 19:8S.
326. Dupont M, Finucan M, Gabi A, Hawwa N, Mullens W, Taylor David O, Young JB, **Starling RC**, Tang WHW. Dose titration following stabilization with vasodilator therapy in contemporary patients with advanced decompensated heart failure. *Journal of Cardiac Failure* Aug 2013; 19:8S.
327. Bennett M, Sweet W, Baicker-McKee S, Tang WHW, **Starling RC**, Moravec C. Lack of relationship between S100A1 protein and β -adrenergic receptors in human heart failure. *Journal of Cardiac Failure* Aug 2013; 19:8S.
328. Halkar E, Nowacki A, Kendall K, Moazami N, Gorodeski E, Tang WHW, **Starling RC**, Young J, Lee S. Utility of the Psychosocial Assessment of Candidates for Transplantation (PACT) Scale in patients undergoing mechanical circulatory support. *Journal of Cardiac Failure* Aug 2013; 19:8S.
329. Wong YW, Heizer G, McMurray JVJ, Felker GM, Califf RM, Armstrong P, O'Connor CM, Ezekowitz JA, **Starling RC**, Hasselblad V, Hernandez AF. Nesiritide administration in patients hospitalized for acute decompensated heart failure: Does timing matter? *Journal of Cardiac Failure* Aug 2013; 19:8S.
330. Grodin JL, Dupont M, Mullens W, **Starling RC**, Tang WH. Intracardiac pressure mismatch is associated with renal recovery following medical therapy in acute decompensated heart failure. Poster presentation at American Heart Association 2013 Scientific Sessions [Abstract 15324], Dallas, Texas, Nov 2013. *Circulation* 2013; 128:A15324.
331. Moravec CS, Sweet WE, French JA, Schneeberger DL, McKee MG, Tang WH, **Starling RC**. Differential regulation of muscarinic cholinergic receptors in human heart failure and reverse remodeling. Poster presentation at 17th HFSA Annual Scientific Meeting [Abstract 019], Orlando, Florida, Sep 2013. *Journal of Cardiac Failure* 2013; 19(8S1): S8.
332. Bennett M, Sweet W, Baicker-McKee, Tang WH, **Starling RC**, Moravec CS. Lack of relationship between S100A1 protein and beta-adrenergic receptors in human heart failure. Poster presentation at 17th HFSA Annual Scientific Meeting [Abstract 148], Orlando, Florida, Sep 2013. *Journal of Cardiac Failure* 2013; 19(8S1): S52.
333. Vijaykrishnan R, Tang WH, Mountis M, Taylor DO, **Starling RC**, Hanna M. Impact of digoxin loading on hemodynamics in advanced low output heart failure: A case-series review. Poster presentation at 17th HFSA Annual Scientific Meeting [Abstract 255], Orlando, Florida, Sep 2013. *Journal of Cardiac Failure* 2013; 19(8S1): S88.
334. Dupont M, Finucan M, Gabi A, Hawwa N, Mullens W, Taylor DO, Young JB, **Starling RC**, Tang WH. Dose titration following stabilization with vasodilator therapy in contemporary patients with advanced decompensated heart failure. Poster presentation at 17th HFSA Annual Scientific Meeting, Orlando, Florida, Sep 2013.

335. Grodin JL, Halker M, **Starling RC**, Tang WH. Electrolyte depletion during decongestive treatment adversely impacts outcomes of acute decompensated heart failure in a contemporary heart failure population. Abstracts from the 18th HFSA Annual Scientific Meeting [Abstract 264], Las Vegas, Nevada, Sep 2014. *Journal of Cardiac Failure* 2014;20(S 8).
336. Lander BS, Blackstone EH, Nordseth T, **Starling RC**, Gorodeski EZ. Trajectories of post-acute care in the first 30-days following hospital discharge for left ventricular assist device implantation. Abstracts from the 18th HFSA Annual Scientific Meeting [Abstract 266], Las Vegas, Nevada, Sep 2014. *Journal of Cardiac Failure* 2014; 20(S8).
337. Birks EJ, Drakos S, Selzman C, **Starling RC**, Cunningham C, Slaughter M, Spevack DM, Salahuddin A, Alturi P, Um J, Lowes B, Patel S, Farrar D, Kallel F, Rame JE. Remission From Stage D Heart Failure (RESTAGE-HF): Early Results From a Prospective Multi-Center Study of Myocardial Recovery. Abstracts from *ISHLT 2015* [Abstract 85], Nice, France, April 2015.
338. Estep JD, **Starling RC**, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O'Connell J, Boyle AJ, Kallel F, Farrar DJ. FEATURED ABSTRACT: Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (**ROADMAP**). Abstracts from *ISHLT 2015* [Abstract 199], Nice, France, April 2015
339. Loyaga-Rendon RY, **Starling RC**, Cantor RS, Pamboukian SV, Tallaj JA, Acharya DA, Naftel DC, Kirklin JK. Duration of Heart Failure Influences the Outcomes After Mechanical Circulatory Support. Abstracts from *ISHLT 2015* [Abstract 200], Nice, France, April 2015.
340. Rao P, Hong L, Gjertson D, Balaz I, Fishbein MC, Deng M, Harre N, Leuchter R, Banchs HL, DeNofrio D, Eisen HF, Ewald GA, Kfoury A, Kobashigawa JA, **Starling RC**, Torre-Amione G, Van Bakel A, Reed EF. Effect of Everolimus Immunotherapy on HLA Antibody Production in Heart Transplantation. Abstracts from *ISHLT 2015* [Abstract 217], Nice, France, April 2015.
341. Askar M, Rodriguez R, Klingman L, Thomas D, Zhang A, Morf H, Hamon N, Moazami N, Hsieh E, Taylor D, **Starling RC**, Tan C. IgM De Novo Donor Specific HLA Antibodies (dnDSA) Claws Switch to IgG and DQ dnDSA Are Associated With C4d+ Biopsies Conversion to C4d+/C3d+ and Progression of Subclinical Antibody Mediated Rejection in Heart Transplant Recipients. Abstracts from *ISHLT 2015* [Abstract 266], Nice, France, April 2015.
342. Lee S, Young JB, Naftel D, Kirklin J, Moazami N, Myers S, Strueber M, Dickinson M, and **Starling RC**. Impact of Concomitant Cardiovascular Surgeries at the Time of CF-LVAD Implantation: An INTERMACS Analysis. Abstracts from *ISHLT 2015* [Abstract 398], Nice, France, April 2015.
343. Zeltzer SM, Wang Z, Li L, Coughlin J, Hudec T, Askar M, Taylor DO, **Starling RC**, Hazen S, Tang WH. Dietary-Derived Trimethylamine N-Oxide (TMAO) Levels Are Associated With Coronary Allograft Vasculopathy Following Heart Transplantation. Abstracts from *ISHLT 2015* [Abstract 804], Nice, France, April 2015.
344. Rose SL, Highland JD, Dobbie KR, Patel CA, Gutsell T, Kodish E, Smith ML, Grey C, **Starling RC**, Gorodeski E, Carrino C, & Daly BJ. (2015, April). Outpatient Palliative Medicine for Advanced Heart Failure Patients and Their Families: A Pilot Study. Poster session presented at the annual *Translational Science Meeting, 2015*. Washington, DC.
345. Grodin JL, Hernandez AF, Butler J, Metra M, Felker GM, Voors A, McMurray J, Armstrong P, **Starling RC**, O'Connor C, Tang WH. The Clinical Implications of Cardiac Troponin I Measured by an "Ultrasensitive" Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. Abstract from *HFSA 2015* [Abstract 034], National Harbor, Maryland, September 2015.
346. Nagatomo Y, McNamara DM, Alexis JD, Cooper LT, Dec GW, Pauly DF, Sheppard R, **Starling RC**, Tang WH. The Presence of IgG3 Autoantibody Against β 1 Adrenergic Receptors is Associated with Favorable Myocardial Recovery in Patients with Recent Onset Cardiomyopathy - a Post-hoc Analysis of IMAC-2 Study. Abstract from *HFSA 2015* [Abstract 040], National Harbor, Maryland, September 2015.

347. Solomon S, Packer M, Zile M, Swedberg K, Rouleau J, Lefkowitz M, Shi V, Desai A, Claggett B, **Starling RC**, McMurray J. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in Heart Failure With Reduced Ejection Fraction. Abstract from *HFSA 2015* [Abstract 088], National Harbor, Maryland, September 2015.
348. Verbrugge FH, Grodin JL, Mullens W, Taylor DO, **Starling RC**, Tang WH. Hyponatremia Patterns During Hospitalization for Acute Heart Failure. Abstract from *HFSA 2015* [Abstract 194], National Harbor, Maryland, September 2015.
349. Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson J, Halkar M, **Starling RC**, Testani J, Tang WH. Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. Abstract from *HFSA 2015* [Abstract 196], National Harbor, Maryland, September 2015.
350. Samsky M, Dunning A, Schulte P, DeVore A, Mentz R, Patel C, **Starling RC**, Teerlink J, Tang WH, Armstrong P, Ezekowitz J, Metra M, Voors A, McMurray J, Butler J, O'Connor C, Hernandez A. Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients with Acute HF: Insights From ASCEND-HF. Abstract from *HFSA 2015* [Abstract 294], National Harbor, Maryland, September 2015.
351. Grodin J, Mullens W, Dupont M, Taylor D, McKie P, **Starling R**, Testani J, Tang WH. Hemodynamic Determinants of Serum Chloride in Ambulatory Patients With Advanced Heart Failure. Abstract from *ACC.16* [Abstract 1102-066], Chicago, IL, April 2016.
352. Ambrosy A, Armstrong P, Butler J, Cerbin L, Coles A, DeVore A, Ezekowitz J, Fudim M, Greene S, Hernandez A, O'Connor C, Schulte P, **Starling R**, Teerlink J, Voors A, Mentz R. The Relationship between Body Weight Change During Hospitalization for Acute Heart Failure and Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. Abstract from *ACC.16* [Abstract 1171-048], Chicago, IL, April 2016.
353. Grodin J, Sun JL, Anstrom K, Chen H, **Starling R**, Testani J, Tang WH. Lower Serum Chloride Is Associated With Lower Diuretic Efficiency and Adverse Post-Discharge Outcomes: Insights from ROSE-AHF. Abstract from *ACC.16* [Abstract 1171-054], Chicago, IL, April 2016.
354. Perez A, Kittipibul V, Tang WH, **Starling R**. Two-Thirds of Heart Failure Patients Who Meet the FDA-Approved Indication for Sacubitril/Valsartan Do Not Meet PARADIGM-HF Enrollment Criteria After Recent Hospitalization. Abstract from *ACC.16* [Abstract 1251-075], Chicago, IL, April 2016.
355. Greene S, Hernandez A, Sun JL, Metra M, Butler J, Ambrosy A, Ezekowitz J, **Starling R**, Teerlink J, Voors A, Armstrong P, O'Connor C, Mentz R. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and Endpoints: Insights From the ASCEND-HF Trial. Abstract from *ACC.16* [Abstract 1251-083], Chicago, IL, April 2016.
356. Gold M, Berman B, Borggrefe M, Djordjevic S, Hauptman P, Kubo S, Lieberman R, Milasinovic G, Neelagaru S, Schwartz P, **Starling R**, VanVeldhuisen D, Mann D. The Effect of Vagal Nerve Stimulation in Heart Failure: Primary Results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) Trial. Abstract from *ACC.16* [Abstract 412-12], Chicago, IL, April 2016.
357. Barakat A, Sperry B, Popovic Z, Griffin B, **Starling R**, Desai M. Depressed Right Ventricular Longitudinal Strain Is Negatively Prognostic After Adjusting for Traditional Risk Factors After Heart Transplantation. Abstract from *ACC.16* [Abstract 1290M-05], Chicago, IL, April 2016.
358. **Starling RC**, Estep J, Horstmanshof D, Milano C, Selzman C, Shah K, Bruckner B, Lee S, Long J, Stehlik J, Kasirajan V, Haas D, Boyle A, Chuang J, Farrar Rogers J. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients ROADMAP) – 2 Year Results. Abstract from *JHLT* [Abstract 38], Volume 35, Issue 4, Supplement, Page S22, April 2016.
359. Stehlik J, Estep J, Selzman C, Rogers J, Shah K, Chuang J, Farrar D, **Starling RC** for the ROADMAP Study

Investigators. Patient Reported Quality of Life with Mechanical Circulatory Support vs Continued Medical Therapy in Ambulatory Heart Failure Patients. Abstract from *JHLT* [Abstract 47], Volume 35, Issue 4, Supplement, Page S26, April 2016.

360. Lanfear DE , Levy WC, Stehlik J, Estep JD, Rogers JG, Shah KB, Boyle AJ, Chuang J, Farrar DJ, Starling RC. Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope Dependent Advanced Heart Failure Patients: Insights from the ROADMAP Study. Abstract from *JHLT* [Abstract 274], Volume 35, Issue 4, Supplement, Page S109, April 2016.
361. Steffen R, Blackstone E, Smedira N, Soltesz E, Hoercher K, Thuita L, **Starling RC**, Mountis M, Moazami N. Optimal Timing of Heart Transplantation After HeartMate II Left Ventricular Assist Device Implantation. Abstract from *JHLT* [Abstract 570], Vol. 35, Issue 4, Supplement, Pages S212–S213, April 2016.
362. Cruz VB, Steffen R, Koprivanac M, **Starling RC**, Taylor DO, Hoercher K, Rajeswaran J, Smedira N, Soltesz E, Blackstone EH, Moazami N. Time-Varying Mortality Risk Score for Candidates Awaiting Cardiac Transplantation. Abstract from *JHLT* [Abstract 593], Volume 35, Issue 4, Supplement, Page S220, April 2016.
363. Karimov JH, Tong M, Byram N, Sunagawa G, Dessoffo R, Moazami N, **Starling R**, Fukamachi K. Evaluation of Changes in Flow Associated with HeartMate II Inflow Cannula Angle Change. Abstract from *JHLT* [Abstract 899], Volume 35, Issue 4, Supplement, Pages S325-S326. April 2016.